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1. Renin angiotensin-aldosterone system  
The renin-angiotensin-aldosterone system (RAAS) plays an important role in the 
regulation of blood pressure, body fluid volume and sodium-potassium balance. It 
has been demonstrated that dysregulation of RAAS, including increased circulating 
angiotensin II (Ang II) and aldosterone, may contribute to the development of 
hypertension, atherosclerosis, left ventricular hypertrophy, stroke, myocardial 
infarction, heart failure and/or renovascular disorders 1.  
The conventional RAAS begins with the biosynthesis of the glycoprotein hormone 
renin, by the juxtaglomerular cells in the kidneys, in response to reduced renal 
perfusion pressure, low levels of intratubular sodium, sympathetic activation and 
lack of negative feedback by Ang II 1 (Figure 1.1). Renin converts 
angiotensinogen into angiotensin I (Ang I), which is subsequently hydrolyzed by 
angiotensin-converting enzymes (ACEs) to form Ang II 2,3.  Ang II mediates its 
effects via Ang II type 1 (AT1R) and Ang II type 2 (AT2R) receptors.  
 
 
Figure 1.1. Overview of the RAAS.  The diagram depicts the cell membrane bound angiotensin type 1 
receptor (AT1R), angiotensin type 2 receptor (AT2R), Mas receptor (MasR), alamandine receptor 
(MrgDR) ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; Ang I, 
angiotensin I; Ang II angiotensin II; Ang1-7, angiotensin 1-7.Figure adapted from Wilkinson-Berka et al. 
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Ang II has been regarded as a major peptide of the RAAS.  AT1R activation by Ang 
II elicits vasoconstriction, water intake, and Na+ retention. However, 
pathophysiological activation of the ACE/ANG II/AT1R axis is associated with 
oxidative stress, hypertrophy, inflammation and fibrosis. High levels of Ang II can 
promote tubulointerstitial damage by inducing epithelial mesenchymal transition 
(EMT) 5. The key role of EMT in hypertensive kidney disease is discussed in detail 
in Chapter 2. The RAAS also possesses a ‘protective arm’, mediated through the 
AT2R, Mas receptor (MasR) and alamandine receptor (MrgDR).  The activation of 
AT2R seems to counterbalance some of the actions of the AT1 receptor 6,7. 
Furthermore, the cleavage of Ang II by ACE2 produces angiotensin 1-7 (Ang1-7) 
which also acts on the AT2R and MasR to partially antagonize the effects of AT1R 
8. One of the major effects of Ang II is the regulation of aldosterone synthesis, 
mediated via the AT1 receptor in the zona glomerulosa of the adrenal cortex 9.  
1.1 Aldosterone  
Aldosterone is a steroid hormone that is produced in the adrenal cortex. The 
human adrenal cortex can be divided into three functionally distinct area; the zona 
glomerulosa (ZG), the zona fasciculata (ZF), and the zona reticularis (ZR).  Each 
zone secretes different types of adrenocortical steroid hormones. The zona 
glomerulosa is the site of aldosterone synthesis. The zona fasciculata, 
corresponding to 75% of the cortex, is the site of cortisol synthesis. The inner 
cortex corresponds to the zona reticularis and is the site where androgens are 
synthesized. 
Biosynthesis of aldosterone involves multiple enzymes common to all the zonas 
and is exerted at two rate-limiting steps in the steroidogenic pathway. The first step 
common to the cortisol synthesis is the transport of cholesterol into the 
mitochondria by StAR protein, where it is converted to pregnenolone 10. 
Pregnenolone in the endoplasmic reticulum is converted to progesterone by 3β-
hydroxysteroid dehydrogenase (3β-HSD). 21-hydroxalase (CYP21A2) then 
converts progesterone to 11-deoxycorticosterone and is transported back into the 
mitochondria in which the second rate-limiting step occurs, i.e. the sequential 
hydroxylation by aldosterone synthase (CYP11B2) leading to the synthesis of 
aldosterone. CYP11B2 is only expressed in the ZG, while expression of 11β-
hydroxylase (CYP11B1), which is required for the final step in the biosynthesis of 
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Figure 1.2. Steroidogenic pathway for the production of aldosterone and cortisol  
 
The production of aldosterone is controlled by multiple factors including Ang II, 
potassium (K+), endothelin-1, vasopressin, urotensin II, and circulating 
adrenocorticotrophic hormone (ACTH) 12,13. 
In the classic pathway aldosterone binds to the intracellular mineralocorticoid 
receptor (MR) in the epithelial cells of the distal convoluted tubule and the 
collecting duct of the nephrons 14. By up-regulating the epithelial sodium channel 
(ENaC) and the basolateral Na+/K+-ATPase, aldosterone promotes reabsorption of 
sodium and water which contributes directly to increased blood pressure. 
Aldosterone regulates the transcription of genes coding for these channels and the 
exchange pump via its receptor. Besides this genomic effect, non-genomic effects 
of aldosterone are described and they are mediated either via MR dependent - or 
MR independent pathways (Figure 1.3). Aldosterone via MR dependent pathways 
can promote the activation of second messenger responses such as the 
biosynthesis of cAMP, as well as the activation of extracellular signal-regulated 
kinase (ERK1/2) and mitogen-activated protein kinase (MAPK) cascades through 
the transactivation of the epidermal growth factor receptor (EGFR) 15.   





Figure 1.3. Genomic and non-genomic actions of aldosterone. In the genomic pathway, 
aldosterone diffuses across the cytoplasmic membrane and binds to mineralocorticoid receptor 
(MR) in the cytosol inducing receptor translocation to the nucleus and expression of genes. In 
contrast, the non-genomic effects of aldosterone are not dependent on transcription. Non-genomic 
pathways are MR dependent or independent and act via second messenger systems. 
Abbreviations: G-protein coupled estrogen receptor (GPER). Figure created with BioRender.com 
 
Recently, several studies have shown rapid, non-genomic effects of aldosterone in 
the renal tubule, but also several other tissues, such as vascular tissue, and heart 
16–19. Of note, MR is also distributed across a range of extraepithelial tissues such 
as endothelial cells, vascular smooth muscle cells, and kidney mesangial cells and 
podocytes, suggesting that the physiological effects of aldosterone are not limited 
to the MR on the renal epithelial cells 20. Moreover, the non-genomic effect of 
aldosterone can involve other receptors such as G-protein coupled estrogen 
receptor (GPER) 21. Although GPER was first characterized as an orphan G-protein 
coupled receptor (aka GPR30), later it was demonstrated to mediate rapid 
intracellular signaling of estrogens 22. The expression of GPER is ubiquitous, and in 
the last decade it has been reported that aldosterone can activate GPER mediated 
pathways in both in-vitro and in-vivo models 23. These include the rapid activation 
of ERK1/2 and apoptosis in vascular smooth muscle cells (VSMCs) of rat aorta via 
activation of both GPER and MR 24, while activation of ERK1/2 in endothelial cells 
25  and an increase in cytosolic Ca2+ concentration and depolarization in cardiac 






Although the RAAS in general and aldosterone in particular, has an important 
physiological role in blood pressure regulation, chronic activation of RAAS is a key 
factor in the pathophysiology of cardiovascular diseases, including hypertension 
and heart failure. Elevated aldosterone levels not only contribute to the 
development of hypertension but also induce a proinflammatory condition which 
ultimately leads to end-organ damage, such as cardiac and vascular fibrosis 4. 
1.2 Hypertension 
Hypertension is one of the most important risk factors for stroke, heart and kidney 
disease, and hardening of the arteries. 
According to the European guidelines, hypertension is defined as a blood pressure 
(BP) ≥ 140/90 mmHg 27, but more recently the American guidelines recommends 
lower threshold of BP ≥130/80 mmHg 28. 
In industrialised countries, the risk of becoming hypertensive during a lifetime 
exceeds 90%. Globally, over 1 billion people are afflicted by hypertension and it is 
estimated that the number of people with hypertension will increase by 2025, 
approaching a prevalence of 1.5 billion 27,29. The increase in the prevalence of 
hypertension is a consequence of population growth, ageing and lifestyle, such as 
physical inactivity, use of alcohol, and the consumption of diets rich in fat, sugar 
and calories. (World Health Organisation, 2013; Das et al. 2005).  Hypertension 
usually converges with other cardiovascular risk factors such as dyslipidaemia and 
glucose intolerance 30,31. 
Arterial hypertension can be classified into primary or secondary forms. About 80-
95% of arterial hypertension is primary or essential hypertension and does not 
have a precise, identifiable cause. The remaining 5-10% of cases is secondary 
hypertension and is the consequence of hormonal disorders or congenital or 
acquired diseases that affect the kidneys, adrenals, arterial vessels or the heart. In 
secondary hypertension, the identification and removal of the causes, that is, the 
effective treatment of the underlying disease, is accompanied by the normalization 
of the blood pressure. Essential hypertension classically affects the adult 
population and its prevalence increases with age, whereas secondary hypertension 
also affects younger subjects and is often characterized by higher pressure values 
that are more difficult to control with drug therapy. 
1.3 Primary Aldosteronism 
Primary aldosteronism (PA), first described by Jerome Conn in the 1950s, is the 
most common cause of secondary hypertension characterized by excessive 
secretion of the hormone aldosterone from the adrenal glands 32 and thus an 
endogenous continuous exposure to elevated aldosterone levels.  





Large variations of the prevalence of PA have been reported, ranging from <1% to 
30%. This variations can be explained by differences in the selection of the 
patient’s cohorts and heterogeneous diagnostic criteria used in the various studies 
33. However, the PA Prevalence in Hypertensives (PAPY) study, referred to 
specialized hypertension centres, represents the most realistic estimate on the 
prevalence of primary aldosteronism in the hypertensive patients. Based on a 
predefined protocol and standardized diagnostic criteria to diagnose PA, the PAPY 
study provided solid evidence that among referred hypertensive patients the 
prevalence of PA is 11.2% 34. Patients with PA have a higher risk of cardiovascular 
events and target organ damage than age-, sex- and BP-matched patients with 
essential hypertension 35. 
Therefore, early identification and specific treatment of PA is essential to minimize 
the adverse effects of aldosterone excess. However, PA remains largely 
unrecognized by medical professionals and currently available diagnostic tests for 
PA are complex, require long times are relatively expensive and cannot be applied 
to all hypertensive patients. 
1.3.1. Subtypes of Primary Aldosteronism 
The mechanisms that regulate aldosterone production are severely altered in PA. 
This disorder comprises both sporadic and familial forms.  
There are two major subtypes of sporadic PA: the unilateral aldosterone-producing 
adenoma (APA). APA can be optimally treated with unilateral laparoscopic 
adrenalectomy. Bilateral adrenal hyperplasia (BAH, also known as idiopathic 
hyperaldosteronism, IHA) is usually treated with a lifelong treatment with 
mineralocorticoid receptor antagonists. Hence, the distinction between APA and 
IHA is crucial for appropriate treatment 36,37.  
Four familial forms of primary aldosteronism have been identified (FH-I to FH-IV) 
together with the PASNA (PA, seizures, neurologic abnormalities) syndrome, which 
is a genetic disease, but not a familial form of PA 38. 
Familial hyperaldosteronism type I (FH-I), also known as glucocorticoid-remediable 
aldosteronism (GRA), was first described in 1966 39. It is an autosomal dominant 
disease generated by an unequal crossing over during meiosis between the genes 
CYP11B1 (which encodes steroid 11β-hydroxylase) and CYP11B2 (which encodes 
aldosterone synthase). The resulting hybrid gene encodes an enzyme chimera with 
aldosterone synthase activity that is expressed in the adrenal zona fasciculata 
under control of adrenocorticotropic hormone instead of angiotensin II. The majority 
of affected individuals develop early and severe hypertension, often associated 
with hypokalemia. GRA has a presumed prevalence of 0.7-1.0% of all PA 38,40. 
Familial hyperaldosteronism type II (FH-II) is a non-glucocorticoid-remediable form 






or hyperplasia. The prevalence of FH-II is 1.2–6% of adult patients with PA. With 
exome sequencing, de novo mutations in the CLCN2 gene coding for the CLC-2 
chloride channel in patients with FH-II and early-onset PA has been identified and 
the implication of a chloride channel in the regulation of aldosterone production has 
been described 41,42. 
Familial hyperaldosteronism type III (FH-III) was first described in a family with 
hyperaldosteronism, profound hypokalemia and severe hypertension that was 
resistant to medical therapy 43. 
The genetic cause of FH-III has been identified as a germline mutation in the 
KCNJ5 gene  encoding the potassium channel Kir3.4 which is expressed in adrenal 
zona glomerulosa 44.  
Familial hyperaldosteronism type IV (FH-IV) is a non-glucocorticoid-remediable 
form of FH, which has been attributed to germline CACNA1H mutations. 
CACNA1H codes for the pore-forming α1 subunit of the voltage-gated T-type 
calcium channel Cav3.2. Patients with FH-IV showed hyperaldosteronism with low 
plasma renin activity but no evidence of a mass or hyperplasia on adrenal imaging 
45. 
PASNA (primary aldosteronism with seizures and neurologic abnormalities) is a 
genetic disease in patients with primary aldosteronism and neurological symptoms 
characterized by germline CACNA1D mutations 38.  
1.3.2. Aldosterone Producing Adenoma  
Aldosterone-producing adenomas are responsible for about half of PA. 
Patients with APA are characterized by an increase in circulating aldosterone 
independent of plasma renin, and is a major cause of endocrine secondary 
hypertension. 
Currently, the only reliable procedure allowing differentiation of the unilateral from 
bilateral PA and identification of APA side preoperatively is adrenal venous 
sampling (AVS) 46. In AVS, aldosterone and cortisol levels are measured in blood 
collected from both adrenal veins to assess whether aldosterone is unilaterally 
overproduced. The development of specific antibodies against CYP11B2 now 
allows an accurate localization of the cells producing aldosterone and provides a 
conclusive diagnosis of the PA subtype. The diagnosis of APA is usually 
established when the following ‘Five Corners Criteria’ are fulfilled: 1) Biochemical 
evidence of PA (e.g., an inappropriately high aldosterone/renin ratio), 2) 
aldosterone secretion is lateralized at AVS, 3) an adenoma is detected at 
pathology of a nodule by imaging (CT or MRI), 4) PA is biochemically corrected by 
adrenalectomy, 5) a CYP11B2-positive adenoma at pathology is detected 47.  
However, the pathophysiological and molecular mechanisms that lead to the 
development of APA and which determine the hypersecretion of aldosterone are 





still unknown. Numerous recurrent somatic mutations have been identified in APA. 
Pathogenetic somatic mutations in the KCNJ5 potassium channel  were first 
reported in 2011 44 and involves up to 70% of cases of APA, usually the most florid 
PA phenotypes 48. This finding was soon followed by the discovery of mutations in 
other genes affecting ion channel function: in the sodium/potassium ATPase 
ATP1A1, the calcium ATPase ATP2B3 genes, and in the CACNA1D gene 49,50. All 
these mutations induce an increase in intracellular calcium levels, followed by an 
activation of calcium signaling and therefore increase the biosynthesis of 
aldosterone. Recent findings have shown that some macrolide antibiotics and their 
derivatives specifically inhibit in vitro the altered function of mutated KCNJ5 
channels and blunted in dose-dependent manner aldosterone secretion, opening a 
new horizons for the diagnosis and treatment of APA with KCNJ5 mutations 51. 
Autoimmune mechanisms have also been suggested as an important cause of 
human PA. Autoantibodies against type-1 angiotensin II receptor (AT1AAs) were 
found in the plasma of patients with PA at levels comparable to those found in 
preeclamptic women 52. Moreover, circulating AT1AA levels discriminated between 
APAs and IHA, suggesting that they might be useful not only for diagnosing PA but 

















2. The glycation pathway and the formation of AGEs 
In addition to Ang II, a lot of studies have demonstrated the involvement of 
advanced glycation endproducts (AGEs) in the development of vascular 
dysfunction 53, hypertension and chronic kidney disease and cardiovascular 
disease 54,55. Thus, in addition to the activation of the renin-angiotensin system, the 
accumulation of AGEs is recognized as a key driver of macro- and microvascular 
complications. However, if, and if so, how these two mechanisms interact has been 
relatively underexplored. 
2.1. Formation of Advanced Glycation Endproducts (AGEs) 
Glycation is a non-enzymatic reaction of reducing sugars with proteins, lipids and 
nucleic acids. This process was first described by Louis-Camille Maillard in 1912 56. 
The formation of AGEs via the Maillard reaction starts with condensation of the 
carbonyl group of reducing sugars and the amino group of proteins resulting in the 
rapid formation of unstable Schiff base intermediate.  This Schiff base intermediate 
then slowly rearranged to more stable Amadori products (Figure 1.3). Only a small 
part of these Amadori products will be further, and irreversibly, modified to AGEs. 
At body temperature, AGE formation in vivo is a slow process and mainly affects 
long-lived proteins, such as collagen and elastin 57. Besides the endogenous 
formation of AGEs, the accumulation of AGEs in our body can also originate from 
exogenous sources such as tobacco smoke and diet 58,59, and this exogenous AGE 
formation in food is highly dependent on cooking methods. AGEs can be present in 
both the free (modified amino acid) and protein-bound (modified amino acid as part 
of a protein) form.  
In addition to the classical pathway of AGE formation in the Maillard reaction, as 
described above, a rapid AGE formation on short-lived proteins and intracellular 
AGE formation have attracted attention. It should be realized that glucose has a 
very slow glycation rate. In contrast, glucose-derived glycolytic intermediates form 
not only much more glycated proteins than equimolar amounts of glucose, but also 
more rapidly. The glucose-derived glycolytic intermediates glyoxal (GO), 
methylglyoxal (MGO) and 3-deoxyglucosone (3-DG) play an important role in the 
fast intracellular Maillard reaction and are much more reactive than glucose or 
other reducing sugars 60–62. Besides reducing sugars, other sources contribute to 
the formation of these reactive dicarbonyl compounds, including lipid peroxidation. 
Dicarbonyls derived from lipid peroxidation, create so-called advanced lipoxidation 
endproducts (ALEs). The mechanism of formation of ALEs is comparable as those 
formed from glucose-derived glycolytic intermediates. Thus, there is a strong 
interplay between the formation of AGEs and ALEs as their formation is through 
identical reactive dicarbonyls. 





The accumulation of reactive dicarbonyl compounds is known as “dicarbonyl 
stress” and leads to increased AGEs formation. including Nε-(1-
carboxymethyl)lysine (CML), Nε-(1-carboxyethyl)lysine (CEL), and Nδ-(5- hydro-5-
methyl-4-imidazolon-2-yl)-ornithine (MG-H1). 
 
Figure 1.3. Main steps of endogenous AGE formation. Abbreviations: 3DG, 3-deoxyglucosone; CEL, 
Nε-carboxyethyl-lysine; CML, Nε-carboxymethyl-lysine; GO, glyoxal; MG-H1, methylglyoxal-derived 



















2.2. Mechanisms of vascular harm by glycation 
AGEs adverse effects on cellular and tissue function through direct modification of 
extracellular matrix proteins, leading to collagen cross-links and, subsequently,  to 
an increase of vascular stiffness, or through binding to cell surface receptors such 
as RAGE, triggering multiple signaling cascades and the production of reactive 
oxygen species, resulting in proinflammatory cellular responses 63.  
2.2.1. RAGE 
AGEs mediate some of their pathological effects by activating different signaling 
pathways upon binding to different cell surface receptors. Research has identified a 
number of AGE-binding proteins, including macrophage scavenger receptors 
(MRS) type I and II, oligosaccharyltransferase-48 (AGE-R1), 80K-H 
phosphoprotein (AGE-R2), galectin-3, CD36, LOX-1 and RAGE 63,64. RAGE is the 
best characterized and the most-studied receptor so far. RAGE is a multi-ligand 
transmembrane receptor of the immunoglobulin superfamily and is expressed on 
several cell types, including endothelial cells, monocytes, macrophages, 
fibroblasts, and smooth muscle cells. The ligand-binding domain of RAGE resides 
in the V-domain and  recognizes a large variety of ligands of different origin 
including AGEs, amyloid β peptide, S100/calgranulin protein and HMGB1 65.  
Under physiological conditions, the expression of RAGE is low while under 
pathogenic conditions like inflammation and diabetes, RAGE expression is 
upregulated. Interestingly, also at sites of increased levels of AGEs RAGE is 
upregulated, such as  in podocytes in diabetic nephropathy 66. Altered plasma or 
tissue level of RAGE has been identified in patients with diabetic complications and 
in  chronic inflammation 65.  
Binding of AGEs to RAGE is linked to the activation of multiple cellular signal 
pathways including activation of a cascade of mitogen-activated protein kinases 
(MAPK), such as ERK1/2 (p44/p42) 67. Activation of these MAPK results in 
activation of nuclear transcription factor-κB (NF-κB), and subsequently to 
transcription of target genes, including numerous adhesion molecules and pro-
inflammatory cytokines which are involved in vascular inflammation and endothelial 
dysfunction. The AGE-RAGE axis also represents an important mediator of 
oxidative stress as induced by increased NADPH oxidase gene expression, 
mitochondrial oxidase activity and downregulation of endogenous antioxidant 
mediator of oxidative stress 68,69. This interaction of AGEs with RAGE on 
endothelial cells results also in  a decrease of endothelial barrier function and 
hence an increase in the  permeability of an endothelial cell monolayer 70. 
 





2.2.2. Intracellular glycation by methylglyoxal 
Based on the current literature, the predominant mechanism by which AGEs 
damage tissues is by intracellular glycation of proteins leading to impaired cell 
function. MGO is the major precursor in the formation of intracellular AGEs in 
endothelial cells 63. MGO mainly reacts with arginine to generate methylglyoxal-
derived hydroimidazolone (MG-H1) and with lysine to Nε-(carboxyethyl)lysine 
(CEL). In addition to amino acids, specific nucleotides are also susceptible to 
modification by MGO 60. Under physiological conditions, the concentration of MGO 
is maintained in the range of 100-300 nM in human plasma and MGO levels 
increase under conditions of conditions of hyperglycaemia, inflammation and 
hypoxia 71,72. 
Several studies have reported MGO-induced changes in particular proteins 
including hemoglobin 73, mitochondrial proteins 74, and antioxidant enzyme such as 
GAPDH 75, besides changes  in DNA methylation 76, and histone modifications 76. 
Thus, intracellular glycation by MGO may lead to a range of molecular pathways 
that disrupt cellular function or even lead to cell-death 60. The accumulation of 
MGO may cause hemodynamic, inflammatory, metabolic, and structural changes in 
the kidneys 60 that may contribute to the manifestation of diabetic chronic kidney 
disease77 and cardiovascular disease 54,55. Furthermore, plasma MGO levels are 
increased in diabetes 71 and are associated with cardiovascular disease in type 1 
and type 2 diabetes 54,55.  
2.2.3. Glyoxalase pathway 
MGO can be detoxified by the cytoplasmic glyoxalase system. The glyoxalase 
system consists of 2 enzymes, glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2), and a 
catalytic amount of reduced glutathione (GSH). First, MGO is converted to S-
Lactoylglutathione by Glo1, which uses GSH as a cofactor (Figure 1.4). 
Subsequent, S-Lactoylglutathione is metabolized to D-lactate by Glo2. GSH is 
recycled during this last step in the process, making it available for new 
detoxification of MGO.  The conversion of MGO by Glo1 is important because this 
is the rate-limiting step and S- Lactoylglutathione is not as toxic to cells as MGO.   
The formation of AGEs is suppressed by enzymatic metabolism of MGO by Glo1, 
indicating that MGO is the major precursor in the formation of AGEs 60. Indeed, in 
endothelial cells, overexpression of Glo1 prevents hyperglycaemia-induced 
formation of the major AGEs CML and CEL 78  as well as impaired angiogenesis 79.  
In line with these in vitro experiments, overexpression of Glo1 in diabetic animal 
models reduces hyperglycaemia-induced formation of MGO 80, improves diabetes-






reduction of expression of the adhesion molecules vascular cell adhesion molecule 
1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1) 82. 
Furthermore, overexpression of Glo1 attenuated diabetes-induced loss of 
podocytes in the glomerulus 82, one of the early hallmarks of diabetic nephropathy 
83. Glo1 is essential for normal kidney function in protecting cells from MGO stress 
as showed in nondiabetic mice, in which knockdown of Glo1 increases MG-H1 
residues in proteins of renal glomeruli and tubules and oxidative stress with 
subsequent alterations in kidney morphology identical to those caused by diabetes 
84. In accordance, knockdown of Glo1 in human aortic endothelial cells increases 
MGO and promote endothelial inflammation and apoptosis 85.  
The importance of Glo1 has also been demonstrated in human studies. In long-
standing T1D, Glo1 expression was lower in kidneys affected by CKD 86. Similar 
observations were made for carotid atherosclerotic plaques, in which Glo1 
expression was lower in ruptured in comparison with stable plaque segments 87. 
Furthermore, a very large genomic study revealed that Glo1 is a major driver of 
coronary artery disease 88.  
 
Interestingly, Miller and coworkers 89 found a downregulation of Glo1 by Ang II in 
retinal vascular cells, and the downregulation of Glo1 was blocked by the 
angiotensin type 1 receptor blocker candesartan. This was one of the first 













































3. The interaction of RAAS and AGEs 
The RAAS, which is upregulated in diabetes 90, plays a central role in the 
development of renal and cardiovascular diseases 90. Blockade of the RAAS with 
the use of angiotensin receptor blockers (ARBs) is one of the most successful 
interventions to combat diabetic complications, as evidenced by the seminal 
publications of the IRMA-2 study 91. In the IRMA-2 study irbesartan lowered 
albuminuria in individuals with type 2 diabetes mellitus (T2DM), and this effect 
occurred independently of blood pressure 91.  
Although an effect of the RAAS on AGE levels is largely unknown, Miller and 
coworkers have shown that Ang II increased the formation of AGEs, most likely 
caused by a Ang II-induced downregulation of Glo1 89,  indicated an interaction of 
the RAAS with the AGE pathway. However, data about the effects of Ang II and 
ARBs on MGO levels is lacking.  We have studied this in more detail and described 
the results in Chapter 7-9.    
Accumulation of AGEs and activation of the RAAS are both implicated in diabetic 
vascular complications 77,90.  An interaction between the AGE/RAGE axis and the 
RAAS has been described in several in vitro systems. For example, in vascular 
smooth muscle cells, S100B-RAGE interaction augmented both Ang II–induced 
tyrosine phosphorylation of JAK2 and proliferation of vascular smooth muscle 
cell92. Several other in vitro studies have shown that the in vitro production of AGEs 
and dicarbonyl compounds and the AGE-induced activation of RAGE were 
attenuated by RAAS blockade 92–94.   
In accordance with in vitro studies, a study in rats demonstrated that Ang II–
dependent renal injury was ameliorated by inhibition of AGE formation by ALT-946 
and aminoguanidine (AG) 95. 
Ang II is an important vasoconstrictor and exerts multiple functional effects on 
endothelial cells, including excessive oxidative stress and vascular inflammation96.  
In diabetic retinopathy, Ang II mediates increases in RAGE and AGE-induced 
apoptosis of retinal pericytes 97. Although the biological action of Ang II is mainly 
mediated by the AT1R, some studies have suggested a link between AT1R and 
RAGE receptor as an important signaling pathway in vascular smooth muscle cells 
and podocytes 98,99. Recently, a direct crosstalk between the AT1R and RAGE has 
been shown 100. Using a variety of mouse models, assay systems, and different 
RAGE domains the authors showed that RAGE and the AT1R form a heteromeric 
complex at the plasma membrane, which upon Ang II activation, induces NF-κB 
expression and the subsequent proinflammatory signaling events of RAAS.  Thus, 
RAGE deletion prevented proinflammatory signaling events induced by AT1R 
activation.  At the same time, RAGE deletion or inhibition did not affect blood 






The interactions between the AGE/RAGE pathway and RAAS may have important 
clinical implications and may provide further therapeutic targets. The possibility to 
develop novel therapeutics that are able to specifically target the adverse effects of 
RAGE transactivation by AT1R can be an effective mean to control diabetic 
vascular complications, atherosclerosis and other important inflammatory 













































Outline of the thesis  
In the first part of the thesis, we investigated several aspects that regulate the 
biosynthesis of aldosterone in primary aldosteronism.   
In chapter 2, we first assessed the role of epithelial mesenchymal transition in 
hypertensive kidney disease. In chapter 3, we investigated the functional role of 
the AT2R in aldosterone producing adenomas and APA-adjacent tissues. In 
chapter 4, we investigated the effect of a macrolide antibiotic, clarithromycin on 
aldosterone synthesis in cells isolated ex-vivo from KCNJ5 mutated aldosterone 
producing adenomas. In chapter 5, we addressed the question whether GPER-
mediated mechanisms are involved in biosynthesis of aldosterone. In chapter 6, 
we investigated biological effects of AT1AA as derived from patients with 
aldosterone producing adenoma and studied whether the concentration of these 
AT1AA can be normalized after adrenalectomy.  
  
In the second part, we studied the interactions between the AGE/RAGE pathway 
and RAAS.  
Patients with APA are characterized by high titers agonistic autoantibodies against 
AT1AA. In chapter 7, we made use of the study described in chapter 6 and 
assessed plasma levels of free and protein-bound AGEs and of MGO in patients 
with primary aldosteronism before and 1 month after adrenalectomy. In chapter 8, 
we studied the direct effect of Ang II on Glo1 in endothelial cells and in mice.  
Although previous studies have found that ARBs attenuate in vitro the production 
of AGEs and dicarbonyl compounds, it is unknown whether ARBs may reduce 
plasma levels of dicarbonyls in patients with type 2 diabetes. Therefore, we 
investigated in chapter 9 in a cohort of patients with type 2 diabetes the effects of 
the ARB irbesartan on circulating levels of dicarbonyls including MGO.  
Finally, in chapter 10 we summarized the results and discussed all findings of this 
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Accumulating evidence indicates that epithelial to mesenchymal transition (EMT), 
originally described as a key process for organ development and metastasis 
budding in cancer, plays a key role in the development of renal fibrosis in several 
diseases, including hypertensive nephroangiosclerosis.  
We herein reviewed the concept of EMT and its role in renal diseases, with 
particular focus on hypertensive kidney disease, the second leading cause of end-
stage renal disease after diabetes mellitus. After discussing the pathophysiology of 
hypertensive nephropathy, the ‘classic’ view of hypertensive nephrosclerosis 
entailing hyalinization and sclerosis of interlobular and afferent arterioles, we 
examined the changes occurring in the glomerulus and tubulo-interstitium and then 
the studies that investigated the role of EMT and its molecular mechanisms in the 
hypertensive kidney disease.  Finally, we examined the reasons why some studies 




















More than 20 million people have chronic kidney disease (CKD) in the US, with 3% 
of them developing end-stage renal disease (ESRD) 
(https://www.usrds.org/adr.aspx), which accounts for 7% of the Medicare 
expenditures.  In the EU, the last annual report of the European Renal Association 
– European Dialysis and Transplant Association (ERA-EDTA) Registry indicated 
that about 500 thousand people were on renal replacement therapy in 20181.  
Moreover, the medical spending is held to be much greater, because ESRD 
patients are at high risk for cardio- and cerebrovascular vascular disease, and is 
projected to rise even more owing to population ageing in the next decades 2.  
Arterial hypertension (HT), with a prevalence of 30-45% in the adult population, is 
the major cardiovascular risk factor and the second cause of ESRD after diabetes 
mellitus 3,4.  However, the relationship between the kidney and HT is double-
threaded in that nephropathies usually cause HT and high blood pressure 
damages the kidney 5.   
Even though classically described as nephroangiosclerosis and hyalinosis of the 
glomerular tuft 6,7, hypertensive nephropathy has been more recently found to 
involve not only the glomerular and vascular compartments, but also the 
interstitium because of the development of tubular-interstitial fibrosis (TIF) and 
ultimately ESRD 8,9.  
Depending on underlying pathophysiology and/or severity of HT, multiple 
mechanisms can concur to induce TIF, among which epithelial-to-mesenchymal 
transition (EMT), a process originally described in organ development and 
metastasis budding in cancer, and later observed in several diseases 10,11.  
Although potentially capable of affecting any injured epithelial tissue, whether and 
to what extent EMT plays role of in the kidney in hypertensive nephropathy remains 
unclear 12–14. 
Hence, we shall herein focus on the EMT process and its involvement in 
hypertensive nephropathy by exploiting a methodology to systematically review the 
English-written literature by means of a PICO search strategy (Table 2.1) with 
selection of the articles based on their relevance, rigorousness of study design and 














Table 2.1. PICO strategy used for the literature search  
Kew word Operator Kew word Operator Kew word 
Hypertension OR High blood 
pressure 
  
  AND   
Nephropathy  OR Tubular damage OR Tubulointerstitial 
fibrosis 




OR EMT  Epithelial-to-
mesenchymal 
transdifferentiation 
2. Tubulointerstitial damage in hypertension 
In 1993 an involvement of tubule-interstitium in the hypertensive disease was 
postulated for the first time by Fine 15, who put forward the ‘chronic hypoxia 
hypothesis’. According to this contention, glomerular injury primarily determined by 
HT would induce hypoxia and endothelial damage of peritubular capillaries 15,16, 
thus stimulating tubular inflammation and fibrosis. Although appealing, this 
hypothesis remained unproven until one study showed peritubular capillaries 
rarefaction and tubulointerstitial scarring in human biopsies of CKD hypertensive 
patients 17 and models of hypertensive disease documented an involvement of the 
interstitium in HT 8,9,18,19.  
Fibroblasts are strategically posed in the interstitium to sense circulating toxins or 
factors and environmental changes and can be activated by local tissue injury to 
differentiate into myofibroblasts that synthesize extracellular matrix deposition and 
collagens. However, fibroblasts can act also as inflammatory effector cells: they 
express immune receptors as Toll-like receptors (TLRs) and activate NF-kB 
signaling with ensuing release of cytokines and chemokines that amplify kidney 
damage.  In the hypertensive nephropathy, TIF usually associates with glomerular 
damage, loss of nephrons and decline in renal function. Nephrons are then focally 
replaced by fibrotic tissue along a scarring process finally leading to ESRD 20.  
Thus, chronic and progressive tubular damage invariably leads to TIF. 
Several factors can induce TIF.  One of them is angiotensin II (Ang II), a major 
effector of the renin angiotensin aldosterone system (RAAS), which acts as a 
potent vasoconstricting and pro-inflammatory factor.  Using a transgenic renin-
dependent model of severe HT and cardiovascular and renal damage created with 
insertion of the mouse renin gene into the rat genome, the TG(mRen2)27 rat, we 
found that blockade of the Ang II type 1 (AT1) receptor with irbesartan, prevented 
TIF, thus supporting a fibrogenic role of Ang II 8.  Interestingly, in this model TIF 
was also prevented by bosentan, a mixed ETA – ETB endothelin receptor 
antagonist, but worsened by BMS-182874, a selective ETA receptor antagonist, 
suggesting a key role of endothelin-1 (ET-1) acting via ETB receptor subtype in 
triggering renal fibrosis 8.   




Of note, dual inhibition of ACE and of neutral endopeptidase also prevented TIF; 
moreover, this favorable effect was abolished by the bradykinin B2 receptor 
antagonist icatibant, thus implicating also the B2 subtype receptor in 
counterbalancing the deleterious effects of Ang II in the tubule-interstitium 9.   
Ang II can promote TIF not only by activating resident fibroblasts, but also by 
inducing proteinuria or EMT (see later “EMT in Hypertensive Nephropathy”).  When 
hypertensive nephropathy is associated with proteinuria, filtered proteins are held 
to exert a further toxic effect on proximal tubular cells, which can amplify 
inflammation 21.  Pro-inflammatory factors as Monocyte Chemoattractant Protein-1 
(MCP-1/CCL2), Regulated upon Activation Normal T-cell Expressed and Secreted 
(RANTES/CCL5), and fractalkine/CX3CL1, are chemoattractant for 
monocytes/macrophages and T lymphocytes, which stimulate synthesis of 
transforming growth factor β1 (TGFβ1), a potent fibroblast activator 14.  
3. Epithelial to mesenchymal transition (EMT) 
Renal epithelial cells arise during embryogenesis by mesenchymal-to-epithelial 
transition (MET) 22,23. For decades the dogma was that epithelial cells maintain its 
phenotype until death, but, after the seminal study by Gros in 2014 24, the concept 
that epithelial cells can switch back to a mesenchymal phenotype via epithelial-to-
mesenchymal transition (EMT) was promptly accepted 25,26. First described in 
embryogenesis 24, EMT was then observed in inflammation 27, fibrosis 28–30, wound 
healing 31, and cancer progression 32–34. Epithelia are characterized by apical-basal 
polarity and tight cell–cell junctions between neighboring cells, accounting for cell 
integrity and stability, whereas mesenchymal and interstitial tissues are formed by 
elongated and spindle-shaped cells, known as fibroblast-like cells, which have 
loose cell–cell interactions. Because of their mobility, these cells can migrate and 
create an anchorage distantly. The cells undergoing EMT progressively lose 
epithelial markers, such as E-cadherin, which is the main component of adherent 
junctions, and acquire markers of mesenchymal phenotype, such as α smooth 
muscle actin (αSMA) 35. Loss of cell junctions allows epithelial cells to translate into 
loss of adhesion, change morphology, and loss apical-basal polarity. After 
synthesis of matrix metalloproteinases (MMPs), cells cleave and invade the basal 
lamina to move towards the interstitial space. Migration is driven by newly formed 
matrix of fibronectin and type I collagen. Upon completion of the epithelial-to-
mesenchymal phenotype switch, the cells acquire a myofibroblast phenotype 
synthesizing αSMA and matrix proteins, the major constituents of TIF 35. A number 
of epithelial and mesenchymal markers have been used to track EMT, and a lot of 
factors have been identified as drivers of EMT. Not unexpectedly, most factors 
were also found to be involved in embryogenesis, tissue repair, and cancer, 
suggesting parallels between normal development and malignant growth. TGFβ, a 





cells. After the binding of TGF-β to receptor II TβR-II, TGF-β-bound TβR-II 
phosphorylates type I receptor (TβR-I) leads to the activation of Smad 2 and 3. 
Activated Smad2/3 can form a complex with Smad4, which translocates into the 
nucleus, where it interacts with transcriptional factors and transcriptional co-
activators, ultimately inducing synthesis of mesenchymal proteins 36–38. 
4. Markers of EMT 
In 1995, Strutz et al. detected S100A4 in tubular cells with persistent inflammation.  
Since S100A4 was considered a typical protein of mesenchymal cells and only 
seldom found in tubular cells of healthy kidneys, S100A4 was renamed fibroblast-
specific protein–1 (FSP-1) and proposed to be a marker of cells undergoing EMT 
39.  However, other investigators were not able to localize FSP-1/S100A4 in 
activated fibroblasts, and found this protein in immune cells and occasionally in the 
endothelial cells.  Hence, the specificity of FSP-1/S100A4 as a marker of EMT was 
challenged 40,41. 
Other markers of EMT have been later proposed.  Vimentin is expressed in 
mesenchymal cells, but also in injured tubular cells and/or regenerating cells 42–44, 
which led some investigators to consider it as a marker of EMT and other to 
propose it as a marker of tubular regenerating activity. 
αSMA is characteristically expressed in mesenchymal cells, as vascular smooth 
muscle cells, pericytes, and interstitial cells around injured tubules and 
myofibroblasts 45,46.  In contrast, proximal tubular cells contain F-actin, a different 
isoform that constitutes cytoskeleton microfilaments and that cannot bind 
antibodies against αSMA.  However, detection of αSMA cannot be used as a 
marker specific of EMT, because it cannot discriminate between mesenchymal 
cells physiologically present in the kidney or myofibroblasts.  
The decrease or loss of markers of epithelial cells, as E-cadherin or ZO-1, is 
strongly suggestive of EMT, but could also denote tubular cell damage with no 
transition into mesenchymal cells. 
Collagens and proteins that participate to collagen synthesis, as the collagen-
specific molecular chaperone HSP 47 and prolyl-4-hydroxylase, have been also 
used as markers 47.   
Invasion of the basal membrane and cell migration are markers of fully completed 
EMT. Hence, different markers of EMT have been suggested, with some (loss of E-
cadherin and ZO-1, synthesis of αSMA and vimentin) indicating the early 
phenotypic cell switch and others (collagens, matrix invasion) full transformation of 
epithelial cells into mesenchymal cells.  However, because of the lack of specific 
markers of transforming cells, per se no marker can provide unambiguous 
demonstration of EMT.  As discussed below, EMT is a dynamic and transient 
process difficult to be visualized.  Only an integrated approach evaluating early and 
late steps can allow identification of EMT. 




 5. EMT as mediator of TIF 
Using a mouse model of severe renal fibrosis, i.e., unilateral ureteral obstruction, 
Yang and Liu first described EMT in the kidney as an orchestrated process 
consisting of the classical four steps, i.e., loss of epithelial cell adhesion, de novo 
synthesis of αSMA, disruption of tubular basement membrane, and cell migration 
and invasion 48. In the same model, Iwano et al. found that up to 36% of interstitial 
matrix-producing cells derived from tubular cells through EMT 35. However, using 
models characterized by less pronounced TIF, such as overload proteinuria 48, 
other investigators found that the contribution of EMT was very scant, and, 
Humphreys et al. 49, using the model of unilateral ureteral obstruction, were unable 
to reproduce data from Iwano 35, suggesting that, although renal epithelial cells can 
acquire mesenchymal markers in vitro, they do not contribute to interstitial 
myofibroblast cells in vivo. Thus, whether EMT actually contributes to TIF in vivo in 
all types of nephropathies remains controversial 50,51. According to a popular view, 
EMT would be a process by which epithelial cells under stress conditions escape 
from the unfriendly microenvironment 52. After an injury, tubular epithelial cells 
express genes, such as Wnt, Notch, and Hedgehog, which confer resistance to 
apoptosis and are involved in normal development 52. However, during physiologic 
development differentiated epithelial cells proliferate and in an injured kidney 
epithelial cells acquire partial or full mesenchymal characteristics, thereby 
preventing proliferation and replacement of damaged cells. Hence, tubular 
epithelial cells are not locked in a differentiated state, but are ‘plastic cells’ that 
transform into a different phenotype, but are unable to reach terminal differentiation 
52. Two mechanisms have been proposed: (1) Differentiation of epithelial cells 
needs “turning off” of Wnt and Notch genes, a process that does not happen in 
damaged cells; (2) the over-expression of transcription factors, such as Twist, 
Zeb1, Zeb2, Snai1, and Snai2 favors, mesenchymal reprogramming, preventing 
terminal differentiation. Elegant studies by Kalluri’s and Nieto’s groups support 
such contentions: mice over-expressing Snai1 exhibited epithelial plasticity, 
myofibroblast accumulation, and inflammation, whereas an ablation of Twist and 
Snai1 induced expression of markers of differentiated cells, such as aquaporins 
and solute transporters 29,30. In contrast to other strategies used by epithelial cells 
to avoid threatening conditions, such as apoptosis or necrosis, EMT is hardly 
identifiable because of the difficulty of catching exactly the time-point when cells 
transform into mesenchymal cells and pass the basement membrane 51. Whether 
EMT is too rapid to be detected or visualization of EMT needs an integrated 
methodological approach remains a matter of debate. 
6. EMT in hypertensive nephropathy 
Several in vitro studies showed that some factors that induce HT, fibrosis, or both 





13,53–55. However, only a few studies provided evidences of EMT in vivo in 
hypertensive nephropathy 12,56,57. Ang II was found to induce EMT in cell culture 
models 13,53–55,58. In the rat proximal tubular cell line (NRK52-E), EMT was identified 
as a morphological change of the epithelial cells from the typical cobblestone 
pattern to elongated, spindle-shaped mesenchymal cells, and also as a reduction 
in E-cadherin and synthesis of αSMA protein expression 54. In a rat model of 
accelerated ESRD induced by a 14-day infusion of Ang II after preinjury by 
injection of Habu venom, Falkner et al. observed a progressive increase in αSMA 
staining, starting from 48 h. However, peritubular interstitial myofibroblasts were 
also detected after 7 days of Ang II alone infusion, confirming capability of Ang II of 
inducing EMT 50. It is important to note that a blockade of the AT1 receptor 
prevented EMT in models of HT, caused by partial nephrectomy 56 or unilateral 
ureteral obstruction 57, supporting a role of Ang II in EMT. As mentioned above, we 
recently provided evidence that ET-1 can also induce EMT in the kidney 12: In the 
same kidney sections of TG(mRen2)27 rats, where we observed TIF, we found a 
decrease in the epithelial marker E-cadherin along with an increase in the 
mesenchymal markers αSMA and S100A4, i.e., phenotypic changes that indicated 
the occurrence of EMT. We also demonstrated co-expression of the epithelial with 
mesenchymal markers, thus strongly supporting EMT as the mechanism 
underlying fibrosis in this Ang-II-dependent model of severe hypertension 12. 
Moreover, in vitro experiments confirmed that ET-1 can drive EMT in the proximal 
tubular cells 12. Exposure of HK2 cells to ET-1 caused disruption of cell junctions 
and synthesis of αSMA, causing blunting of E-cadherin along with the increase of 
mesenchymal markers, synthesis of MMP-9, and cell migration12. All steps of EMT, 
such as TIF involved the ETB receptor subtype, which is the predominant receptor 
subtype in the kidney tubular cells (Figure 2.1) 12.  





Figure 2.1. Development of tubule-interstitial damage in the hypertensive disease. When 
angiotensin II and/or endothelin-1 are abnormally produced, such as under conditions characterized by 
excess mechanical or oxidative stress, epithelial-to-mesenchymal transition (EMT) is triggered, leading 
to transformation of tubular cells into myofibroblasts that produce collagens. The final event is tubulo-
interstitial fibrosis. Angiotensin II (Ang II), by binding Ang II type 1 (AT1) receptors in the vascular 
smooth muscle cells, also favors vasoconstriction and vascular remodeling, worsening kidney damage. 
Vasoconstriction is also mediated by endothelin-1 via ETA and ETB receptors, located at the vascular 
smooth muscle cells. 
 
7. Conclusions 
In summary, EMT entails a dynamic sequential process characterized by 
progressive loss of epithelial markers and acquirement of a mesenchymal 
phenotype marker that is key to several physiological and pathological processes 
that need cell plasticity.  Although evidences obtained in model of severe Ang II-
dependent hypertension strongly support the contention that EMT contributes to 
TIF, which is the major determinant of ESRD, likely via the activation of the AT1 
and ETB receptors, it remains debated if EMT contributes to TIF in other forms of 
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The angiotensin II (Ang II) type 2 receptor (AT2R) and the angiotensin-(1–7) (Ang-
(1–7)) receptor (MasR) play a cardiovascular protective role by counter-regulating 
Ang II type 1 receptor (AT1R)-mediated effects, but whether this involves blunting 
of adrenocortical hormone secretion is unknown. We investigated the presence of 
AT1R, AT2R, and MasR in aldosterone-producing adenoma (APA), a condition 
featuring hyperaldosteronism, and in APA-adjacent tissue. The effect of Compound 
21 (C21), an AT2R agonist, on CYP11B1 (cortisol synthase) and CYP11B2 
(aldosterone synthase) gene expression in NCI-H295R and HAC15 cell lines, and 
in APA and APA-adjacent tissue, was also assessed using the AT1R antagonist 
irbesartan to ascertain the specificity of C21 effect. We found that the AT1R, AT2R, 
and MasR were expressed in APA and APA-adjacent tissue, albeit 
heterogeneously. 
The gene expression of AT1R and AT2R was lower, and that of the MasR higher in 
APAs than in APA-adjacent tissue. In steroid-producing NCI-H295R and HAC15 
cell lines, and in APA and APA-adjacent tissue, C21 was ineffective at nanomolar 
concentrations, but increased CYP11B1 and CYP11B2 gene expression at 
micromolar concentrations through AT1R, as this effect was blunted by irbesartan. 
The scant expression of the AT2R, along with the lack of any effect of C21 at low 
concentrations on CYP11B2, do not support the contention that the protective arm 
of renin–angiotensin system (RAS) blunts aldosterone synthase in the normal 















The biosynthesis of aldosterone, the main mineralocorticoid hormone in the 
adrenocortical zonaglomerulosa 1,2 is tightly controlled by multiple factors, as 
angiotensin II (Ang II) 3, potassium (K+), endothelin-1 4,5, vasopressin 6,7, urotensin 
II 8,9, and circulating adrenocorticotrophic hormone (ACTH) 3. Inappropriate 
aldosterone production results in several pathological conditions featuring Na+ and 
water retention, as heart failure, high renin forms of arterial hypertension and 
primary aldosteronism 10,11, the most common form of secondary hypertension. 
Amongst the aldosterone regulators, Ang II is held to act through the Ang II type 1 
receptor (AT1R) 12,13; a role of the Ang II type 2 receptor (AT2R) is suggested by 
some data in animals 14,15, but is unknown in humans. The AT2R expression is 
high in the fetus 16,17, but falls markedly after birth, being restricted to few organs 
and tissues in adults 18; moreover, its role remained undefined, until the first non-
peptide AT2R agonist Compound 21 (C21) was developed 19. In animal models 
C21 induced vasodilatation, inhibition of cell proliferation, inflammation and fibrosis. 
It also caused axonal regeneration and prevention of cancer 20-22, suggesting that 
AT2R activation can be useful for treatment of hypertension, cardiovascular 
diseases and other conditions. 
The existence of a ‘protective arm’ of the renin–angiotensin system (RAS) has also 
been supported by identification of the angiotensin-(1–7) (Ang-(1–7)), itsMas 
receptor (Ang-(1–7) receptor (MasR)) 23,24, the alamandine receptor (Mas-related 
G-coupled receptor type D (MrgD)), and the Ang-(1–7) generating enzyme 
angiotensin-converting enzyme (ACE)-2 (ACE2) 25,26. By binding to MasR, Ang-(1–
7) was shown to exert beneficial actions in experimental heart failure and in AT1R-
mediated inflammation, to improve endothelial function in atherosclerosis, and to 
inhibit lung cancer growth in vitro (for review 27,28). Even less known is the role of 
alamandine, a furtherMasR, although studies in spontaneously hypertensive rats 
suggested that it might also play a protective role 29 in that a single dose of the 
alamandine/β-hydroxypropylcyclodextrin compound induced a long-lasting blood 
pressure lowering effect 30. 
Thus, accumulating evidence indicates that the so-called ‘protective pathway’ of 
the RAS may act by counteracting the effects to the canonical RAS, composed of 
ACE, AT1R, and Ang II. Notwithstanding this, little is known about its presence and 
role in the human adrenal cortex. Thus, given the key role of aldosterone in 
cardiovascular disease, we sought to ascertain the expression of AT1R, AT2R, 
MasR, and MrgD and the functional role of AT2R in aldosterone-producing 
adenoma (APA) and APA-adjacent tissue. 
 
 




Materials and methods 
Cells 
The polyclonal NCI-H295R and clonalHAC15 cell lines, the latter derived 
fromH295R, were used as in vitro models for steroid synthesis 31. NCI-H295Rwere 
grown in Roswell Park Memorial Institute (RPMI)medium supplemented with 10% 
FBS, 1% glutamine, and 1% antibiotic/antimycotic mixture. HAC15 were grown in 
Dulbecco’s modified Eagle’s medium F12 supplemented with 10% cosmic calf 
serum, 1% glutamine, and 1% antibiotic/antimycotic mixture.  
Cells were seeded in 12-well plates at 2 × 105 cells per well and grown to 
subconfluence (80%). Before treatment, cells were starved for 24 h with 
RPMI/Dulbecco’s modified Eagle’s medium F12 medium supplemented with 0.5% 
FBS/cosmic calf serum, 1% glutamine, and 1% antibiotic/antimycotic. This medium 
was also used for cell stimulation. After starvation, the cells were treated with a 
stimulus alone and/or with selective antagonists for 12 h. Experiments were also 
performed by adding receptor antagonists in fresh medium 30 min before 
stimulation. C21 (kindly provided by Vicore Pharma) and irbesartan (from Sigma–
Aldrich) were used as AT2R agonist and AT1R antagonist, respectively. 
Tissues 
APA (n=14) tissue and APA-adjacent tissue (n=7), used as control, were obtained 
from our own tumor bank from patients with a conclusive diagnosis of APA 
following the four corner criteria 32-34. All tissues were collected under sterile 
conditions in the operating room immediately after excision. Small pieces were 
frozen and stored in liquid nitrogen. The creation of the biobank of human adrenal 
tissues was approved by the Ethics Committee; informed consent was obtained 
from each patient. 
For in vitro studies, adrenocortical specimens were cut into 20-mg strips which 
were put in 24-well plates, starved with Dulbecco’s modified Eagle’s medium F12 
supplemented with 0.5% FBS for 6 h, and then treated with C21 alone and/or with 
selective antagonists for 12 h. 
Immunomagnetic isolation of CD56+ cells 
APA cells were obtained by sequential enzymatic digestion and mechanical 
disaggregation of tissues from three patients. We used immunoseparation of 
CD56+ cells on magnetic beads precoated with an antibody specific for neural cell 
adhesion molecule (NCAM-CD56) to obtain a pure population of aldosterone-
secreting cells from the APA-adjacent tissue human zona glomerulosa, as 
previously reported in detail 35. 
 




RNA extraction and quantitative real-time PCR 
RNA from cells was extracted with the Roche RNeasy kit (Roche), and RNA from 
tissue with Qiagen RNA extraction kit (Qiagen) following the manufacturer’s 
protocol. The integrity and quality of total RNA, extracted with the RNeasy Mini kit 
(Qiagen), was systematically checked with a laboratory-on-chip technology in an 
Agilent Bioanalyzer 2100 with the RNA 6000 Nano Assay (Agilent Technologies). 
One microgram total RNA from cells, and 300 ng total RNA from tissues, were 
reverse transcribed with Iscript (Bio–Rad) in a final volume of 20 μl and following 
the manufacturer’s recommendations. The RT-PCR reactions were performed in 
Delphi 1000TM Thermal Cycler (Oracle Biosystems). 
For quantitation of the angiotensin receptor genes, the gene expression of AT1R, 
AT2R, MasR, MrgD were measured in APA-adjacent tissue, APA, and CD56+ cells 
by real-time RT-PCR with Universal ProbeLibrary Probes (Roche) in the 
LightCycler 480 Instrument (Roche). For quantitation of the angiotensin receptors’ 
genes, the ratio of target gene (AT1R, AT2R, MasR) and the housekeeping gene 
porphobilinogen-deaminase (PBGD), Ct was used by applying the Advance 
Relative Quantification Analysis by the LightCycler 480 software. 
In NCI-H295R and HAC15 cells, the relative expression levels of aldosterone 
synthase (CYP11B2), cortisol synthase (CYP11B1) mRNA were measured with 
real time RT-PCR. Primers and probes (Universal ProbeLibrary, Roche) for the 
amplification of the genes of interest were designed using ProbeFinder Software 
(Roche). Sequences are shown in Supplementary Table S3.1. After treatment, 
CYP11B2 and CYP11B1 gene expression were calculated by the comparative Ct 
(2-∆∆Ct) method 36: each sample was quantitated against PBGD and normalized to 
the control group. Each experiment was repeated at least three times in duplicate, 
and the results are presented as mean percentage fold increase ±S.D. Standard 
curves were generated for all the primers by serial dilutions of RT products 
spanning four orders of magnitude, yielding a PCR efficiency close to two for each 
reaction. 
Immunoblotting 
Immunoblotting for AT1R, AT2R, and MasR was performed following a standard 
protocol. In brief, cells were homogenized in lysis buffer (Thermo Scientific) and 
protein concentration was determined in the soluble supernatant with BCA assay 
(Thermo Scientific). Lysate fraction (50 μg) was separated in a polyacrylamide gel 
and then electro blotted on to nitrocellulose or PVDF membrane (Hybond ECL-
Amersham Biosciences, Europe). The membranes were blocked for 30 min at 
room temperature in 5% non-fat dry blocking milk or with 5% BSA and thereafter 
incubated overnight at 4◦C with a primary rabbit monoclonal antibody against 
human AT1R (diluted 1:1000, Abgent), 




AT2R (diluted 1:500, Novus Biologicals), MasR (diluted 1:1000, Novus Biologicals). 
After washing, the membrane was incubated for 1 h with an anti-rabbit secondary 
antibody. Then, band intensity was measured with VersaDoc Imaging System 
(Bio–Rad). 
Protein samples were obtained from APA tissues (n=6) and the APA-adjacent 
tissue (n=6). Images were analyzed by Image Processing and Analysis in Java 
(ImageJ, NIH). Bands for AT1R, AT2R, and MasR were normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Immunohistochemistry 
Paraffin-embedded adrenal glands were cut at 5 μm, and the sections dried and 
then melted at 56◦C for at least 3 h. After deparaffination through alcohols, antigen 
retrieval was performed for 15 min at 121◦C in autoclave followed by treatment with 
0.5% H2O2 for 20 min to inhibit endogenous peroxidases. Slides were blocked with 
PBS, 0.3% Tween, and 5% goat serum for 1 h and then incubated overnight at 4◦C 
with antibodies against angiotensin receptors (1:200 AT1R and 1:150MasR). 
Antigen was detected by incubation with a secondary antibody labeled with 
horseradish peroxidase and diaminobenzidine; sections were counterstained with 
Hematoxylin, dehydrated, cleared, and mounted. The negative control was 
immunostained only with secondary antibody. 
Statistical analysis 
Values are reported as mean and S.D., or median and minimum and maximum of 
data, as appropriate. Quantitative data were analyzed after verification of normal 
distribution. Non-parametric Mann–Whitney test or one-way ANOVA test were 
used, as appropriate. Statistical analysis was performed with GraphPad 
SoftwareTM (version 6 for Mac OS X, La Jolla, CA). 
Results 
Angiotensin receptors in human adrenal tissue 
The relative amounts of AT1R, AT2R, MasR, and MrgD mRNA were investigated 
by real-time RT-PCR in APA and the APA-adjacent tissue, and in CD56+ cells, i.e. 
a pure population of aldosterone-producing cells obtained from APA. In the APA-
adjacent tissue and in APA, AT1R was the most expressed angiotensin receptor 
subtype, whereas AT2R and MasR were expressed at low levels (Figure 3.1A). 
Both AT1R and AT2R mRNA were more abundant in APA-adjacent tissue than in 
APA (Figure 3.1B). At variance, MasR showed the highest expression levels in the 
APA tissue (Figure 3.1B). All angiotensin receptors were expressed in APA CD56+ 
cells (n=3), albeit in varying amounts. RT-PCR showed high expression of AT1R in 
APA CD56+ cells and very low levels of AT2R and MasR (ratio of PBGD to AT1R: 




1.158 ± 0.25, AT2R: 0.0036 ± 0.0007, MasR: 0.0047 ± 0.0001). The MrgD was 
detected in both APA-adjacent tissue and APA, even though at low levels (∼200-




Figure 3.1. Gene expression of angiotensin receptors in human adrenal tissue. 
(A) Relative amount of the different angiotensin receptors (AT1R, AT2R, MasR) in APA (n=14) and in 
control (n=7). Control: APA-adjacent tissues. (B) AT1R, AT2R, and MasR expression levels between 
APA samples and control. Expression is measured as the ratio of Ct of target gene (angiotensin 
receptors) and housekeeping gene (PBGD) Ct (median and minimum and maximum of data). Control: 
APA-adjacent tissues. 
 
Immunoblotting confirmed that AT1R was the predominant subtype angiotensin 
receptor subtype in APA-adjacent tissue and APA tissues, whereas MasR protein 
expression was detectable at low levels in both tissues (Figure 3.2A). 
Immunohistochemistry was used to localize AT1R and MasR receptors in APA-
adjacent tissue and APA. This showed that AT1R staining was much stronger in 
zona glomerulosa layer than in zona fasciculata of the APA-adjacent tissue (Figure 
3.2B), mostly in the cytoplasm and occasionally in the cell membrane. In contrast, 
a diffused immunostaining for MasR was observed in the APA-adjacent tissue 
without differences between the adrenal layers. In the APAs, the immunostaining 
signal pertaining to AT1R was stronger than that for MasR (Figure 3.2B). We 
cannot provide any information on AT2R because all tested antibodies failed to 
specifically recognize AT2R (at immunoblotting, the antibody detected a band with 




molecular weight different fromthat predicted, and at immunohistochemistry it 
provided staining of the nuclei also). 
 
Figure 3.2. AT1R and MasR protein expression in human adrenal tissue. 
(A) Immunoblotting of AT1R and MasR proteins in APA (n=6) and in the control (n=6). Relative 
quantitation is shown in the bar plots. (B) Representative results of immunostaining for AT1R and MasR 
in the APA (n=3) and control (n=3). Middle panel: negative control. Control: APA-adjacent tissues. 
 




Effects of C21 
C21 at concentrations (ranging from 10−8 to 10−5 M) previously used 37 allowed us 
to investigate the role of selective AT2R activation in CYP11B1 (cortisol synthase) 
and CYP11B2 (aldosterone synthase) gene expression. At low concentrations 
(ranging from 10−8 to 10−6 M), C21 did not affect CYP11B1 and CYP11B2 gene 
expression in HAC15 and H295 cell lines. However, it markedly increased 
CYP11B1 and CYP11B2 gene expression at 10−5 M (Figure 3.3). Moreover, to 
determine if AT2R activation could blunt CYP11B2 expression only when 
aldosterone secretion is enhanced, e.g. in hyperaldosteronism, we stimulated both 
cell lines with 10−7 M Ang II and exposed them to increasing concentrations of C21. 
We found that at low concentration C21 was ineffective, while at high concentration 
(10−5 M) it enhanced the effect of Ang II on CYP11B1 and CYP11B2 gene 
expression in HAC15 cell line (Figure 3.4). Pretreatment of H295 and HAC15 cells 
with the AT1R antagonist irbesartan abolished the effect of Ang II as well as high 
concentrations of C21 at high concentrations on CYP1B1 and CYP11B2 gene 
expression (Figure 3.5). 
The effect of C21 on aldosterone and cortisol production was also investigated in 
APA-adjacent tissue and in APA strips. These experiments showed that both in 
APA-adjacent tissue and in APA, C21 was ineffective at low concentrations, but 
augmented CYP11B2 gene expression at 10−5 M (Figures 3.6A and 3.7A). In both 
tissues, C21 had no effects on Ang II-stimulated CYP11B1 and CYP11B2 gene 
expression (Figures 3.6B and 3.7B). 
Effects of C21 on K+-induced aldosterone synthase gene expression 
As physiologically multiple stimuli drive aldosterone secretion, we sought to 
determine the effect of C21 on CYP11B1 or CYP11B2 gene expression driven by 
K+. H295R cells, which unlike HAC15 are known to be sensitive to K+ 32-34, were 
stimulated with 10−2 M and 2×10−2M K+. As for Ang II, C21 did not blunt K+ -
induced CYP11B1 or CYP11B2 gene expression (Figure 3.8). 
 
 






Figure 3.3. Effects of C21 on CYP11B2 and CYP11B1 gene expression in human 
adrenocortical cell lines 
CYP11B2 and CYP11B1 gene expression after stimulation of HAC15 cells (A) and H295R cells (B) with 
10−7 M Ang II or C21 at 10−8,10−7, 10−6, and 10−5 M concentrations, (mean ± S.D.; n=3 in triplicate). 
*P<0.001 compared with vehicle; **P<0.001 compared with Ang II; #P=0.04 compared with Ang I 






Figure 3.4. Effects of Ang II and C21 on CYP11B2 and CYP11B1 gene expression in 
human adrenocortical cell lines. 
CYP11B2 and CYP11B1 gene expression after treatment of HAC15 cells (A) and H295R cells (B) with 
10−7 M Ang II alone or in the presence of increasing concentrations of C21 (10−8, 10−7, 10−6, and 10−5 M) 
(mean ±S.D.; n=3 in triplicate). *P<0.0001 compared with vehicle; #P<0.01 compared with Ang II. 
 





Given the emerging protective role of the non-canonical pathway of the RAS, which 
is being explored as a target for pharmacological intervention, we investigated this 
pathway in the regulation of the human adrenocortical hormones that are keys for 
Na+ and water balance and, therefore, for blood pressure. Inappropriate 
aldosterone secretion contributes substantively to arterial hypertension and heart 
failure, and thereby to cardiovascular damage and events 38-42. 
Seeking for the components of the protective RAS in the human adrenal cortex, we 
could detect the mRNAs of AT1R, AT2R, MasR, and MrgD in both APA and APA-
adjacent tissue, but we found that AT2R was expressed at lower levels than the 
AT1R, keeping with previous reports 43-45. While AT1R and AT2R expression in 
APA and APA-adjacent tissue were already reported 46-49, MasR expression has 
only recently been demonstrated in rats 50. Thus, the presence of MasR and MrgD 
receptors in the human adrenal gland is a novel finding of this study. 
We investigated the effects of the receptors/pathways involved in the protective 
armof the RAS on aldosterone and cortisol synthesis using a pharmacological 
approach and found no appreciable effect of C21, an AT2R agonist, on CYP11B1 
or CYP11B2 gene expression at concentration ranging from10−8 to 10−6 M. At 
these concentrations, C21 had no effect on aldosterone production even when the 
latter was up-regulated by Ang II, as it occurs clinically in secondary aldosteronism, 
indicating that the cardiovascular protective effects of C21 do not seem to involve a 
blunted aldosterone production. Despite being ineffective at low concentrations, at 
10−5 M concentration C21 markedly increased CYP11B1 and CYP11B2 gene 
expression (Figure 3.3) and enhanced the effect of Ang II on expression of these 
genes in HAC15 cells (Figure 3.4). Moreover, pretreatment with the AT1R 
antagonist irbesartan abolished the effect of Ang II and of high C21 concentrations 
of CYP11B1 and CYP11B2 gene expression (Figure 3.5), suggesting that at 10−5 
M and higher concentrations C21 likely acts as an AT1R agonist. In H295 cells, 
another model commonly used for investigating aldosterone synthesis 31, results 
were similar, indicating that at 10−5 M and higher concentrations C21 likely acts as 
an AT1R agonist. Thus, these results support the following conclusions: at 
concentrations ranging between 10−8 and 10−6M, C21 does not lower basal 
aldosterone or cortisol production, and does not counter-regulate the secretagogue 
effect of Ang II and potassium in the human adrenal cortex. 
We used human adrenocortical strips ex vivo to further challenge the findings 
obtained in the cell lines. We found that at concentrations from 10−8 to 10−6 M C21 
does not affect CYP11B2 expression. Thus, together with the low levels of AT2R 
found in the adrenal, these findings suggest that a major protective role of AT2R 
stimulation is unlikely in the human adrenal cortex and in primary aldosteronism 
due to APA. 
 








Figure 3.5. Effects of C21 on top of the AT1R antagonist irbesartan on CYP11B2 and 
CYP11B1 gene expression in human adrenocortical cell lines 
CYP11B2 and CYP11B1 gene expression after stimulation of HAC15 cells (A) and H295R cells (B) with 
C21 at 10−5 M on top of irbesartan at 10−5 M (mean+−S.D.; n=3 in triplicate). *P<0.001 compared with 
vehicle; **P<0.001 compared with Ang II; #P<0.001 compared with C21. 
HAC15 cells 







Figure 3.6. Effects of C21 on CYP11B2 and CYP11B1 gene expression in human 
adrenocortical tissue 
CYP11B2 and CYP11B1 gene expression after treatment with C21 at 10−5 M (A). CYP11B2 and 
CYP11B1 gene expression after stimulation of human adrenocortical tissues with C21 at 10−8, 10−7, 
10−6, and 10−5 M on top of 10−7 M Ang II (B) (mean ± S.D.; n=4 in duplicate). *P<0.001 compared with 
vehicle 





Figure 3.7. Effects of C21 on CYP11B2 and CYP11B1 gene expression in APA tissue 
CYP11B2 and CYP11B1 gene expression after treatment with C21 at 10−7, 10−6, and 10−5 M 
concentrations (A). CYP11B2 and CYP11B1 gene expression after stimulation of APA with C21 at 10−8, 
10−7, 10−6, and 10−5 M on top of 10−7 M Ang II (B) (mean ±S.D.; n=4 in duplicate). *P<0.01 compared 
with vehicle. 
 





Our results may seem to be in contrast with those of Yatabe et al. 51, who found 
that the selective AT2R agonist CGP42112 increased aldosterone secretion in rat 
adrenal zona glomerulosa cells, and that the AT2R antagonist PD123319 
abolished this effect. Moreover, when they combined candesartan with PD123319, 
the latter seemed to blunt but not abolish Ang II-mediated aldosterone secretion 51. 
However, while in that study no quantitation of AT1R and AT2R was performed, it 
should be acknowledged that the agonistic or antagonistic activity of both 
CGP42112 and PD123319 for AT2R depends on their concentrations, in that these 
agents lose their specificity at high concentrations 52. Of note, the blunting effect of 
PD123319 on Ang II-stimulated aldosterone secretion was significantly weaker 
than that of candesartan. Moreover, both candesartan and PD123319 were able to 
abolish the Ang-II secretagogue effect on aldosterone only when used together at 
10−7 M concentrations, and no experiments with CGP42112 stimulation on top of 
AT1R blockade were performed, not allowing to confirm the specificity of both 
CGP42112 and PD123319 for the AT2R at these concentrations. Thus, besides 
the species-related differences, our results in humans are by no means challenged 
by the studies previously done in rats. Lack of specific antibodies binding to the 
AT2R and non-feasibility of radioactive-based techniques limited our investigation, 
but the functional studies using the antagonists provide compelling evidence for a 
predominant role of the AT1R, although a larger number of experiments in APAs 
can be necessary to conclusively confirm our present findings. 
In conclusion, all the main components of the protective RAS are scantly 
expressed in APA and APA-adjacent tissue. C21, a putative novel therapeutic tool 
for conditions featuring hyperaldosteronism, as heart failure, does not affect 
CYP11B1 or CYP11B2 gene expression at concentrations at which it acts as an 
AT2R agonist. By contrast, it significantly increased CYP11B2 gene expression at 
high concentrations by acting via AT1R. Whether an enhanced expression of 
ACE2, which leads to generation of the MasR agonist Ang-(1–7), plays a role in the 
human adrenal cortex, and whether pharmacological stimulation of this enzyme 
with diminazene aceturate regulates CYP11B2 gene expression are being 
investigated in our laboratory. 
 
 





Figure 3.8. Effects of C21 on K+ induced CYP11B2 and CYP11B1 gene expression in 
H295R cell line 
CYP11B2 and CYP11B1 gene expression after treatment of H295R cells with C 21 at 10−8, 10−7, 10−6, 
and 10−5 M, on top of K+ (10−2 or 2 × 10−2 M concentration) (mean +−S.D.; n=4 in duplicate). *P<0.001 
compared with Vehicle. 
 
 





• The AT2R and MasR play a cardiovascular protective role by counter-regulating 
AT1R-mediated effects in various tissues, but whether they mediate blunting of 
adrenocortical hormone secretion is unknown. 
• Angiotensin receptors AT1R, AT2R, and MasR are expressed in the human 
adrenal cortex and in APA. The AT2 agonist C21 did not affect aldosterone or 
cortisol secretion at low concentrations, but it significantly increased aldosterone 
secretion at high concentrations, likely by acting via the angiotensin AT1R. 
• The cardiovascular protective effects of C21 are unlikely to involve a blunted 
production of adrenocortical hormones. 
  





1. Miller, W.L. and Auchus, R.J. (2011) The molecular biology, biochemistry, and physiology of 
human steroidogenesis and its disorders. Endocr. Rev. 32, 81–151, 
https://doi.org/10.1210/er.2010-0013 
2. Hattangady, N.G., Olala, L.O., Bollag, W.B. and Rainey, W.E. (2012) Acute and chronic     
regulation of aldosterone production. Mol. Cell. Endocrinol. 350, 151–162, 
https://doi.org/10.1016/j.mce.2011.07.034 
3. Guagliardo, N.A., Yao, J., Hu, C. and Barrett, P.Q. (2012) Minireview: Aldosterone byosynthesis: 
electrically gated for our protection. Endocrinology 153, 3579–3586, 
https://doi.org/10.1210/en.2012-1339 
4. Rossi, G.P., Albertin, G., Neri, G., Andreis, P.G., Hofmann, S., Pessina, A.C. et al. (1997) 
Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and 
ETB receptor subtypes. J. Clin. Endocrinol. Metab. 82, 3445–3449, 
https://doi.org/10.1210/jcem.82.10.4279 
5. Rossi, G.P., Ganzaroli, C., Cesari, M., Maresca, A., Plebani, M., Nussdorfer, G.G. et al. (2003) 
Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in 
primary aldosteronism and high-to-normal renin hypertension. Cardiovasc. Res. 57, 277–283, 
https://doi.org/10.1016/S0008-6363(02)00658-2 
6. Perraudin, V., Delarue, C., Lefebvre, H., Contesse, V., Kuhn, J.M. and Vaudry, H. (1993) 
Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of 
V1 receptors. J. Clin. Endocrinol. Metab. 76, 1522–1528 
7. Gallo-Payet, N. and Guillon, G. (1998) Regulation of adrenocortical function by vasopressin. 
Horm. Metab. Res. 30, 360–367, https://doi.org/10.1055/s-2007-978899 
8. Caroccia, B., Menegolo, M., Seccia, T.M., Petrelli, L., Antonello, M., Limena, A. et al. (2017) 
Urotensin II exerts pressor effects by stimulating renin and aldosterone synthase gene 
expression. Sci. Rep. 7, 13876, https://doi.org/10.1038/s41598-017-12613-y 
9. Giuliani, L., Lenzini, L., Antonello, M., Aldighieri, E., Belloni, A.S., Fassina, A. et al. (2009) 
Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: 
novel insights for the pathophysiology of primary aldosteronism. J. Clin. Endocrinol. Metab. 94, 
684–690, https://doi.org/10.1210/jc.2008-1131 
10. Rossi, G.P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C. et al. (2006) A prospective 
study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. 
Cardiol. 48, 2293–2300, https://doi.org/10.1016/j.jacc.2006.07.059 
11. Nakamura, Y., Yamazaki, Y., Konosu-Fukaya, S., Ise, K., Satoh, F. and Sasano, H. (2015) 
Aldosterone biosynthesis in the human adrenal cortex andnassociated disorders. J. Steroid 
Biochem. Mol. Biol. 153, 57–62, https://doi.org/10.1016/j.jsbmb.2015.05.008 
12. Timmermans, P.B., Wong, P.C., Chiu, A.T., Herblin, W.F., Benfield, P., Carini, D.J. et al. (1993) 
Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45, 205–251 
13. Kaschina, E. and Unger, T. (2003) Angiotensin AT1/AT2 receptors: regulation, signalling and 
function. Blood Press. 12, 70–88, https://doi.org/10.1080/08037050310001057 
14. Wintour, E.M ., Moritz, K., Butkus, A., Baird, R., Albiston, , A. and Tenis, , N. (1999) Ontogeny and 
regulation of AT1 and AT2 receptors in the ovine fetal adrenal gland . Mol. Cell. Endocrinol. 157 , 
161–170 , https://doi.org/10.1016/S0303-7207(99)00149-5 
15. Moritz, K.M., Boon, W.C. and Wintour, E.M. (1999) Aldosterone secretion by the mid-gestation 
ovine fetus: role of the AT2 receptor. Mol. Cell. Endocrinol. 157, 153–160, 
https://doi.org/10.1016/S0303-7207(99)00148-3 
16. Chamoux, E., Breault, L., Lehoux, J.G. and Gallo-Payet, N. (1999) Involvement of the angiotensin 
II type 2 receptor in apoptosis during human fetal adrenal gland development. J. Clin. Endocrinol. 
Metab. 84, 4722–4730 
17. Moritz, K.M., Boon, W.C. and Wintour, E.M. (1999) Aldosterone secretion by the mid-gestation 
ovine fetus: role of the AT2 receptor. Mol. Cell. Endocrinol. 157, 153–160, 
https://doi.org/10.1016/S0303-7207(99)00148-3 




18. Yu, L., Zheng, M., Wang, W., Rozanski, G.J., Zucker, I.H. and Gao, L. (2010) Developmental 
changes in AT1 and AT2 receptor-protein expression in rats. J. Renin. Angiotensin Aldosterone 
Syst. 11, 214–221, https://doi.org/10.1177/1470320310379065 
19. Wan, Y., Wallinder, C., Plouffe, B., Beaudry, H., Mahalingam, A.K., Wu, X. et al. (2004) Design, 
synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. 
Chem. 47, 5995–6008, https://doi.org/10.1021/jm049715t 
20. Lucius, R., Gallinat, S., Rosenstiel, P., Herdegen, T., Sievers, J. and Unger, T. (1998) The 
angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. 
J. Exp. Med. 188, 661–670, https://doi.org/10.1084/jem.188.4.661 
21. Kaschina, E., Namsolleck, P. and Unger, T. (2017) AT2 receptors in cardiovascular and renal 
diseases. Pharmacol. Res. 125, 39–47, https://doi.org/10.1016/j.phrs.2017.07.008 
22. Zhao, Y., Lu¨ tzen, U., Fritsch, J., Zuhayra, M., Schu¨ tze, S., Steckelings, U.M. et al. (2015) 
Activation of intracellular angiotensin AT 2 receptors induces rapid cell death in human uterine 
leiomyosarcoma cells. Clin. Sci. 128, 567–578, https://doi.org/10.1042/CS20140627 
23. Santos, R. A.S., Simoes e Silva, A.C., Maric, C., Silva, D. M.R., Machado, R.P., de Buhr, I. et al. 
(2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. 
Natl. Acad. Sci. U.S.A. 100, 8258–8263, https://doi.org/10.1073/pnas.1432869100 
24. Bader, M., Alenina, N., Andrade-Navarro, M.A. and Santos, R.A. (2014) MAS and its related G 
protein-coupled receptors, Mrgprs. Pharmacol. Rev. 66, 1080–1105, 
https://doi.org/10.1124/pr.113.008136 
25. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N. et al. (2000) A 
novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to 
angiotensin 1-9. Circ. Res. 87, E1–E9, https://doi.org/10.1161/01.RES.87.5.e1 
26. Lautner, R.Q., Villela, D.C., Fraga-Silva, R.A., Silva, N., Verano-Braga, T., Costa-Fraga, F. et al. 
(2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin 
system. Circ. Res. 112, 1104–1111, https://doi.org/10.1161/CIRCRESAHA.113.301077 
27. Patel, V.B., Zhong, J.C., Grant, M.B. and Oudit, G.Y. (2016) Role of the ACE2/angiotensin 1-7 
axis of the renin-angiotensin system in heart failure. Circ. Res. 118, 1313–1326, 
https://doi.org/10.1161/CIRCRESAHA.116.307708 
28. Passos-Silva, D.G., Verano-Braga, T. and Santos, R. A.S. (2013) Angiotensin-(1-7): beyond the 
cardio-renal actions. Clin. Sci. (Lond.) 124, 443–456, https://doi.org/10.1042/CS20120461 
29. Mendoza-Torres, E., Oyarzun, A., Mondaca-Ruff, D., Azocar, A., Castro, P.F., Jalil, J.E. et al. 
(2015) ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and 
hypertension. Ther. Adv. Cardiovasc. Dis. 9, 217–237, 
https://doi.org/10.1177/1753944715597623 
30. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N. et al. (2000) A 
novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to 
angiotensin 1-9. Circ. Res. 87, E1–E9, https://doi.org/10.1161/01.RES.87.5.e1 
31. Wang, T., Rowland, J.G., Parmar, J., Nesterova, M., Seki, T. and Rainey, W.E. (2012) 
Comparison of aldosterone production among human adrenocortical cell lines. Horm. Metab. Res. 
44, 245–250, https://doi.org/10.1055/s-0031-1298019 
32. Funder, J.W., Carey, R.M., Mantero, F., Murad, M.H., Reincke, M., Shibata, H. et al. (2016) The 
management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine 
Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 101, 1889–1916, 
https://doi.org/10.1210/jc.2015-4061 
33. Rossi, G.P., Seccia, T.M. and Pessina, A.C. (2007) Clinical use of laboratory tests for the 
identification of secondary forms of arterial hypertension. Crit.Rev. Clin. Lab. Sci. 44, 1–85, 
https://doi.org/10.1080/10408360600931831 
34. Rossi, G.P., Pitter, G., Bernante, P., Motta, R., Feltrin, G. and Miotto, D. (2008) Adrenal vein 
sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone 
excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J. Hypertens. 26, 
989–997, https://doi.org/10.1097/HJH.0b013e3282f9e66a 




35. Caroccia, B., Fassina, A., Seccia, T.M., Recarti, C., Petrelli, L., Belloni, A.S. et al. (2010) Isolation 
of human adrenocortical aldosterone-producing cells by a novel immunomagnetic beads method. 
Endocrinology 151, 1375–1380, https://doi.org/10.1210/en.2009-1243 
36. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402–408, 
https://doi.org/10.1006/meth.2001.1262 
37. Menk, M., Graw, J.A., von Haefen, C., Sifringer, M., Schwaiberger, D., Unger, T. et al. (2015) 
Stimulation of the angiotensin II AT2 receptor is anti-inflammatory in human lipopolysaccharide-
activated monocytic cells. Inflammation 38, 1690–1699, https://doi.org/10.1007/s10753-015-0146-
9 
38. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J. G.F., Coats, A. J.S. et al. (2016) 
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task 
Force for the diagnosis and treatment of acute and chronic heart failure of the European Society 
of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) 
of the ESC. Eur. Heart J. 37, 2129–2200, https://doi.org/10.1093/eurheartj/ehw128 
39. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A. et al. (1999) The effect of 
spironolactone on morbidity and mortality in patients with severe heart failure. Randomized 
Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717, 
https://doi.org/10.1056/NEJM199909023411001 
40. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B. et al. (2003) Eplerenone, a 
selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial 
infarction. N. Engl. J. Med. 348, 1309–1321, https://doi.org/10.1056/NEJMoa030207 
41. Pfeffer, M.A., Claggett, B., Assmann, S.F., Boineau, R., Anand, I.S., Clausell, N. et al. (2015) 
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function 
Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131, 34–42, 
https://doi.org/10.1161/CIRCULATIONAHA.114.013255 
42. Zannad, F., McMurray, J.J.V., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H. et al. (2011) 
Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21, 
https://doi.org/10.1056/NEJMoa1009492 
43. Pawlikowski, M., Winczyk, K. and Sledz, B. (2008) Immunohistochemical detection of angiotensin 
receptors AT1 and AT2 in adrenal tumors. Folia Histochem. Cytobiol. 46, 51–55, 
https://doi.org/10.2478/v10042-008-0006-7 
44. Harada, K., Matsuoka, H., Fujimoto, N., Endo, Y., Hasegawa, Y., Matsuo, A. et al. (2010) 
Localization of type-2 angiotensin II receptor in adrenal gland. J. Histochem. Cytochem. 58, 585–
593, https://doi.org/10.1369/jhc.2010.955575 
45. Wu, Z., Ni, D., Yan, Y., Li, J., Wang, B., Ouyang, J. et al. (2010) Expression of angiotensin II 
receptors in aldosterone-producing adenoma of the adrenal gland and their clinical significance. J. 
Huazhong Univ. Sci. Technolog. Med. Sci. 30, 486–489, https://doi.org/10.1007/s11596-010-
0454-0 
46. Tanabe, A., Naruse, M., Arai, K., Naruse, K., Yoshimoto, T., Seki, T. et al. (1998) Gene 
expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. Horm. 
Metab. Res. 30, 490–495, https://doi.org/10.1055/s-2007-978918 
47. Allen, A.M., Zhuo, J. and Mendelsohn, F.A. (2000) Localization and function of angiotensin AT1 
receptors. Am. J. Hypertens. 13, 31S–38S, https://doi.org/10.1016/S0895-7061(99)00249-6 
48. Pawlikowski, M., Winczyk, K. and Sledz, B. (2008) Immunohistochemical detection of angiotensin 
receptors AT1 and AT2 in adrenal tumors. Folia Histochem. Cytobiol. 46, 51–55, 
https://doi.org/10.2478/v10042-008-0006-7 
49. Wu, Z., Ni, D., Yan, Y., Li, J., Wang, B., Ouyang, J. et al. (2010) Expression of angiotensin II 
receptors in aldosterone-producing adenoma of the adrenal gland and their clinical significance. J. 
Huazhong Univ. Sci. Technolog. Med. Sci. 30, 486–489, https://doi.org/10.1007/s11596-010-
0454-0 




50. Shefer, G., Marcus, Y., Knoll, E., Dolkart, O., Foichtwanger, S., Nevo, N. et al. (2016) Angiotensin 
1-7 is a negative modulator of aldosterone secretion in vitro and in vivo. Hypertension 68, 378–
384, https://doi.org/10.1161/HYPERTENSIONAHA.116.07088 
51. Yatabe, J., Yoneda, M., Yatabe, M.S., Watanabe, T., Felder, R.A., Jose, P.A. et al. (2011) 
Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 
2 receptor but not angiotensin II type 1 receptor. Endocrinology 152, 1582–1588, 
https://doi.org/10.1210/en.2010-1070 
52. de Gasparo, M., Whitebread, S., Criscione, L., Buehlmayer, P. and Furet, P. (2017) The AT2 
receptor: historical perspective. The Protective Arm of the Renin Angiotensin System (RAS): 










































For : 5’-atgattccagcgcctgac- 3’ 
Rev : 5’- ggtccagacgtcctgtcact- 3’ 
AT2R 
NM_000686.4 
For: 5’- ggtttctagcatatacatcttcaacct- 3’ 
Rev: 5’- ttgcccatagaggaagagtagc- 3’ 
MasR 
NM_002377.2 
For: 5’- ttcgctatgcccatgagact- 3’ 
Rev: 5’- tggtgtaggttcccaaaggt- 3’ 
MrgD 
NM_198923.2 
For: 5’- cgtggaccttgtcagtggta- 3’ 







For: 5’- ttcagccgccctcaaca- 3’ 




Rev: 5’- agatggctccgatggtga -3 
































Macrolides blunt aldosterone biosynthesis 


























Aldosterone-producing adenoma, a major subtype of primary hyperaldosteronism, 
the main curable cause of human endocrine hypertension, involves somatic 
mutations in the potassium channel Kir3.4 (KCNJ5) in 30-70% of cases, typically 
the more florid phenotypes.  Since KCNJ5 mutated channels were reported to be 
specifically sensitive to inhibition by macrolide antibiotics, which concentration-
dependently blunt aldosterone production in HAC15 transfected with the G151R 
and L168R mutated channel, we herein tested the effect of clarithromycin on 
aldosterone synthesis and secretion in a pure population of aldosterone-secreting 
cells obtained by immunoseparation (CD56+ cells) from aldosterone-producing 
adenoma tissues with/without the two most common KCNJ5 mutations.  From a 
large cohort of patients with an unambiguous aldosterone-producing adenoma 
diagnosis we recruited those who were wild-type (n=3), or had G151R (n=2) and 
L168R (n=2) mutations.  We found that clarithromycin concentration-dependently 
lowered CYP11B2 gene expression (by 60%) and aldosterone secretion (by 70%) 
(p<0.001 for both) in CD56+ cells isolated ex vivo from KCNJ5-mutated 
aldosterone-producing adenomas, while it was ineffective in CD56+ cells from wild-
type aldosterone-producing adenomas.  By proving the principle that the over 
secretion of aldosterone can be specifically blunted in aldosterone-producing 
adenoma cells ex vivo with G151R and L168R mutations, these results provide 
compelling evidence of the possibility of specifically correcting aldosterone excess 
in patients with aldosterone-producing adenoma carrying the two most common 














In 2011 Choi et al.1 identified mutations in the Kir 3.4 (KCNJ5) K+ channel in about 
one third of 24 aldosterone-producing adenoma (APA), which were shown to lead 
to a loss of selectivity for Na+ and thus to Ca2+ influx, via opening of T-type calcium 
channel and activation of the Na+/Ca2+ exchange 2,3, and thus increased 
aldosterone production. Of note, these mutations were found to involve from 30% 
to 70% of all APA in a very large meta-analysis, albeit with marked geographic 
variations 4. 
Some macrolide antibiotics and their derivatives were recently shown to correct the 
altered electrophysiology of HEK293T cells transfected with the L168R and G151R 
KCNJ5 mutated Kir3.4 channel, and to concentration-dependently lower 
aldosterone synthesis in HAC15, an adrenocortical carcinoma cell line transfected 
to overexpress these mutated channels 5. Notably, these effects were suggested to 
be specific in that they were not seen in the same cells carrying the wild type Kir 
3.4 channel 5. These seminal discoveries might open the way to personalized 
diagnosis and treatment of primary aldosteronism, the most common, albeit often 
overlooked, form of secondary arterial hypertension 6, which carries an excess 
cardiovascular damage, as well as a worse outcome 7,8. In fact, if these in vitro 
findings could be confirmed in vivo, the fall of plasma aldosterone concentration 
(PAC) after administration of a macrolide antibiotic might represent a proxy for the 
presence of an APA carrying a KCNJ5 mutation.  Likewise, if associated with a 
blood pressure lowering, this PAC fall would suggest the feasibility of controlling 
the aldosteronism and arterial hypertension with a macrolide or derivatives devoid 
of antibiotic activity. 
As APA are known to be highly heterogeneous at the molecular level 9, and 
therefore could respond differently to stimuli and drugs, a first inevitable step 
toward these clinical applications is to prove that the effects seen in these two 
models of genetically engineered cell lines, which are far from APA cells, do occur 
also in the APA cells taken ex vivo from APA patients.  Therefore, by taking 
advantage of the availability of primary culture of aldosterone-producing cells 
isolated ex vivo from wild-type APA and from G151R and L168R mutated APA, we 
conducted a pilot study to test the effect on aldosterone synthase (CYP11B2) gene 
expression and aldosterone production of clarithromycin, one of the macrolides that 
effectively corrected the altered electrophysiology of G151R and L168R 
overexpressing HEK293T cells 5. 
Methods 
Patients  
From a large databank of cells from APA patients we selected for this study a total 





“four corners criteria” 6. Approval for this study was obtained from the Ethics 
Committee of the University of Padova and all participants gave informed written 
consent to the study and to the use of their adrenocortical specimen; all procedures 
followed the Helsinki Declaration Principles. 
 
Table 4.1 Demographic and Clinical Features of the APA Patients and Diagnostic 
Indexes 
Data presented as mean±SD or median (IQR), as appropriate. Normal values: SK+ : 3.5–4.5 mmoL/L; 
on a Na+ intake 200–300 mmoL/d: DRC: 2.5–32 mUL/L; PAC: <15.0 ng/dL; ARR <2.06 
(ng/dL)/(mUI/L).12 The predominant pattern at histopathology (% ZF like/ZG like/mixed) is also indicated. 
Statistical significance was not calculated because of the small number of cases. APA indicates 
aldosterone-producing adenoma; ARR, aldosterone–renin ratio; BP, blood pressure; DRC, direct renin 
concentration; N.A., not applicable; PAC, plasma aldosterone concentration; serum K+ , serum 
potassium levels; U-Na+ , urinary Na+ ; ZF, zona fasciculata; and ZG, zona glomerulosa. 
*At pathology. 
Detection of KCNJ5 mutations 
DNA was extracted from APAs removed from the consecutive APA patients 
referred to our specialized hypertension center with a standard procedure as 
reported 10. PCR was performed on 250 ng DNA in a final volume of 50 µl 
containing 300 nM MgCl2, 400 nM of each primer, 200 µM deoxynucleotide 
triphosphate, and 2.6 U expand high-fidelity enzyme mix (Roche Applied Science, 
Milan, Italy).  Purified PCR products underwent direct Sanger sequencing using the 
ABI Prism Big Dye Terminator version 3.1 cycle sequencing kit (Applied 
Biosystems, Foster City, CA) on an ABI Prism 3700 DNA analyzer (Applied 
Biosystems, Foster City, CA).  
Isolation of aldosterone producing cells  
Dispersed APA cells were obtained by sequential enzymatic digestion, mechanical 
disaggregation and incubation in 5 mL of Krebs Ringer solution supplemented with 
2 mg/mL collagenase-I, 0.1 mg/mL deoxyribonuclease-I, 4% bovine serum albumin 
at 37°C for 40 min with gentle shaking.  Single-cell suspension obtained was 





washed with PBS containing 0.1% BSA and then incubated with CD56 pre-coated 
magnetic beads by gentle shaking for 1 hour at 4°C.  Beads were used at a ratio of 
5 beads per cell 11. After separating the bead-bound CD56–positive (CD56+) cells 
with a magnet, the CD56+ cells were seeded at a density of 104 cells/cm2 into 24-
well plates and treated with 5 umol/L, 20 umol/L or 50 umol/L of clarithromycin. 
Electron microscopy 
Freshly immunoseparated CD56+ APA cells were fixed in 3% phosphate-buffered 
glutaraldehyde and processed following a standard protocol, as described.12  
CYP11B2 gene expression quantification 
CYP11B2 mRNAs were measured in duplicate in CD56+ APA cells after incubation 
for 18 hours in DMEM-F-12 medium with 5% FBS added with increasing 
concentrations of clarithromycin.  
After treatment, the cells were lysed and mRNA was isolated using the high-pure 
RNA isolation kit (Roche Applied Science, Milan, Italy).  Gene expression was 
quantified by real-time RT-PCR with universal probe library probes in the 
LightCycler 480 instrument (Roche Applied Science, Milan, Italy) using the 
comparative cycle threshold (2-ΔΔCt) method and the porphobilinogendeaminase 
(PBGD) as reference gene.  
 
Aldosterone measurement  
Aldosterone levels were quantified by an aldosterone ELISA kit (Alpha Diagnostic 
International, San Antonio, Texas).  A total of 50 μL of cell medium was added to 
aldosterone-coated wells following the manufacturer’s instructions; the signal was 
detected in an ELISA Reader (Berthold Technologies, Milan, Italy).  Aldosterone 
levels were normalized to the amount of cell RNA content. 
 
Statistical analysis  
Data are expressed as mean and SD.  One-way ANOVA followed by Bonferroni’s 
post hoc test and repeated measure ANOVA were used to test the effect of 
clarithromycin and its increasing concentration amongst APA groups.  The non-
parametric Mann Whitney test was used to compare CD56+ and CD56- cells for 
quantitative variables.  Significance was set at p< 0.05.  The GraphPad for Mac 
(vers. 6.0 GraphPad Software, Inc., San Diego, CA) and SPSS (version 24 for 








Characteristics of the APA patients.   
We selected seven PA patients, who were unambiguously diagnosed with APA by 
the “four corners criteria” 6; of them 3 were found to be wild-type, 2 had G151R and 
2 had L168R mutations at sequencing.  All showed the florid PA phenotype 
expected in APA patients, with no clear-cut differences among genotypes from the 
clinical standpoint (Table 4.1).  By definition all were biochemically cured of PA and 
became normotensive without treatment after unilateral adrenalectomy.  
Figure 4.1. Characterization of aldosterone-producing adenoma (APA) CD56+ cells. 
A,The bar graph shows that the relative expression of CYP11B2 gene expression was significantly 
higher in CD56+ than in CD56− cells isolated from APA. Data represent mean±SD, n=7, *P=0.01 by 
Mann–Whitney test. B, Representative electron microscopy pictures of CD56+ APA wild-type cells 
showing binding to CD56 precoated beads. CD56 + APA cells are characterized by the presence of 
mitochondria with tubule-vesicular cristae, abundant lipid droplets, some liposome, all of which are the 
typical features of steroidogenic aldosterone-producing cells (B, n=3). Magnification: ×20 000. B 
indicates bead; L, lysosomes; Ld, lipid droplets; M, mitochondria; and N, nucleus. 
 
Characterization of APA CD56+ cells   
Real-time PCR showed that expression of CYP11B2 was 21.23 ± 9.15-fold 
(p=0.01) higher in CD56+ cells than in CD56− cells isolated from APA cells (Figure 
4.1, panel A, n=7).    Electron microscopy demonstrated that dispersed CD56+ APA 
cells were selectively bound to CD56-precoated beads. These cells showed the 
classical features of steroidogenic aldosterone-producing APA cells 13, e.g. 
abundant mitochondria with tubule-vesicular cristae, abundant lipid droplets, some 
liposomes, and smooth endoplasmic reticulum (SER) profiles (Figure 4.1, panel B).   
 





Effect of clarithromycin on CYP11B2 gene expression and 
aldosterone release  
Compared to the CD56+ cells isolated from the wild-type APA, the G151R and 
L168R mutated APA showed a significantly higher in vitro production of 
aldosterone (Figure 4.2, panels B and D).  When CD56+ cells isolated from G151R 
mutated (Figure 4.2 panel A, circle symbols) and L168R APAs (Figure 4.2 panel A, 
square symbols) were exposed to increasing concentrations [5 to 50 umol/L] of 
clarithromycin, we found a consistent concentration-dependent blunting effect of 
clarithromycin on both CYP11B2 gene expression (Figure 4.2, panel A) and 
aldosterone release  (Figure 4.2, panel B), which did not occur in wild-type APA 
cells (Figure 4.2 panel A and B, triangle symbol).  No differences in CYP11B2 gene 
expression changes and the aldosterone production lowering between the G151R 
and the L168R mutated APA cells were seen at post hoc Bonferroni’s test.  
Therefore, the results obtained in the mutated APA cells were examined jointly and 
compared to the wild-type APA cells (Figure 4.2, panels C and D).  This showed a 
highly significant (p<0.001) effect of clarithromycin concentration and group at 








Figure 4.2. Effects of clarithromycin on aldosterone in wild-type and mutated KCNJ5 
aldosterone-producing adenoma (APA). A and B, Average values of CYP11B2 gene 
expression (A) and aldosterone production (B) obtained from the CD56+ APA cells. Clarithromycin 
concentration dependently blunts CYP11B2 gene expression and aldosterone release in CD56+ cells 
isolated from G151R mutated (circle symbols, n=2) and L168R APAs (square symbols, n=2) but not in 
those wild-type APAs (triangle symbols, n=3). Each experiment was performed in duplicate: please note 
the consistency of the findings. Aldosterone production was significantly higher at baseline in the 
KCNJ5 mutated than in wild-type APA (*P<0.01). Given the similar response to clarithromycin of G151R 
and L168R APA cells, the downstream analysiswas performed by cumulating these 4 APA together (C 
and D). At repeated measures ANOVA, there was a highly significant (P<0.001) lowering of both 
CYP11B2 mRNA and aldosterone production in the mutated group and a highly significant (P<0.001) 
difference of the change when compared with wild- type APA cells. 0 denotes exposure to vehicle. Data 
represent mean±SD. 






In this proof-of-principle study we selected seven patients, who were 
unambiguously diagnosed with APA by the “four corners criteria”, as confirmed by 
biochemical cure of PA and normotension without treatment after unilateral 
adrenalectomy 6. They showed the florid PA phenotype expected in APA patients, 
but no clear-cut differences among genotypes from the clinical standpoint.  Of 
them, 3 were found to be wild-type, 2 had G151R and 2 had L168R mutations at 
sequencing.  The APA tissue obtained at adrenalectomy was used to obtain 
dispersed APA cells from which a pure population of aldosterone-secreting cells 
could be immunoseparated using CD56 pre-coated magnetic beads, as described 
in detail11.   
When exposed to increasing concentrations of clarithromycin the CD56+ cells 
obtained from wild-type APAs showed no change of CYP11B2 gene expression 
and aldosterone secretion in response to the macrolide (Figure 4.2).  By contrast, 
both G151R or L168R APA cells exposed to clarithromycin showed a 
concentration-dependent consistent blunted expression of the aldosterone 
synthase gene (CYP11B2), the step-limiting enzyme, which in a 3-step process 
converts deoxycorticosterone to aldosterone in the mitochondria.  Moreover, both 
G151R and L168R mutated CD56+ APA cells, which exhibited a higher in vitro 
production of aldosterone than wild-type APA cells at baseline in keeping with the 
literature 4,14, showed a concentration-dependent consistent brisk fall also of 
aldosterone release (Figure 4.2, panels B and D).   Therefore, these experiments 
extend the finding obtained in vitro in the HAC15 cell line engineered to over 
express the mutated G151R and L168R Kir3.4 channel 5, to APA cells obtained ex 
vivo, which had these two common somatic mutations. 
Perspectives 
These results, albeit obtained in a small dataset, provide compelling evidence of 
the feasibility of blunting aldosterone synthesis specifically in aldosterone-
producing cells from tumors carrying two most common KCNJ5 mutations. 
Whether these effects occur in all KCNJ5 mutated APA cells and whether they can 
happen in vivo in patients with KCNJ5 mutated APA, and whether the lowering of 
PAC and blood pressure after acute administration of a macrolide can be a proxy 
for pinpointing the PA patients harboring a mutated APA is the currently under 
investigation at our center. If proven, this principle will open the way to 
personalized diagnosis and treatment of the PA patients, who show the most florid 










What Is New?  
This study extends to aldosterone-producing cells obtained ex vivo from tumors 
carrying two most common KCNJ5 mutations and to clarithromycin the observation 
that roxithromycin, another macrolide, blunts aldosterone synthesis specifically in 
genetically engineered HAC15 cells. 
What Is Relevant? 
Macrolides and their derivatives devoid of antibiotic activity may be a novel 
diagnostic and therapeutic tool for blunting aldosterone synthesis specifically in 
aldosterone-producing cells from tumors carrying two most common KCNJ5 
mutations. 
Summary 
In a pure population of aldosterone-producing cells isolated ex vivo from KCNJ5-
mutated APAs, clarithromycin specifically blunted aldosterone secretion, while it 
was ineffective in CD56+ cells from wild-type APAs.  This discovery opens new 
horizons for the diagnosis and treatment of APA with KCNJ5 mutations, which 
entail the most common and severe cases of PA.   
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Context: The G protein–coupled estrogen receptor (GPER) mediates an 
aldosterone secretagogue effect of 17b-estradiol in human HAC15 adrenocortical 
cells after estrogen receptor b blockade. Because GPER mediates 
mineralocorticoid receptor-independent aldosterone effects in other cell types, we 
hypothesized that aldosterone could modulate its own synthesis via GPER 
activation. 
Methods: HAC15 cells were exposed to aldosterone in the presence or absence of 
canrenone, a mineralocorticoid receptor antagonist, and/or of the selective GPER 
antagonist G36. Aldosterone synthase (CYP11B2) mRNA and protein levels 
changes were the study end points. Similar experiments were repeated in strips 
obtained ex vivo from aldosterone-producing adenoma (APA) and in GPER-
silenced HAC15 cells. 
Results: Aldosterone markedly increased CYP11B2 mRNA and protein expression 
(vs untreated samples, P<0.001) in both models by acting via GPER, because 
these effects were abolished by G36 (P<0.01) and not by canrenone. GPER-
silencing (P< 0.01) abolished the aldosterone-induced increase of CYP11B2, thus 
proving that aldosterone acts via GPER to augment the step-limiting mitochondrial 
enzyme (CYP11B2) of its synthesis. Angiotensin II potentiated the GPER-mediated 
effect of aldosterone on CYP11B2. Coimmunoprecipitation studies provided 
evidence for GPER- angiotensin type-1 receptor heterodimerization. 
Conclusion: We propose that this autocrine-paracrine mechanism could enhance 
aldosterone biosynthesis under conditions of immediate physiological need in 
which the renin-angiotensin- aldosterone system is stimulated as, for example, 
hypovolemia. Moreover, as APA overexpresses GPER this mechanism could 
contribute to the aldosterone excess that occurs in primary aldosteronism in a 
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Introduction  
The mechanisms regulating aldosterone biosynthesis remain incompletely known 
despite several decades of investigation (for review 1).  For example, what causes 
the inappropriate over-secretion of aldosterone in primary aldosteronism (PA), the 
most common cause of endocrine hypertension where the renin-angiotensin 
system is shut off 2,remained unknown until agonistic autoantibodies against the 
angiotensin type 1 receptor 3,4, elevated serum levels of PTH 5 that stimulates 
aldosterone secretion 6, downregulation of TWIK-related acid-sensitive K1 channel 
2 7, and somatic and germline loss- and gain-of-function mutations in both cations 
and anions channels 8-13 were discovered (for review 1,14,15).  
Multiple observations have also suggested a role for estrogens in the regulation of 
aldosterone under physiological and pathophysiological conditions 16-19.  
Accordingly, GPER, a G-protein coupled receptor initially described as an 
estrogen-specific receptor 20-22, but subsequently discovered to promiscuously bind 
other steroids23, and to mediate mineralocorticoid receptor (MR)-independent 
aldosterone effects in different cell types 24-28, was found to be overexpressed in 
aldosterone-producing adenoma (APA), a main subtype of human PA29.  In human 
adrenocortical cells we previously observed that GPER mediates a potent 
secretagogue effect of 17β-estradiol (E2) on aldosterone when the estrogen β 
receptor (ERβ) is pharmacologically blocked or molecularly silenced 29.  Based on 
evidences suggesting the possibility of promiscuous activation of GPER by steroids 
other than E2 , we hypothesized that aldosterone could activate GPER and act as 
its own secretagogue.  If proven, this mechanism could be relevant for rapidly and 
potently enhancing the biosynthesis of aldosterone when the renin-angiotensin-
aldosterone system is stimulated.  It could be also important for understanding the 
autonomous aldosterone production in human PA 2,30.  Hence, by acting in an 
autocrine-paracrine fashion in GPER-overexpressing APA 29,31, that generate high 
local concentrations of the hormone, aldosterone could self-perpetuate the 
hyperaldosteronism despite a blunted renin-angiotensin system.  This study was, 
therefore, set up to test in vitro this hypothesis using two different models that are 
characterized by sizable differences of aldosterone production, i.e. a human 
adrenocortical carcinoma cell line that produces relatively small amounts of 
aldosterone, and strips obtained ex vivo from APA that produce substantial 
amounts of aldosterone. 
Methods 
Adrenocortical cell line HAC15 
Adrenocortical cell line HAC15, a gift of William E. Rainey (University of Michigan 
at Ann Arbor, USA), was grown in Dulbecco’s Modified Eagle Medium (DMEM F12) 
supplemented with 10% Cosmic Calf serum (CCS), 1% glutamine, and 1% 




antibiotic/antimycotic mixture.  For the experiments, the cells were seeded in 12-
well plates at 2*105 cells per well and grown to sub-confluence (80%).  Prior to 
experiment, they were synchronized by incubation for 24 hours with DMEM/F12 
medium supplemented with 0.5% dextran-coated charcoal-stripped CCS, 1% 
glutamine, and 1% antibiotic/antimycotic.  Cells were treated with increasing 
concentrations of aldosterone (from 10-11 to 10-7 M; Sigma-Aldrich, Milan, Italy) for 
12 hours.   The treatment with 10-7 M aldosterone was then performed at different 
time points (2, 8, 12, 24, 48 hours).  To establish if aldosterone effect was 
mediated by mineralocorticoid receptor, glucocorticoid receptor or GPER receptor, 
the selective MR antagonist, canrenone (10-5 M; Sigma-Aldrich, Milan, Italy), or the 
selective GR antagonist RU486 (10-6 M or 10-5 M; generous gift of Prof. 
Massimiliano Caprio), or the selective GPER antagonist G3632 (10-5 M; Tocris 
Bioscience, Bristol, UK),  were added to fresh media 1 hour before aldosterone 
treatment.   
To establish if angiotensin type-1 receptor (AT1R) and GPER activation interacted 
in altering CYP11B2 expression and if these two receptors formed heterodimers, 
HAC15 cells were treated for 12 hours with aldosterone 10-7 M on top of 
angiotensin II (Ang II) 10-7 M, in the absence or presence of the selective AT1R 
antagonist irbesartan, G36, and of both antagonists. 
Tissues 
APA tissues were obtained from consenting patients with a conclusive diagnosis of 
APA, as established by the five corner criteria, which include i) biochemical 
evidence of PA; ii) lateralized aldosterone secretion by adrenal vein sampling; iii) 
detection of an adenoma by imaging (TC or MR) and at pathology; iv) biochemical 
correction of PA after adrenalectomy; v) detection of a CYP11B2-positive adenoma 
in the resected adrenal cortex at immunohistochemistry with a monoclonal antibody 
for human CYP11B2 1,2. 
Briefly, tissues were obtained under sterile conditions in the operating room 
immediately after excision.  For the functional studies, APA tissues were cut into 2 
to 3-mm strips, which were transferred into 48-well plates containing 500 uL of 
serum-free DMEM/F12 culture medium.  After 6 hours of starvation, the strips were 
treated with 10-7 and 10-8 M aldosterone alone or in presence of 10-5 M G36.  All 
procedures were approved by the local Ethics Committee and informed written 
consent was obtained from each individual patient. 
RNA extraction and quantitative real-time PCR 
RNA from cells was extracted after treatments with the Roche RNeasy kit (Roche, 
Monza, Italy) and RNA from tissues with Qiagen RNA extraction kit (Qiagen, 
Hilden, Germany) following the manufacturer’s protocol.  The quantity and quality 
were also determined by spectrophotometric readings at 260/280/230 nm.    
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One µg total RNA from cells and from tissues was reverse transcribed in a final 
volume of 20 μL using the iScriptTM cDNA Synthesis kit (Bio-Rad, Milan, Italy) 
following the manufacturer’s recommendations.  The RT-PCR reactions were 
performed in Delphi 1000TM Thermal Cycler (Oracle BiosystemsTM Watertown, MA, 
USA).  We measured the levels of aldosterone synthase (CYP11B2) mRNA with a 
real time RT-PCR by the comparative Ct (2-ΔΔCt) method: each sample was 
quantified vs its housekeeping gene transcript, porphobilinogen deaminase 
(PBGD), and normalized to the control group.  Each experiment was repeated at 
least 5 times in duplicate, and the results are presented as fold increase ± SD.  
Primers used in real time RT-PCR are reported in are reported in an online 
repository 33.   
Immunoblotting  
Immunoblotting for CYP11B2, GPER and AT1R was performed following a 
standard protocol.  In brief, after treatment, cells were homogenized in lysis buffer 
(Thermo Scientific, Milan, Italy) and protein concentration was determined in the 
soluble supernatant with BCA (Thermo Scientific, Milan, Italy).  Lysate fraction (50 
µg) was separated in a polyacrylamide gel and then electro-blotted onto 
nitrocellulose or polyvinyldene fluoride (PVDF) membrane (Amersham-Hybond EC, 
GE Healthcare Life Sciences, Milan, Italy).  The membranes were blocked for 30 
minutes at room temperature in 5% non-fat dry blocking milk and thereafter 
incubated overnight at 4°C with a primary mouse monoclonal antibody CYP11B234 
(diluted 1/500) or GPER or AT1R.  After washing, membranes were incubated 1 
hour with an anti-mouse secondary antibody.  After that, the band intensity was 
measured in a VersaDoc Imaging System (Bio-Rad, Milan, Italy).  Images were 
analyzed by Image Processing and Analysis in Java (Image J- NIH).  Bands for 
CYP11B2 were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). 
Small interfering RNA (siRNA)  
The expression of GPER was silenced in HAC15 cells by RNA interference using 
the Nucleofector technology (Amaxa Biosystems, Thermo Scientific, Milan, Italy) 
following the manufacturer's protocol.  To silence GPER, HAC15 were transfected 
with 50 nM ON-TARGET plus GPER siRNA (GPER siRNA; Dharmacon, Carlo 
Erba Reagents, Milan, Italy). An ON-TARGET plus Non-targeting Pool 
(Dharmacon, Carlo Erba Reagents, Milan, Italy) transfection in mock-transfected 
cells was used as control.  Cells were seeded in 6-well culture plates at the density 
of 1 × 106 cells per well.  After 24 hours of transfection, mock-transfected and 
silenced cells were treated with aldosterone.  Protein extraction was performed 
after 24 hours of treatment and followed by immunoblotting analysis for GPER and 
CYP11B2. 




Cytosolic Ca2+ measurements in CD56+ cells 
A pure population of aldosterone-secreting cells from APA was obtained by 
sequential enzymatic digestion and immune-separation of CD56+ cells on magnetic 
beads pre-coated with an antibody specific for neural cell adhesion molecule 
tissues from 3 patients, as previously reported 35.  At electron microscopy we 
showed that these CD56+ cells had a high content in mitochondria and lipid 
droplets, thus entailing the ultrastructural features of aldosterone-producing cell.  
Moreover, they also showed aldosterone production in vitro 35,36.  CD56+ cells were 
plated on L-polylysine pre-coated coverslips two day before the experiments.  Cells 
were loaded with 2 µM Fura-2-AM (Life Technologies, Milan, Italy) diluted in Krebs-
Ringer modified buffer containing 0.02% pluronic acid and 250 µM sulfinpyrazone 
for 20 min at 37°C and then washed two times for 10 min with Krebs-Ringer 
modified buffer.  Images were acquired every 2 s with a Nikon Ti-E microscope 
equipped with a Nikon 20x air objective (Nikon, Tokyo, Japan) and the software 
used for the acquisition was NIS Element AR (Nikon).  Exposure time was set to 
100 ms.  Excitation was performed with a Cairn OptoScan equipped with a 150W 
Xenon arc lamp.  Changes in Fura-2 fluorescence (340/380 nm ratio) were 
expressed as R/R0, where R is the ratio at time t and R0 is the ratio at the 
beginning of the experiment.  CD56+ cells from APA tissues were treated with 
aldosterone, Ang II and 17 β-estradiol (E2), the two latter used as control. 
Aldosterone measurement in human adrenocortical tissues 
We measured aldosterone levels in APA-adjacent tissue and in APA to determine 
how the concentration of aldosterone that increased CYP11B2 expression in our in 
vitro experiments compared with those occurring in vivo in these tissues.  To this 
end, adrenal tissue samples (10-20 mg wet weight per sample) were grinded under 
liquid nitrogen.  The obtained frozen tissue powder was then rapidly dissolved in 
ice-cold guanidine hydrochloride (6 mol/L) supplemented with 1 % (v/v) TFA at a 
100 mg tissue/mL concentration.  Resulting homogenates were spiked with 500 pg 
of deuterated aldosterone (D4) for internal standardization.  Following C18-based 
solid phase extraction, samples were analyzed by UPLC-MS/MS using a reversed 
phase analytical column operating in line with a Xevo TQ-S mass spectrometer 
(Waters, Milford, MA).  The tissue concentration of aldosterone was 
calculated considering the corresponding response factors determined in 
calibration curves in tissue extract matrix, under condition in which the integrated 
signals exceeded a signal to-noise ratio of 10.  
Coimmunoprecipitation studies 
Interaction between AT1R and GPER was investigated in HAC15 cells using 
Pierce Co-Immunoprecipitation Kit (Thermofisher, Milan, Italy) and following the 
manufacturer’s protocol, as described in detail in an online repository 33.  HAC15 
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cells harvested from four 15 cm culture dishes were centrifuged and pelleted.  Cell 
pellet was dissolved into the solution for protein isolation.  For co-
immunoprecipitation studies, protein complexes were immunoprecipitated with anti-
AT1R (Cusabio, Paris, France) or anti-GPER antibody (Novus biologicals, Milan, 
Italy).  The presence of GPER in AT1R immunoprecipitated protein was 
investigated with immunoblot; the presence of AT1R in GPER immunoprecipitated 
protein was also verified with immunoblot. 
Statistical analysis 
Statistical analysis was performed with GraphPad Software™ (vers. 8.02 for Mac 
OS X, La Jolla, CA).  Non-parametric Mann Whitney test or one-way ANOVA test 
and repeated-measures ANOVA were used, as appropriate. 
Results 
Aldosterone treatment enhances CYP11B2  
In concentration-response and time-course experiments for up to 48 hours in 
HAC15 cells, we found that aldosterone enhanced CYP11B2 gene expression at 
10-8 and 10-7 M and that this effect was clearly evident after 12 hours (Figure 5.1 
panel A and B).  The latter concentration and time point were therefore used to 
analyze the changes of CYP11B2 mRNA and protein in the further experiments in 
HAC15 cells.   
To investigate the role of the MR in mediating CYP11B2 gene expression changes 
we preincubated HAC15 cells with either the MR antagonist canrenone, or the 
GPER antagonist G36.  At concentration between 10-6 - 10-4 M canrenone alone 
slightly, but significantly, increased CYP11B2 mRNA (Figure 5.1, panel D) 33, but 
blunted CYP11B2 expression at 10-3 M 33.   
Cell viability studies carried out in parallel in HAC15 cells showed a cytotoxic effect 
of canrenone at the latter concentration 33.  Importantly, at 10-5 M, i.e. a 
concentration 100-fold higher than that of aldosterone, but not cytotoxic, canrenone 
did not blunt aldosterone-induced CYP11B2 mRNA increase.  By contrast, 1-hour 
pretreatment with 10-5 M G-36 abolished the CYP11B2 gene expression enhanced 
by aldosterone (Figure 5.1, panel D). 
To rule out the possibility that at 10-8 M - 10-7 M aldosterone could activate the 
glucocorticoid receptor (GR) 37, we treated HAC15 cells with the GR antagonist 
RU486 at two different concentrations (10-6 M - 10-5 M), alone or in the presence of 
aldosterone.  RU486 neither affected by itself CYP11B2 gene expression, nor did it 
alter aldosterone-induced CYP11B2 gene expression 33. 
The stimulatory effect of aldosterone on CYP11B2 was confirmed at protein levels: 
HAC15 cell exposure to aldosterone for 24 hours increased CYP11B2 protein 




expression, while G-36 abolished this increase, and canrenone left it unaffected 
(Figure 5.1, panel E). 
Practically identical results were found in strips obtained ex vivo from two female 
and two male APA patients upon exposure to 10-7 and 10-8 M aldosterone 
concentrations: the hormone augmented CYP11B2 gene expression; this effect 
was prevented by G-36 but not by canrenone, that per se elicited no effects (Figure 
5.1, panel C).  
Importantly, in parallel experiments the changes in CYP11B2 gene expression 
were found to be consistently associated with aldosterone release in the medium 
33.   
GPER silencing blunted aldosterone-induced CYP11B2 protein 
expression 
We used siRNA technology to confirm the finding that GPER modulates 
aldosterone synthase expression after aldosterone treatment.  After 48 hours 
transfection GPER-silenced HAC15 cells showed a 50% significant reduction of 
GPER protein expression, as compared to control HAC15 cells mock-transfected 
with non-targeting siRNA (Figure 5.2, panel A).  In the GPER silenced cells 10-7 M 
aldosterone induced no increase of CYP11B2 protein expression after 24-hour, 
thus confirming that the aldosterone-activated CYP11B2 expression was GPER-
mediated (Figure 5.2, panel B). 
Cytosolic Ca2+ measurements 
We measured cytosolic Ca2+ levels after exposure to 10-7 M  aldosterone to gain 
insight into the pathways downstream GPER activation, using the ratiometric Fura-
2 Ca2+ indicator and E2 and Ang II, as controls, in CD56+ cells freshly isolated from 
APA.   We found that, although exposure to 10-8 M Ang II caused a significant 
increase of cytosolic Ca2+ that was followed by prominent Ca2+ oscillations (Figure 
5.2, panel C), cytosolic Ca2+ was not affected by E2 or by aldosterone, indicating 
that the GPER-mediated stimulatory effect of these steroids on CYP11B2 gene 
expression does not involve detectable increases of cytosolic Ca2+ (Figure 5.2, 
panel C).   
 
Aldosterone concentration in human adrenocortical tissues ex vivo  
To investigate how the concentrations of aldosterone that elicited a clear-cut effect 
on CYP11B2 mRNA levels and aldosterone synthase protein expression compared 
with those present in the APA tissue, we measured tissue concentrations of 
aldosterone by using a state-of-the-art UPLC-MS/MS spectrometry after C18-
based solid phase extraction.  We found 3.9*104 fmol/g (1.8*104- 9.1*104 fmol/g, 
median, 95% CI) and 1.8*106 fmol/g (7.0*105- 3.8*106 fmol/g, median, 95% CI) of 
aldosterone in the APA-adjacent tissue and in APA obtained ex vivo, respectively 
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(Figure 5.2, panel D).  By assuming 1 g of adrenal tissue to correspond 
approximatively 1 ml of tissue, we estimated that 1.8*106 fmol/g is equivalent to 
1.8*106 M, i.e. about 18-fold higher than the highest concentration (10-7 M) of 
aldosterone used in our in vitro and ex vivo experiments in HAC15 cells and APA 
strips.  
Cross-talk between G protein-coupled receptors AT1 and GPER-1 
Because functional interactions between GPCRs have been reported, we 
investigated whether cross-talk between AT1R and GPER could help 
understanding of the mechanism(s) by which aldosterone-induced GPER activation 
promoted CYP11B2 gene expression.  We quantified GPER and AT1R gene and 
protein expression in APA and APA adjacent tissues by digital droplet PCR, a 
technique held to furnish absolute copies number of gene transcripts.  We found 
that GPER and AT1R showed comparable mRNA levels; however, immunoblotting 
studies showed that only GPER was more abundant in APA than in APA adjacent 
tissue at the protein level 33.  Both aldosterone and Ang II increased CYP11B2 
gene expression in APA strips (Figure 5.3, panel A); when given on top of Ang II, 
aldosterone potentiated the secretagogue effect of the peptide.  Moreover, the 
additive effect of aldosterone and Ang II was inhibited by either irbesartan or G36 
(Figure 5.3, panel B).  Similarly, in HAC15 cells aldosterone potentiated the effect 
of Ang II, whilst pre-treatment with irbesartan and/or G36 blunted this augmentation 
(Figure 5.3, panels C, D).   
To investigate if the interaction between GPER and AT1R activation could be 
sustained by heterodimer formation, we performed co-immunoprecipitation 
experiments in HAC15 cells.  GPER protein expression was detected by 
immunoblot after AT1R immunoprecipitation and vice versa, thus confirming the 
presence of heterodimers (Figure 5.3, panel E). 
 
 





Figure 5.1: Aldosterone treatment enhances CYP11B2 via GPER activation. 
Panel A: CYP11B2 gene expression after exposure of HAC15 cells to increasing concentration of 
aldosterone. Data represent mean ± SD (n= 5). Panel B: CYP11B2 expression levels in HAC15 cell 
exposed for 2, 8, 12, 24 and 48 hours to aldosterone 10-7 M. Data represent mean ± SD (n= 5). Panel 
C: Aldosterone-induced CYP11B2 mRNA expression in APA strips obtained from 4 different patients. 
APA strips were treated with aldosterone 10-8 M and 10-7 M alone or on top of G36 10-6 M or 10-5 M, 
respectively. Data represent median and 95% CI of 4 different experiments performed in triplicate. 
Panel D: CYP11B2 gene expression after treatment of HAC15 cells with aldosterone 10-7 M on top of 
canrenone 10-5 M or G36 10-5 M.  Data represent median and 95% CI of 7 different experiments 
performed in duplicate. Panel E: CYP11B2 protein expression after treatment with aldosterone 10-7 M 
alone or on top of canrenone 10-5 M or G36 10-5 M for 24 hours. Data represent median and 95% CI of 5 
different experiments performed in duplicate. ALDO: Aldosterone; * P < 0.01; ** P < 0.001,*** P < 
0.0001; # P = 0.002 
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Figure 5.2: GPER silencing blunted aldosterone-induced CYP11B2 protein 
expression.  
Panel A: GPER-1 protein levels in HAC15 cells after transfection with GPER siRNA compared with 
mock-transfected cells. Data represent mean ± SD of 4 different experiments performed in duplicate. 
Panel B: CYP11B2 protein expression after exposure of mock transfected HAC15 cells and of silenced 
GPER-1 cells to aldosterone 10 -7 M. Data represent mean ± SD (n= 4). Panel C: Representative 
traces of cytosolic Ca2+ measurement in CD56 + cells obtained from APA performed with the Ca2+ -
sensitive fluorescent dye Fura-2 after treatment with 10-7 M aldosterone (A), 10-8 M 17 β-estradiol (E2) 
and 10-8 M angiotensin II (Ang II). Experiments were performed in CD56+ cells obtained from 3 different 
APAs. Panel D: Tissue concentration of aldosterone in APA and in APA-adjacent tissue. Data represent 
median and 95% CI, n = 10. * P = 0.01; ** P < 0.01; # P < 0.001 





Figure 5.3: Cross talk between G protein-coupled receptors AT1 and GPER-1.  
Panel A:Aldosterone on top of Ang II increased the expression of CYP11B2 gene in APA strips. Panel 
B: CYP11B2 gene expression in APA strips after pretreatment with aldosterone and Ang II on top of 
irbesartan or G36, or both. Panel C: Aldosterone on top of Ang II increased the expression of CYP11B2 
gene in HAC15 cells. Panel D: CYP11B2 gene expression in HAC15 cells after pretreatment with 
aldosterone and Ang II on top of irbesartan or G36, or both. For panels A-D data represent mean ± SD 
of 4 different experiments performed in duplicate. Panel E: Representative results of co-
immunoprecipitation experiments performed in HAC15 cells; after AT1R immunoprecipitation, GPER 
protein expression was detected by immunoblot; the presence of heterodimers in GPER-
immunoprecipitated protein was also confirmed (n=3). Rabbit IgG control: negative control. ALDO: 
Aldosterone; # P = 0.04; * P =0.03; **P < 0.01; ***P < 0.001 
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Discussion 
In this study we found that aldosterone stimulated the expression of CYP11B2, the 
mitochondrial Ca2+- and NADH-dependent step-limiting enzyme of its biosynthesis.  
This effect occurred both in a female-derived adrenocortical carcinoma cell line 
(HAC15), and in strips obtained ex vivo at adrenalectomy from a mixed-gender 
cohort of primary aldosteronism patients with aldosterone-producing adenoma 
(Figure 5.1).  These are novel important pieces of information on the regulation of 
aldosterone secretion under physiological and pathophysiological conditions, as 
several parallel studies 33 showed that increased levels of CYP11B2 mRNA and 
protein are proxies of enhanced aldosterone release 29.  They could also improve 
understanding of what happens in primary aldosteronism, the most common, albeit 
often overlooked, cause of endocrine hypertension 2,30. 
By using pharmacological tools to specifically block the MR or the GPER, and also 
by means of molecular silencing, we could identify GPER as the main mediator of 
CYP11B2 activation in response to aldosterone (Figures 5.1 and 5.2).  The 
selective MR antagonist canrenone was chosen because it is an active metabolite 
of spironolactone, which, at variance with spironolactone, does not require 
cytochrome P450 activation 38.  In accordance with the notion that MR antagonists 
are not very potent drugs and require a high molar antagonist/agonist ratio to 
display their antagonistic effects 39 we used canrenone at concentrations 100-fold 
higher than those of aldosterone and we found that canrenone did not blunt the 
effect of aldosterone.   
The effect of canrenone on CYP11B2 expression was further investigated in a 
concentration-dependent experiment that showed a dual action: at 10-6 and up to 
10-4 M canrenone stimulated CYP11B2 gene expression, while at 10-3 M it blunted 
it 33.  We contend that the stimulatory effect seen at lower concentrations might 
involve an off-target antagonist effect on the ERβ 33, because previous studies 
showed that ERβ blockade unmasks the GPER-mediated stimulatory effect on 
CYP11B2 expression of steroids as E2 29.  Moreover, the fall of CYP11B2 seen at 
the highest concentrations of the MR antagonist likely occurred because of a 
cytotoxic effect as shown by our cell viability ex- periments based on the 3-(4,5-
Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide for dye (MTT assay). 
Of further note, the effect of aldosterone on CYP11B2 did not involve the 
glucocorticoid receptor (GR), as it was be unaffected by the GR antagonist RU486 
33,37.  As the adrenocortical carcinoma cells HAC15 might not reflect what occurs in 
vivo in human PA, which is usually caused by an aldosterone-producing adenoma, 
we wished to corroborate the findings by using strips of these tumours obtained ex 
vivo at adrenalectomy from a mixed gender cohort of patients presenting with florid 
clinical PA phenotypes. These results provided additional proof that aldosterone 
increased CYP11B2 gene expression (Figure 5.1, panel C) via GPER, and not the 




MR or GR, as its effect was abolished by G36 and unaffected by canrenone and 
RU48633.   
As regards signaling pathways, we herein found no detectable changes of cytosolic 
Ca2+ levels in response to aldosterone (Figure 5.2, panel C), consistently with  the 
previous finding that E2-induced GPER-mediated expression of CYP11B2 and 
aldosterone secretion does not involve the protein kinase A–cAMP signaling 
pathway but not cytosolic Ca2+  mobilization 29.  
Some limitations are, however, to be acknowledged: first, experiments with 
mitochondria-specific Ca2+ sensitive probes are necessary to investigate the 
possibility that GPER activation of CYP11B2 can involve Ca2+ influx into the 
mitochondria.  Second, although strips from APA represent the experimental model 
that is closest to the in vivo conditions, caution is advised before extrapolating our 
findings to what occurs clinically in PA patients.  Finally, it might be argued that we 
have merely identified a pharmacologic effect of aldosterone, because we used 
high concentrations of the hormone, possibly higher than those in plasma or in 
adrenocortical tissue of patients with PA.  However,because aldosterone is locally 
produced in the zona glomerulosa and in APA cells, and then released in the 
interstitial fluid, it might attain local concentrations greater than in the bloodstream.  
To address the lack of information on aldosterone concentrations in APA tissue, we 
measured aldosterone concentrations in APA by a state-of-the art tandem mass 
spectrometry technique.  We found that the local tissue concentrations of 
aldosterone in APA tissue were about 18-fold higher than those enhancing 
CYP11B2 expression in vitro (Figure 5.2, panel D).  As we used exogenous 
aldosterone as a secretagogue, we could not measure aldosterone release in the 
medium of our cell and strip preparations, because of the impossibility of 
discriminating between endogenously made and exogenously added aldosterone, 
without using radiolabeled precursors, which are no longer allowed in our 
laboratory.  However, in multiple parallel experiments with angiotensin II and E2, as 
secretagogue, we found that changes in CYP11B2 mRNA were consistently 
followed by aldosterone secretion 33, finding consistent with the view that 
aldosterone is not stored but constitutively secreted. 
One additional point deserves a comment: aldosterone-mediated GPER activation 
did not require prior ERβ receptor blockade at variance with results with E2 29.  
Because data on relative affinity of aldosterone and E2 for human adrenocortical 
cells lack, at present we could only speculate that this might be due to a higher 
affinity of aldosterone for GPER and/or to lower binding affinity of E2 for GPER 
than for ERβ41. 
A further novel and intriguing observation in this study was the finding that 
aldosterone potentiated in an additive fashion the secretagogue effect of 
angiotensin II in adrenocortical cells, which suggested a functional interaction 
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between the angiotensin II type 1 receptor (AT1R) and GPER.  This could be due 
to functional heterodimer formation between GPER and AT1R as shown in HAC15 
cells (Figure 5.3), which were found to be stable at coimmunoprecipitation studies 
with proper controls in spite of no prior cross-linking (Figure 5.3, panel E).   
Based on these in vitro and ex vivo studies, we would like to propose an autocrine-
paracrine mechanism whereby aldosterone, acting via GPER, can swiftly increase 
its own biosynthesis and release, under conditions when the renin-angiotensin-
aldosterone system needs to be rapidly activated to preserve vital organ perfusion 
as, for example, during acute hypovolemia and dehydration.  This mechanism can 
play a pathophysiological role also in maintaining an inappropriately high secretion 
of aldosterone in PA patients, where the high blood pressure and volume 
expansion would also be expected to blunt renin and angiotensin II synthesis and 
to diminish aldosterone biosynthesis.  Finally, we suggest that this autocrine-
paracrine mechanism could explain the occurrence of aldosterone-producing cell 
clusters (APCCs), which can coexist with APA, and possibly represent an early 
stage of the latter tumor 41. 
Whether this mechanism could be implicated in idiopathic hyperaldosteronism that 
might be sustained by APCCs 42, and whether this mechanism can be further 
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AT1AA (Angiotensin II type-1 receptor autoantibodies) were first detected in 
patients with primary aldosteronism (PA) because of aldosterone-producing 
adenoma (APA) with an in-house developed assay, but it remained unclear if they 
can be ascertained also with commercially available assays and if they have a 
functional role. Aims of our study were to investigate if (1) commercially available 
kits allow detection of raised AT1AA titer in APA; (2) this titer is normalized by 
adrenalectomy; and (3) AT1AA display any biological roles in vitro. We measured 
with 2 ELISA kits the AT1AA titer in serum of APA patients and its changes after 
adrenalectomy. We also investigated AT1AA bioactivity by using AT1-R 
(angiotensin type-1 receptor)–transfected Chinese hamster ovary and human 
adrenocortical carcinoma cells, and by measuring aldosterone synthase 
(CYP11B2) expression in human adrenocortical carcinoma cells after incubation 
with IgG. Both kits allowed detection of higher AT1AA levels in APA patients than 
in healthy subjects; surgical cure of PA did not decrease this titer at 1-month 
follow-up. Human adrenocortical carcinoma cells stimulation with IgG purified 
from sera of APA patients increased both CYP11B2 expression and aldosterone 
release (+40% and +76%, respectively, versus healthy subjects). However, no 
detectable effect of IgG was seen in Chinese hamster ovary cells expressing 
AT1-R. These findings support the contentions that (1) the raised AT1AA titer 
does not seem to be a consequence of hyperaldosteronism as it did not normalize 
after its cure; (2) AT1AA act as weak stimulators of aldosterone biosynthesis, but 


























Primary Aldosteronism (PA) is the most common endocrine form of arterial 
hypertension.  The distinction between its major subtypes, i.e. unilateral 
aldosterone-producing adenoma (APA) and bilateral adrenocortical hyperplasia 
(BAH), is key for optimal clinical management inasmuch as the former is best 
treated surgically, while the latter requires life-long medical treatment with 
mineralocorticoid receptor (MR) antagonists, alone or combined with other agents 
1,2. 
Immunohistochemical studies using monoclonal antibodies specific for human 
aldosterone synthase (CYP11B2) developed in Gomez-Sanchez’s laboratory 
highlighted that the pathology underlying PA is far more complex than simply BAH 
and APA, as a single APA usually coexists with clusters of aldosterone-producing 
cells (APCC) 3–5,  which seem to accumulate with aging in humans 6, and might be 
an early stage of APA formation 7.  Along with the concept of asymmetrical 
aldosterone excess in PA (Celso Gomez-Sanchez, personal communication), 
these findings suggested that a systemic stimulus can lead to APCC and 
eventually to APA formation, which could account for the existence of a continuum 
between APA and BAH.  
In 2013 using an in-house made ELISA kit, we described elevated titers of 
autoantibodies against type-I angiotensin II receptor (AT1AA) in serum of patients 
with APA at levels comparable to those seen in women with preeclampsia, a 
prototype disease of raised AT1AA 8.  This finding was thereafter confirmed by 
others 9 10, and particularly by Kem et al. 9, who proposed that these AT1AA could 
have agonistic properties based on their finding of an AT1AA-activated β-arrestin-
dependent chemiluminescent signal in CHO cells engineered to express the 
angiotensin type-1 receptor (AT1-R) and enhanced aldosterone production in a 
human adrenocortical carcinoma cell-line (HAC15).   
It remained, however, altogether unknown if this titer could be corrected by cure of 
PA by means of adrenalectomy and/or medical treatment targeting the MR, thus 
leaving uncertain if the raised titer of AT1AA was a cause or a consequence of 
hyperaldosteronism. Hence, we set out this prospective study to answer the 
following questions: 1) does treatment with adrenalectomy normalize the titers of 
AT1AA? 2) Can the reported agonist effect of AT1AA be confirmed in genetically 
engineered cells by using purified IgG from APA patients with high AT1AA titers?  
Methods 
The authors declare that all supporting data are available within the article and its 
online supplementary file.  Further data supporting the findings of this study are 
available from the authors upon request.  
 







We recruited for this study patients who had an APA confirmed by the “five 
corners” criteria 2 (Table 6.1).  At variance with recently proposed criteria 11, to 
assess clinical and biochemical success, recognizing the long known fact that 
normalization of renin can lack even in patients who were unambiguously cured 
after surgery 12, we defined as ‘biochemically cured’ the patients who showed 
normalized PAC, serum K+ and 24-h K+ excretion, besides a clearcut lowering of 
blood pressure, enailing cure or improvement by the aforementioned criteria.11  
Serum for measurement of AT1AA was obtained before and 1 month after 
adrenalectomy.  Patients furnished written consent to the study, which was 
approved by the Institutional Review Board.  
Table 6.1.  “Five corners” criteria for the diagnosis of APA.2    
 
Enzyme-linked immunosorbent assays (ELISA) 
On the day of the assay serum samples for AT1AA stored at −80°C were thawed at 
room temperature.  AT1AA were detected with two commercially available 
sandwich ELISA kits. The first exploits use of horseradish peroxidase labeled-anti-
human IgG and TMB substrate solution for AT1AA detection (CellTrend kit, 
Luckenwalde, Germany)(See also Supplementary Data).  The second uses biotin-
conjugate in addition to horseradish peroxidase labeled-anti-human IgG and TMB 
(Cusabio, Wuhan, China). Intra- and inter-assay CV found in our laboratory were 
5% and 6% for the first kit, and 4% and 7% for the second.  Both kits are currently 
used to measure AT1AA in kidney transplant recipients to identify those at high risk 
of allograft rejection 13–16. 
In both assays, standard and diluted samples were added to the wells of a 
microtiter plate pre-coated with AT1-R and incubated for 2 h. Optical density was 




1. Biochemical evidence of PA (e.g., an inappropriately high aldosterone/renin 
ratio) 
2. Lateralized aldosterone secretion by AVS 
3. Detection of a nodule by imaging (CT or MRI) or an adenoma at pathology 
4. Biochemical correction of PA after adrenalectomy 
5. Detection of a CYP11B2-positive adenoma in the resected adrenal cortex 
at  immunohistochemistry with a monoclonal antibody for human CYP11B2 







IgG were purified from APA or control patients’ sera using the NAbTM Protein A/G 
spin kit following the manufacturer’s recommendations (Pierce Biotechnology 
Rockford, Illinois) and quantified using the Nanodrop® 2000c spectrophotometer. 
CYP11B2 gene expression 
The HAC15 human adrenocortical carcinoma cells (a gift of Doctor W. E. Rainey, 
University of Michigan, Ann Arbor, Michigan) were cultured in DMEM-F12 
supplemented with 10% Cosmic Calf serum at 37°C under an atmosphere of 5% 
CO2 17.  They were stimulated for 12 hours with angiotensin II (10-7M) or IgG (0.3 or 
0.6 mg/mL).  Irbesartan, or candesartan (both 10-5 M), were used as AT1-R 
antagonists at concentrations chosen to be 100-fold higher than those of 
angiotensin II based on previous studies that showed abolishment of angiotensin II 
effects.18  After treatment, cells were lysed and mRNA was isolated with high-pure 
RNA isolation kit (Roche Applied Science, Penzberg, Germany).  CYP11B2 gene 
expression was quantified by real-time RT-PCR with universal probe library probes 
in the LightCycler 480 software (Roche Applied Science, Penzberg, Germany) 
using the comparative cycle threshold (2−ΔΔCt) method: each sample was quantified 
against its PBGD transcript content and normalized to the control group. 
Measurement of aldosterone production 
Aldosterone levels were quantified by an aldosterone ELISA kit (Alpha Diagnostic 
International, San Antonio, TX).  A total of 50 μL of cell medium was added to 
aldosterone-coated wells following the manufacturer’s instructions; the signal was 
detected in an ELISA reader (Berthold Technologies, Milan, Italy).  Aldosterone 
levels were normalized to the amount of cell RNA content 19. 
β‐arrestin recruitment assay 
The bioactivity of AT1AA was measured in AT1R-transfected CHO cells 
engineered to express both the AT1 receptor and an intracellular β-arrestin 
signaling pathway that, when activated by agonist binding AT1-R, develops a 
luminescent signal (DiscoveRx, Fremont, Canada).  Briefly, CHO cells (n= 104) 
were dispensed into each well of a 96-well culture plate and incubated for 48 hrs.  
Ten µl serum or purified IgG were then added and incubated for 90 min.  
Each assay also comprised proper negative (buffer) and positive (angiotensin II) 
controls following manufacturer’s recommendation.  Detection reagents were then 
added and chemiluminescent signal was read on a luminometer (LB960 Berthold, 
Bad Wildbad, Germany).  A standard curve with angiotensin II was obtained 
(Supplementary Figure S6.1), and β-arrestin recruitment by sera or IgG was 
expressed as bioactivity of angiotensin II (pM/L).  
 






DRC, PRA, PAC, and ARR values, which showed a skewed distribution, were 
analyzed after log transformation.  Distribution of categorical variables was 
investigated by χ2 analysis.  Bland-Altman plot was used to detect systematic and 
proportional errors, and magnitude-dependent bias between AT1AA titers 
measured with the two assays 20.  Deming regression was also used to look for 
systematic differences between methods.  Paired t-test was used to compare 
quantitative variables between baseline and follow-up, and between buffer-
stimulated and IgG-stimulated cells.  The significance was set at p < 0.05.  
Analyses were performed with Prism (vers. 8.1.2, GraphPad, San Diego, CA) and 
SPSS™ (vers. 25.0, IBM, Armonk, NY) for Mac. 
Results 
Clinical features and AT1AA levels of the APA patients 
We recruited for this study 27 APA patients (48% men, 52% women) aged 51±8 
years, whose main clinical features at baseline and after adrenalectomy are shown 
in Table 6.2.  
In 12 such patients we measured AT1AA titer using both assays, and found that 
they showed significantly higher titers of AT1AA than healthy volunteers (n=7) (p 
<10-4 and p =3*10-3 for assays 1and 2, respectively) (Figure 6.1, Panels A and B).  
A Bland-Altman plot of the results obtained with the two commercially available kits 
showed a good agreement, with no systematic or proportional errors, as all points 
fell within 2 SD; however, a funnel-like shape appearance suggested some 
magnitude-dependent bias (Figure 6.1, Panel C).  Deming regression analysis 
confirmed that results obtained with the two assays did not differ by a constant 
amount or a proportional difference, thus supporting their interchangeability (Figure 
6.1, Panel D).  Hence, we used assay 1 in a larger cohort of APA patients (n=27) to 
confirm that they had AT1AA titers higher than healthy donors, which was actually 
the case (p=3*10-2) (Figure 6.2, Panel A). 
 
Table 6.2. Clinical profiles of APA patients before and after adrenalectomy. 
Data are presented as mean ± SD, or median [interquartile range].  
 Pre-adrenalectomy Post-adrenalectomy P 
Patients (n) 27 27 -- 
SBP (mmHg) 153 ± 16 126 ± 7 10-4 
DBP (mmHg) 93 ± 9 80 ± 6 10-4 
K+ (mmol/L) 3.2 ± 0.4 4.2 ± 0.4 3*10-3 
PAC (ng/dL) 20.9 (14.3-43.62) 5.5 (4.4-8.7) 10-4 
DRC (mIU/L) 2 (2.0-3.1) 7.1 (2.5-16.9) 10-4 
ARR (ng/mIU) 90.5 (57-214.2) 7.3 (3.8-16.9) 10-4 






SBP: systolic blood pressure; DBP: diastolic blood pressure; PAC: plasma aldosterone concentration; 
DRC: direct renin concentration; ARR: aldosterone to renin ratio. 
 
 
Figure 6.1.  Box and whisker plots showing show AT1AA titers measured with two commercially 
available ELISA kits in healthy normotensive subjects (HD, n=7) and patients with aldosterone 
producing aldosterone (APA, n=12).  Both assays showed higher AT1AA titers in APA patients than in 
healthy donors. The Bland Altman test shows no systematic or proportional errors (Panel C); the 
Deming regression analysis confirmed the lack of systematic differences between the assays (Panel D).  





See Supplementary Data for interpretation of the Deming regression line (dotted line). The grey and 
black lines represent the identity and linear regression, respectively. Because of the different units of 
measurement, Z score values (Z) were plotted instead of raw values in panels C and D. 
Post-adrenalectomy results 
Of the 27 patients with APA submitted to adrenalectomy, 26 showed full 
biochemical cure of PA after surgery, as evidenced by normalization of plasma 
aldosterone concentration (PAC) and serum potassium levels; one patient showed 
persistent hyperaldosteronism.   
As regards blood pressure outcome, all patients were cured or markedly improved.  
Serum was available at follow-up in 14 patients and therefore assessment of 
biochemical cure was not feasible in all.  In those who showed biochemical cure 
and cure or a marked improvement of blood, we could not observe any evident 
decrease of AT1AA levels at one-month follow-up after removal of APA (Figure 6.2, 
Panel B).   
 
Figure 6.2.  Panel A shows AT1AA titers in an expanded series of patients with aldosterone producing 
aldosterone (APA, n=27) and in control donors (HD, n=11).  No significant change in AT1AA titers of 
APA patients was seen before (Pre) and after (Post) adrenalectomy in either the patients who were 
cured (biochemically and hemodynamically) or in those who were not (both n=14) (Panel B). Grey 
squares represent patients not biochemically cured at follow-up. 
Bioactivity of AT1AA 
Two sets of experiments were undertaken to investigate if circulating AT1AA from 
APA patients could activate the AT1-R.  In the first, Chinese hamster ovary cells 






engineered to express the AT1R were exposed to sera from APA patients using 
increasing concentrations of angiotensin II, ranging from 10-10M to 10-5M, as 
positive control. While angiotensin II elicited a clearcut concentration-dependent 
chemiluminescent response (Supplementary Figure S6.1, Panel A), the serum did 
not induce any detectable response as the readings were below the lowest 
detection threshold of the angiotensin II concentration response curve 
(Supplementary Figure S6.1, Panel B). 
Several attempts to improve the sensitivity of this assay failed in that we could not 
detect a reproducible chemiluminescent signal.  These results suggested that 
either the activity of AT1AA was below the detection threshold of this assay and/or 
that they were not biologically active.  
To further investigate these hypotheses, in a second set of experiments, HAC15 
cells were exposed to IgG purified from serum of APA patients (n=10) with the 
highest AT1AA titer with both commercially available kits and CYP11B2 mRNA 
was measured as experimental endpoint (Figure 6.3).  IgG induced a 40% increase 
in CYP11B2 gene expression (Figure 6.3, Panel B), which, albeit statistically 
significant, was much lower than that induced by angiotensin II (Figure 6.3, Panel 
A).  However, the purified IgG (n=8) enhanced the release of aldosterone in the 
medium (Figure 6.4, Panels A and Panel B).  Pre-treatment of HAC15 cells with 
irbesartan provided quite variable effects among patients; however, on average 
irbesartan blunted, albeit did not abolish, the increase in CYP11B2 mRNA induced 
by IgG from APA patients (Figure 6.3, Panel B).  






Figure 6.3.  CYP11B2 gene expression increased after exposure of HAC15 cells to angiotensin II, 
used as positive control (Panel A), or to IgG purified from serum of the APA patients that showed the 
highest AT1AA titer (n=10) (Panel B).  While irbesartan prevented the response to angiotensin II (Panel 
A), it reduced, but did not abolish that induced by IgG from APA patients (Panel B).  







Figure 6.4.  IgG purified from serum of the APA patients induced aldosterone release from HAC15 cells 
higher than IgG purified from serum of healthy subjects (HD).  Panel A shows aldosterone levels 
normalized to the amount of cell RNA content, whereas Panel B shows the increase of aldosterone 
levels in APA patients normalized to those of healthy subjects. Data obtained from two experiments in 
triplicate 
Discussion 
The discovery that APA patients, who usually show the most florid clinical PA 
phenotypes, have an increased titer in serum of autoantibodies against the 
angiotensin type I receptor 8, followed by the report that these autoantibodies could 
have an agonistic effect on AT1-R, opened a new line of investigation as to why 
excess aldosterone production occurs in PA, in a fashion seemingly autonomous 
from angiotensin II 9.  
The present results provided novel pieces of information in this area by showing 
that the increased AT1AA titer could be detected not just with an in-house 
developed method using a peptide corresponding to the second extracellular loop 
of the human AT1 receptor, as originally reported 8, but also with two commercially 
available assays that uses microtiter plate pre-coated with recombinant AT1-R 
protein (Figure 6.1, Panels A and B).  These findings indicate that the recombinant 
AT1-R protein used in the microplate retains a conformation similar to that of cell 
membrane AT1-R, which renders it accessible to the AT1AA. Accordingly, they 
testify the possibility of expanding research in this field by means of commercially 





available kits to groups of investigators that do not have in-house generated 
assays.  
The second important question to answer was if the elevated AT1AA titer is a 
cause or a consequence of PA.  We addressed this issue at two levels: first, we 
investigated the effect of surgical cure of PA by unilateral laparoscopic 
adrenalectomy on AT1AA titers, and found no normalization of the raised 
autoantibodies titers, suggesting that PA by itself does not raise the titer of AT1AA.  
Accordingly, AT1AA might not simply represent a biomarker of the excess 
cardiovascular damage, which in PA has been well documented at the level of the 
heart, kidney and vasculature 21.  However, this contention needs, in our view, to 
be tempered by considering the following.  First, serum was available at follow-up 
in only 14 patients, because some cured patients, who were from far away 
municipalities, after the initial follow-up visit one month after surgery could not to 
come back for further blood testing.  Second, autoimmune diseases may need long 
time to resolve, which implies that the disappearance of circulating AT1AA levels 
could take a time longer than exploited in this study.  Therefore, whether AT1AA 
production can be long-lasting and, moreover, if T memory cells involved in AT1AA 
production are harbored in the APA, are important issues that deserve further 
investigations.  
As regards the biological role of AT1AA, when tested in vitro in AT1-R engineered 
CHO cells, under several experimental conditions and in a consistent manner, 
purified IgG from our APA patients with the highest antibodies titers did not elicit 
any detectable effect.  These cells showed a clear-cut concentration-dependent 
response to angiotensin II even when tested in the presence patients’ serum, 
which ruled out a matrix effect.   Hence, we could not confirm the elegant results 
reported by Kem et al. using a similar cell system.  The reasons for these 
discrepant results are currently unclear; however, we would like to suggest that 
engineered CHO cells might be not sensitive enough to allow detection of a weak 
biological activity of AT1AA, at least in our hands and at the titers found in our PA 
patients.  
In line with this proposition, HAC15 cells exposed to purified IgG isolated from APA 
patients showed a 40% increase of CYP11B2 mRNA over IgG isolated from 
healthy subjects (Figure 6.3).  This CYP11B2 mRNA increase was associated with 
a 76% increase in aldosterone levels in the medium.  Hence, AT1AA from APA 
patients exerted a weak effect, which was detectable only using highly sensitive in 
vitro assays, on aldosterone biosynthesis and secretion.  Finally, it should also be 
considered that the the proportion of AT1AA in the IgG fraction is currently 
unknown; therefore, differences between cohorts of APA patients could explain the 
different findings obtained in different cohorts of patients.  
An involvement of AT1-R activation in the stimulation of CYP11B2 gene expression 
induced by the IgG fraction of APA patients was suggested by our experiments 






with irbesartan, which exerted a blunting effect, albeit in a variable fashion.  Further 
research is, however, necessary to dissect the reasons for these variable effects in 
different patients. 
Conclusions 
In summary, our results confirmed that elevated titers of AT1-R autoantibodies can 
be detected in serum of APA patients with two commercially available kits.  These 
AT1AA might represent a biomarker of florid forms of PA, but are unlikely to result 
from the excess cardiovascular damage documented in APA patients, as they 
remain elevated after biochemical cure of PA 22.  Moreover, the AT1AA act as 
weak stimulators of aldosterone biosynthesis, albeit their effect could only be 
shown under well-defined conditions with a sensitive assay.  
Perspectives 
We found AT1AA not only in APA, but also in some healthy donors, as similarly 
observed for other G protein-coupled receptors (GPCR) autoantibodies 23.  A 
number of relevant questions remain, however, to be answered as, for example, 
which is the cut-off between normal subjects and APA patients, what proportion of 
purified IgG entails AT1AA, and even more importantly, if healthy normotensive 
subjects represent a preclinical phase of PA as recently suggested 24. 
The persistence of an elevated AT1AA titer at times longer than 1 month after 
unilateral PA curative adrenalectomy, as well as investigation of an involvement of 
T memory cells as possible determinants in an autoimmune process leading to the 
development of APA seem important lines of future investigation at a stage when 
the mechanisms leading to APCCs and possible APA are being investigated with a 




















Novelty and Significance 
What Is New. 
• The titer of AT1AA is increased in primary aldosteronism (PA) patients and 
these autoantibodies are stimulators of aldosterone biosynthesis. 
• This agonistic effect can be identified by using purified IgG and a sensitive in 
vitro technique.  
• The raised AT1AA titer persisted one month after biochemical cure of PA and 
therefore does not seem to be a consequence of hyperaldosteronism. 
What Is Relevant? 
• The AT1AA titer can be a biomarker of PA and can be measured with 
commercially available assays. 
Summary 
The raised AT1AA titer in APA patients, which persisted after cure of 
hyperaldosteronism suggests a pathogenetic role of AT1AA in raising aldosterone 
biosynthesis in PA. 
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Enzyme-linked immunosorbent assays (ELISA) 
Both kits employ the quantitative sandwich enzyme immunoassay technique with 
microtiter plates pre-coated with AT1-R.  Standards and samples are pipetted into 
the wells and, after washing the wells to remove any unbound reagent, a substrate 
solution is added to the wells to develop color in proportion to the amount of AT1-R 
bound antibody. After stopping the color development, the intensity of the color is 
measured and the AT1AA concentration can be interpolated by the standard curve. 
The first kit (CellTrend kit, Luckenwalde, Germany) exploits use of horseradish 
peroxidase labeled-anti-human IgG and TMB substrate solution for AT1AA 
detection. Intra- and inter-assay CV are 3.9% and 5.1%.  The second kit (Cusabio, 
Wuhan, China) uses biotin-conjugated AT1-R and avidin conjugated horseradish 
peroxidase (HRP). Intra- and inter-assay CV are <8% and 10%.   
Statistical Analysis 
Deming regression was used to look for systematic differences between methods.  
The null hypothesis of identity (i.e. that Y = X) was tested by individual tests: the 
95% confidence interval for the intercept to test the hypothesis that A=0.  This 
hypothesis is accepted if the confidence interval for A contains the value 0, and 
rejected if A is significantly different from 0 and both methods differ at least by a 
constant amount.  The 95% confidence interval for the slope was used to test the 
hypothesis that B=1; this hypothesis is accepted if the confidence interval for B 
contains the value 1. If the hypothesis is rejected, then it is concluded that B is 
significantly different from 1 and there is at least a proportional difference between 
the two methods.  
Supplemental Figure S6.1. Panel A. Dose-response curve of Angiotensin II (10-10M to 10-5M) in 
engineered AT1R‐transfected Chinese hamster ovary (CHO) cells, assessed as chemiluminescent 
response.  Chemiluminescence measured in CHO cells exposed to sera from APA patients was used to 
interpolate Angiotensin II (pM/L), which was considered as equivalent bioactivity. Engineered cells 





exposed to such sera provided low chemiluminescent responses that fell in the shaded area, 
corresponding to 5% equivalent bioactivity of the maximal response elicited by Angiotensin II.  Per cent 
activity was calculated as follows:  
% Activity=100%*[(Mean RLU(test sample) - Mean RLU(vehicle control))  / (Mean RLU(control ligand, 
i.e. Angiotensin II) - Mean RLU(vehicle control))] Panel B. The plot shows that bioactivity (calculated as 
Angiotensin II equivalents, pM/L) measured in CHO cells exposed to sera from APA patients did not 
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Individuals with an aldosterone producing adenoma (APA) carry a 
disproportionately high cardiovascular risk relative to primary hypertension. 
Patients with APA have high levels of activating autoantibodies (AT1AA) against 
the angiotensin II type I receptor (AT1R). Activation of the AT1R is linked to an 
increase of the glucose metabolite methylglyoxal (MGO), a potential precursor of 
advanced glycation endproducts (AGEs)  and a driver of cardiovascular disease. 
We investigated whether serum AT1AA levels in individuals with APA are 
associated with serum MGO and AGE levels.  
Methods 
In 26 patients with APA (51±7.7y) and in a subset of 14 of these patients before 
and 1 month after adrenalectomy, we measured serum levels of the dicarbonyls 
methylglyoxal (MGO), glyoxal (GO) and 3-deoxyglucosone (3-DG), as well as the 
major dicarbonyl-derived AGEs 5-hydro-5-methylimidazolone (MG-H1), Nε-
(carboxyethyl)lysine (CEL) and Nε-(carboxymethyl)lysine (CML) by ultra-
performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS). 
AT1AA were measured by ELISA. 
Results 
Baseline AT1AA levels were not associated with baseline serum MGO, GO and 3-
DG, or protein-bound and free MG-H1, CEL and CML levels. No changes were 
observed in any of the dicarbonyl and protein-bound AGE levels after 
adrenalectomy. Surprisingly, we found a significant increase of free CML, CEL and 
MG-H1 levels after adrenalectomy (CML from 86 nmol/L to 142 nmol/L, CEL from 
46 nmol/L to 63 nmol/L and MG-H1 from 110 nmol/L to 237 nmol/L; all p<0.02)). 
Conclusion and discussion 
In patients with APA, serum levels of AT1AA are not associated with serum 
dicarbonyls, or protein-bound and free AGE levels. Serum free AGEs level were 
higher after adrenalectomy, potentially due to changes in kidney function or the use 
of less co-medication after surgery. 






Primary aldosteronism (PA) is the most common form of endocrine hypertension, 
with a prevalence of 11% of the patients referred to specialized centers for 
hypertension 1. Aldosterone producing adenoma (APA) and bilateral adrenal 
hyperplasia (BAH) are the leading causes of PA. Individuals with PA have a 
severely increased risk of cardiovascular disease (CVD), even compared to 
individuals with primary hypertension 2,3, for reasons that remain incompletely 
understood. We previously reported that patients with APA are characterized by 
high levels of activating autoantibodies against the angiotensin II type I receptor 
(AT1AA)4. AT1AA may have agonistic properties to the  angiotensin II receptor 
type I (AT1R), similar to angiotensin II (Ang II) 4,5. In turn, activation of the AT1R by 
Ang II has been linked to increased formation of methylglyoxal (MGO), a highly 
reactive glucose-metabolite that leads to the formation of advanced glycation 
endproducts (AGEs) 6. MGO and its derived AGEs are key players in the 
development of CVD 7,8. Glyoxalase 1 (Glo1) is the rate-limiting enzyme in the 
degradation of MGO to D-lactate  and  increased activation of AT1R by Ang II  has 
been linked to decreased expression of Glo1 9. Therefore, we hypothesize that 
higher serum levels of AT1AA, as putative ligands for AT1R, are associated with 
higher MGO levels and MGO-derived AGEs in individuals with APA.  
Therefore, we have analyzed the associations between serum AT1AA levels and 
serum levels of MGO and two other well-known dicarbonyls, glyoxal (GO) and 3-
deoxyglucosone (3-DG), and the major dicarbonyl-derived AGEs 5-hydro-5 
methylimidazolone (MG-H1), Nε-(carboxyethyl)lysine (CEL) and Nε-
(carboxymethyl)lysine (CML), in patients with APA before and after adrenalectomy.  
Furthermore, we investigated associations between serum AT1AA levels and 
serum D-lactate levels, as a reflection of MGO. 
Methods 
Patients 
We recruited for this study 26 patients who had an APA confirmed by the “five 
corners” criteria 10.  The Primary Aldosteronism Surgical Outcome (PASO) criteria 
were used to assess complete or partial clinical and biochemical success 11. 
Patients provided written consent to the study, which was approved by the 
Institutional Review Board.  
A subset of 14 of these patients underwent adrenalectomy. To assess clinical and 
biochemical success, we defined as biochemically cured, the patients who showed 
normalized plasma aldosterone concentrations, serum K+, and 24-hour K+ 
excretion, and a clear-cut lowering of blood pressure, entailing cure, or 
improvement of the aforementioned criteria 11. 
The AT1AA titer in these patients has been reported previously 4. Serum samples 





3-DG, the free and protein-bound AGEs CML, CEL and MG-H1 and D-lactate 
levels were analyzed at base-line and 1-month follow-up of adrenalectomy. 
Measurement of dicarbonyl, AGEs, D-lactate 
Serum levels of the dicarbonyls MGO, GO, and 3-DG, the protein-bound CML, 
CEL, MG-H1, and free CML, CEL and MG-H1 were analysed using ultra-
performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) as 
described in detail previously 12–14. 
Measurement of endothelial dysfunction and low-grade inflammation 
markers 
Serum markers of endothelial dysfunction (soluble vascular adhesion molecule 
(sVCAM-1) and soluble intercellular adhesion molecule 1 (sICAM-1)) and of low‐
grade inflammation (C‐reactive protein (CRP), and serum amyloid A (SAA)) were 
measured with a commercially available 4-plex sandwich immunoassay kits with 
different standards and antibodies (Meso Scale Discovery, Rockville, Maryland). 
For this technique, the intra- and inter-assay coefficients of variation for these 
markers were below 10%.  
Statistical analysis  
Direct renin concentrations, plasma renin activity, plasma aldosterone 
concentrations, aldosterone to renin ratio values, plasma creatinine and eGFR 
showed a skewed distribution, and were analyzed after log transformation. 
Distribution of categorical variables was investigated by χ2 analysis.  
A paired t test was used to compare quantitative variables between baseline and 
follow-up. Spearman correlation coefficients were calculated to study the 
correlation between the AT1AA and serum dicarbonyl, free and protein-bound 
AGEs levels. The significance was set at P<0.05. Analyses were performed with 
Prism (vers. 5.03, GraphPad, San Diego, CA). 
Results 
Clinical Features of the APA Patients 
The clinical characteristics of the 26 APA patients in this study are shown in Table 
7.1. In the subset of 14 individuals that underwent adrenalectomy, plasma 
aldosterone concentrations, blood pressure serum potassium levels, eGFR, but not 
AT1AA levels, were markedly improved at 1-month after removal of APA (Table 
7.2).  The use of antihypertensive drugs was strongly reduced after adrenalectomy. 
Markers of inflammation and endothelial function were not associated with AT1AA 
(data not shown) and did not change after surgery (Table 7.2).       
 
 





Table 7.1. Clinical characteristics of the APA patients. 
 





Patients (n) 26 
Gender (M%) 46% 
Age (Y) 51 ± 7.7 
Systolic blood pressure (mmHg) 152 ± 16 
Diastolic blood pressure (mmHg) 93 ± 9 
K+ (mmol/L) 3.2 ± 0.4 
Plasma aldosterone concentration 
 
19.9 (13.2-43.9) 
Direct renin concentration (mIU/L) 2 (2.0-2.9) 
Aldosterone to renin ratio (ng/mIU) 90.6 (57-214.2) 
Plasma creatinine (µmol/L) 75 (59.3-84) 
eGFR CDK-EPI (ml/min/1,73m2) 90 (86-104) 





































































CRP (ug/mL) 2.1 (0.5-5.1) 
 






Table 7.2. Characteristics of APA patients before and after 
adrenalectomy 
 











    
Patients (n) 14 14 -- 
Gender (M %) 50% 50% -- 
Age (Y) 51 ± 8.7 51± 8.9 -- 
Systolic blood pressure (mmHg) 153 ± 16 124 ± 7 0.0005 
Diastolic blood pressure (mmHg) 92 ± 7 81 ± 2.3 0.002 
K+ (mmol/L) 3.3 ± 0.4 4.3 ± 0.4 0.000  
Plasma aldosterone 
  
19.3 (12.3-38.5) 5.8 (4.3-8.4) 0.000  
Direct renin concentration 
 
2 (2.0-3.5) 5.9 (2.5-17.1) 0.0005 
Aldosterone to renin ratio 
 
82.5 (48.9-156.4) 9.9 (3.6-18.9) 0.000  
Plasma creatinine (umol/L) 75 (67.3-84.8) 91.5 (77-99.5) 0.003 
eGFR CDK-EPI (ml/min/1,73m2) 89.5(85.7-99.5) 75 (67-.3-88.3) 0.003 
Antihypertensive drugs     
α-Blockers (%) 43% 7% -- 
ARBs (%) 7% 0% -- 
Calcium channel blockers (%) 
 
86% 29% -- 
Centrally acting drugs (%) 7% 0% -- 
Diuretics (%) 
 
14% 0% -- 




   
CML (nmol/L) 
 






488 (439-642) 607 (484-897) 0.17 
MG-H1 (nmol/L) 
 














46 (31.5-60.5) 62.5 (47.3-121) 0.01 
MG-H1(nmol/L) 
 





















1654 (1247-2079) 1510 (1341-1876) 0.63 
D-Lactate (µmol/L) 6.4 (4.6-10.3) 10.4 (5.3-23.2) 0.43 
L-Lactate (µmol/L) 
 


















   





SAA (ug/mL) 3.8 (2.2-7.2) 4.1 (2.5-9.9) 0.17 
 
 
   
  





Association of serum AGEs, and dicarbonyls with AT1AA 
Serum levels of MGO, GO and 3-DG and free AGEs were not associated with 
AT1AA levels (Figure 7.1A and 7.1B). Furthermore, no association was observed 
between protein–bound AGEs and AT1AA (Figure 7.1C).   
 
Figure 7.1. Scatter plot of correlation between serum levels of AT1AA and dicarbonyls MGO, GO and 
3-DG at baseline (A); Scatter plot of correlation between serum levels of AT1AA and free and protein-
bound (PB) AGEs CML, CEL and 3-DG at baseline (B-C); p-value of Spearman rank correlation test, 
and “r” is the linear correlation coefficient. 
Pre- and Post-adrenalectomy levels of AGEs, dicarbonyls and D-
lactate 
Serum levels of MGO, GO and 3-DG did not change significantly after 
adrenalectomy (Figure 7.2A).   Furthermore, we observed no change after 
adrenalectomy of serum D-lactate levels (Table 7.2). Free plasma AGEs CML, CEL 
and MG-H1 (Figure 7.2B), but not protein-bound AGEs (Figure 7.2C), were 








Figure 7.2. Serum levels of MGO, GO and 3-DG before (Pre) and 1-month after adrenalectomy (Post) 
(A); serum levels of free and protein-bound (PB) AGEs CML, CEL and 3-DG before (Pre) and 1-month 
after adrenalectomy (Post) (B-C)  
Discussion  
The main finding of this study was that serum AT1AA levels were not associated 
with serum levels of MGO or the other dicarbonyls GO and 3-DG, or the free and 
protein-bound AGEs CML, CEL and MG-H1, and the MGO metabolite D-lactate. In 
addition to these cross-sectional findings, we did not observe changes in 
dicarbonyls after adrenalectomy, albeit in the context of a AT1AA titer that did not 
change. 
We focused on AT1AA and markers and glycation since it has been demonstrated 
that activation of the AT1R by Ang II leads to the decreased expression of Glo1 
enzyme and subsequent increase formation of AGEs 9. However, it is not fully 
established whether AT1AA are capable of stimulating AT1R. Although Kem at al. 
found that AT1AA have agonistic properties similar to Ang II on the AT1R 5, we 
were not able to confirm a similar biological effects of AT1AA 4 and  we could only 
demonstrate a very weak biological activity of AT1AA on aldosterone biosynthesis 
and secretion in  cultured adrenal cells 4, suggesting a low affinity, if any, of AT1AA 
for AT1R. This is in line with the current study in which we did not find an 





association of the titers of AT1AA with markers of dicarbonyls stress and free 
AGEs.  
Although there was no association between AT1AA and serum AGE levels, 
unexpectedly we found an increase of free CML, CEL and MG-H1 levels after 
adrenalectomy. This could be explained by the fact that adrenalectomy is 
associated with a small decrease in eGFR or a reduction of medication after 
surgery. Furthermore, some antihypertensive medications may decrease AGEs 
levels, such as angiotensin receptor blockers such as olmesartan 15 valsartan 16,17 
or  angiotensin-converting enzyme inhibitors (ACEi)  15,18. Because of the small 
sample size in the present study, we lacked the statistical power to address the 
question whether the increase of free CML, CEL and MG-H1 levels after 
adrenalectomy could be explained by eGFR or a reduction of medication use after 
surgery. 
Emerging evidence indicates that aldosterone plays an important role in the 
development of endothelial dysfunction 19. We investigated for the first time 
whether surgical cure of PA by unilateral laparoscopic adrenalectomy altered the 
levels of markers of inflammation (CRP, SAA) and endothelial dysfunction 
(sVCAM, sICAM-1). Although adrenalectomy decreased aldosterone levels in 
patients with APA in this study, changes in aldosterone did not correlate with 
systemic inflammation or endothelial dysfunction. In contrast, a prospective cohort 
study showed a significant decrease in CRP level in PA patients 1 year after 
initiation of therapy with mineralocorticoid receptor antagonists or adrenalectomy 
20. It might be that in our current study the sample size of patients with APA was 
not large enough or follow-up times were too short to demonstrate the effect of 
adrenalectomy on systemic inflammation.  
However, it should also be emphasized that several studies provided conflicting 
results concerning  a pro-inflammatory profile in PA patients 21,22. In line with our 
results,   a very recent study  reported no difference in circulating hsCRP and other 
markers of inflammation and endothelial dysfunction between PA patients and 
essential hypertension controls 22.  
The major strengths of the present study include its in-depth phenotyping of the 
APA who had an APA confirmed by the “five corners” criteria and the large state-of-
the-art equipment for estimating plasma dicarbonyl levels and of AGEs. However, 
there are also several limitations. A major limitation of this study includes a small 
sample size that may have led to a type I error, and limited our ability to do 
extensive multivariate analysis. Furthermore, the use of antihypertensive drugs 
may have affected the production of AGEs and dicarbonyl compounds. Larger 
studies with a long-term follow-up time are required to further clarify the importance 
of post-adrenalectomy levels on AGEs. 
In conclusion, our study shows that in APA patients serum levels of AT1AA do not 
correlate with serum dicarbonyls, free and protein-bound AGEs levels. In this 





after-adrenalectomy are likely due to changes in kidney function or the use of less 
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Angiotensin receptor blockers (ARBs) reduce vascular complications in diabetes 
independently of blood pressure. Experimental studies suggested that ARBs may 
restore the detoxifying enzyme glyoxalase 1, thereby lowering dicarbonyls such as 
methylglyoxal. Human data on the effects of ARBs on plasma dicarbonyl levels are 
lacking. We investigated in individuals with type 2 diabetes (T2D) whether 
irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-
deoxyglucosone, and their derived Advanced Glycation End products (AGEs), and 
increased D-lactate, reflecting greater methylglyoxal flux. 
Methods 
We analysed a subset of the Irbesartan in Patients with T2D and Microalbuminuria 
(IRMA2) study.  We measured plasma dicarbonyls methylglyoxal, glyoxal and 3-
deoxyglucosone, free AGEs and D-lactate with ultra-performance liquid 
chromatography tandem mass-spectrometry (UPLC-MS/MS) in the treatment arm 
receiving 300 mg irbesartan (n=121) and placebo group (n=101) at baseline and 
after 1 and 2 years. Effect of treatment was analyzed with repeated measurements 
ANOVA. 
Results 
There was a slight, but significant difference in baseline median methylglyoxal 
levels (placebo 1119 (907-1509) nmol/L versus irbesartan 300mg: 1053 (820-
1427) nmol/L), but no significant changes were observed in any of the plasma 
dicarbonyls over time in either group and there was no effect of irbesartan 
treatment on plasma free AGEs or D-lactate levels at either 1 or 2 years.  
Conclusion 
Irbesartan treatment does not change plasma levels of the dicarbonyls 
methylglyoxal, glyoxal and 3-deoxyglucosone, free AGEs or D-lactate in T2D.  This 
indicates that increased dicarbonyls in T2D are not targetable by ARBs, and other 














Type 2 diabetes (T2D) is associated with development of cardiovascular disease 
(CVD), chronic kidney disease (CKD), and is a main cause of end-stage kidney 
disease (ESKD). The Renin-Angiotensin-Aldosterone System (RAAS)  plays an 
important role in the development of CVD and CKD in T2D 1,2. Inhibition of the 
RAAS with ARBs reduces the incidence of CKD and CVD in T2D 3,4. However, the 
mechanisms through which ARBs attenuate renal and cardiovascular risk remains 
incompletely understood. This was highlighted by the seminal original Irbesartan in 
T2D With Microalbuminuria 2 (IRMA2) investigation, where the ARB irbesartan 
reduced progression of diabetic CKD, independently of blood pressure 4.Therefore, 
research into the mechanisms of action of ARBs is still needed to maximize the 
benefit of this vital class of medications for the prevention of diabetic complications. 
This is highly relevant since the incidence of CVD and CKD in T2D remains high 
and many individuals still progress towards ESKD despite optimal treatment with 
ARBs 5. 
A potential underlying mechanism of the protective effects of ARBs is a reduction in 
the accumulation of methylglyoxal, a highly reactive glucose metabolite and the 
major precursor in the rapid formation of advanced glycation endproducts (AGEs) 
6. Methylglyoxal levels are increased in T2D 7, and higher plasma methylglyoxal 
levels were associated with CVD, albuminuria and a decline in estimated 
glomerular filtration rate (eGFR) in T2D 8–10. Methylglyoxal is detoxified by the 
glyoxalase system to D-lactate, with glyoxalase 1 (Glo1) as  the rate-limiting 
enzyme 11. Glo1 expression is lower in kidneys affected by CKD 12. In line, Glo1 
overexpression attenuated albuminuria in diabetic rats 13, while Glo1 knockdown 
caused a CKD-like phenotype even in normoglycaemic mice 14. These findings 
imply that Glo1 is a major protective factor against CKD. Interestingly, it has been 
shown in an experimental study that the ARB candesartan attenuates the formation 
of methylglyoxal levels through enhanced Glo1 expression 15. These observations 
led to the hypothesis that health benefits of ARBs are due, at least in part, to 
increased expression of Glo1 and a decrease of methylglyoxal levels.  However, 
human studies about the effect of ARBs on systemic methylglyoxal levels are 
lacking. To explore whether irbesartan lowers dicarbonyl stress, we have now 
investigated plasma levels of methylglyoxal and two other major dicarbonyls, 
glyoxal and 3-deoxyglucosone, as well as D-lactate and free levels of the major 
dicarbonyl derived AGEs Nε-carboxymethyllysine (CML), Nε-carboxyethyllysine 
(CEL) and methylglyoxal-derived hydroimidazolone (MG-H1) in the IRMA2 sub-







Study design and participants  
The IRMA 2 study was a 2-year multicenter, double-blind, parallel randomized 
controlled trial in individuals with T2D and microalbuminuria in which the main goal 
was to compare the effects of irbesartan (150 or 300 mg once daily) versus 
placebo, in addition to conventional antihypertensive treatment, on the 
development of overt nephropathy 4. Briefly, we enrolled individuals with T2D 
(diagnosed according to the World Health Organization criteria) and hypertension 
(defined as mean systolic blood pressure >135 mmHg and/or mean diastolic blood 
pressure >85 mmHg in two of three consecutive measurements 1 week apart) and 
persistent microalbuminuria (defined as an albumin excretion rate of 20–200 
mg/min in two of three consecutive overnight urine samples) and a serum 
creatinine concentration of 133 µmol/L for men and 97 µmol/L for women. A total of 
590 (186 women) individuals, aged 30–70 years, were included and randomly 
assigned to receive 150 mg irbesartan once daily (n=195), 300 mg irbesartan once 
daily (n=194) or matching placebo (n=201) (Figure S8.1). Results regarding the 
primary end point, and other secondary end points such as markers of 
inflammation and endothelial dysfunction, have been reported previously 4. The 
aim of the present study was to evaluate the effect of irbesartan treatment on 
glycation, using several state-of-the art panels to quantify plasma levels of the 
plasma dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, the free AGE 
levels of CML, CEL, MG-H1 and D-lactate. Samples for the assessment of these 
markers at baseline and at 1- and 2-year follow-up were still available from 121 
participants in the treatment arm receiving 300 mg irbesartan and from 101 
participants receiving placebo. In the initial analyses of this study, no significant 
effects of 150 mg irbesartan treatment versus placebo were found on the 
development of nephropathy, creatinine clearance or blood pressure. The 150mg 
irbesartan samples were not included in the current analyses because they are no 
longer available as they unfortunately have been discarded by mistake in the past. 
Individuals included in the current analyses had similar base-line characteristics as 
the original investigation (data not shown) 4 
Biochemical measurements  
HbA1c was measured by ion-exchange HPLC. Serum creatinine concentration was 
originally measured by the Jaffe reaction with the use of a Hoffmann LaRoche kit 
and creatinine clearance (in mL/min/1.73m2 body surface area) was estimated with 
the Cockcroft-Gault equation. These variables were evaluated at the time of 







Measurement of plasma dicarbonyls 
Plasma samples were stored at -80Co until analyses. Plasma dicarbonyls were 
measured with ultra-performance liquid chromatography tandem mass-
spectrometry (UPLC-MS/MS)16. In brief, EDTA plasma samples (25 μL) were 
mixed with 75 μL d8-O-phenylenediamine (oPD) (10 mg oPD in 10 mL 1.6 mol/L 
perchloric acid) in an Eppendorf cup. After an overnight (20h) reaction, at room 
temperature and shielded from light, 10 μL of internal standard solution was added. 
Samples were mixed and subsequently centrifuged for 20 min at 21,000 g at a 
temperature of 4°C; 10 μL was injected for UPLC/MSMS analysis. The inter-assay 
variations for methylglyoxal, glyoxal and 3-deoxyglucosone were 4.3, 5.1 and 
2.2%, respectively16. 
Plasma D-lactate levels were measured with UPLC-MS/MS17. 25 μL of plasma was 
derivatized with diacetyl-L-tartaric anhydride and separated on a C(18)-reversed 
phase column. D-lactate inter- and intra-assay variations were between 2% and 
9%. 
Plasma free MG-H1 levels were measured with UPLC-MS/MS18. 50 µL plasma was 
used, samples were derivatized with butanolic hydrochloric acid and subsequently 
detected in multiple reaction monitoring (MRM) mode using a Xevo TQ MS 
(Waters, Milford, USA). Quantification of free MG-H1 was performed by calculating 
the peak area ratio of each unlabeled peak area to the corresponding internal 
standard peak area. In plasma, the intra- and inter-assay variation of protein-bound 
CML, CEL and MG-H1 were between 4.8 and 18.8% and for free CML, CEL and 
MG-H1 between 2.8 and 7.1%. 
Statistics  
Variables with skewed distribution (plasma dicarbonyls) were Ln-transformed prior 
to further analyses. Changes in plasma dicarbonyl levels over the 2-year follow-up 
time were examined according to the intention-to-treat principle and with the use of 
repeated measurement analysis of variance. As a sensitivity analysis, we stratified 
our dataset on the median baseline HbA1c value of the current dataset to 
investigate whether the effect of irbesartan differed by glycaemic control. For this 
analyses n=19 individuals were initially excluded because of missing baseline 
HbA1c values. When we added these individuals to the above median HbA1c group, 
reasoning that individuals with missing values on average have poorer control, the 
results did not change. All statistical analyses were performed using SPSS version 
23. 
Results 
Baseline characteristics of the current subset of the IRMA2 trial are shown in Table 








 Placebo (n=101) 300mg Irbesartan (n=121) 
Sex (% women) 32.1 30.8 
Age (years) 57.7 ± 9.3 57.3 ± 7.8 
Known duration of diabetes (years) 7.0 (3.0-14.5) 7.0 (4.0-12.0) 
HbA1c (%) 7.0 ± 1.6 6.9 ± 1.7 
HbA1c (mmol/mol) 53 ± 18 52 ± 19 
Body mass index (kg/m2) 30.4 ± 4.3 29.9 ± 4.3 
Total cholesterol (mmol/L) 5.7 ± 1.1 5.8 ± 1.1 
Current smoking (%) 19.3 14.6 
Systolic blood pressure (mmHg) 153.1 ± 14.3 154.5 ± 13.2 
Diastolic blood pressure (mmHg) 89.8 ± 8.4 91.9 ± 9.7 
Creatinine clearance (mL/min/1.73m2) 110.0 (89.5-130.5) 106.0 (92.5-124.3) 
Urinary albumin excretion (mg / 24h) 51.0 (33.0-82.0) 51.0 (35.0-87.0) 
Table 8.1: Baseline characteristics of the study participants  
Data are expressed as mean ± SD, median (interquartile range) or percentages as appropriate and 
stratified according to treatment group (300 mg irbesartan or placebo). 
Effects of 300mg irbesartan treatment on plasma levels of 
methylglyoxal, glyoxal and 3-deoxyglucosone  
Plasma methylglyoxal levels were significantly lower at baseline in the group 
randomized to 300mg irbesartan (Table 8.2, Figure 8.1). Plasma levels of 
methylglyoxal, glyoxal and 3-deoxyglucosone did not change significantly over the 
1 and 2 year follow-up time in either group and did not differ between groups 
(Table 8.2, Figure 8.1). These results did not change when we adjusted the 
repeated measurements in ANOVA for sex, age, HbA1c, duration of diabetes and 
BMI (data not shown). 
 Figure 8.1. 2-way plots of plasma levels of Ln-transformed methylglyoxal, glyoxal and 3-
deoxyglucosone at baseline, 1-year and 2-year follow-up for the irbesartan (IRB) 300mg group and the 
placebo (PL) group. Data are presented as mean ± standard error. *<P0.05 versus placebo. Differences 
between groups and over time were tested with repeated measures ANOVA, after Ln-transformation of 







Effects of 300mg irbesartan treatment on plasma levels of D-lactate  
Plasma levels of D-lactate did not change significantly in either group after 1 and 2-
year follow-up time and no difference was found between groups (Table 8.2, Figure 
8.2). 
 
Figure 8.2. 2-way plot of plasma levels of D-lactate at baseline, 1-year and 2-year follow-up for the 
irbesartan (IRB) 300mg group and the placebo (PL) group. Data are presented as mean ± standard 
error. *<P0.05 versus placebo. Differences between groups and over time were tested with repeated 
measures ANOVA after Ln-transformation of the outcome variable. 
Effects of 300mg irbesartan treatment on plasma levels of free CML, 
CEL and MG-H1 
We next analysed levels of the free plasma AGEs CML, CEL and MG-H1 (Table 
8.2, Figure 8.3). At baseline, prior to treatment, plasma CML, CEL and MG-H1 
appeared to be higher in the group randomised to placebo treatment, and this was 
statistically significant for CML and CEL (Table 8.2, Figure 8.3). However, at 1 and 
2 years follow-up we observed no differences between the placebo or irbesartan 
groups.  
 
Figure 8.3. 2-way plots of plasma levels of free CML, CEL and MG-H1 at baseline, 1-year and 2-year 
follow-up for the irbesartan (IRB) 300mg group and the placebo (PL) group. Data are presented as 
mean ± standard error. *<P0.05 versus placebo. Differences between groups and over time were tested 








Table 8.2: Plasma dicarbonyls, D-lactate and free AGE levels at baseline and at 1- and 2-year follow-up 
Data are expressed as median (interquartile range) and stratified according to treatment group (300 mg irbesartan or placebo). 
 
    
 Placebo 300mg 
Irbesartan 
Placebo 300mg Irbesartan Placebo 300mg Irbesartan 
Methylglyoxal (nmol/L) 1119 (907-1590) 1053 (821-1448) 1131 (873-1488) 1147 (824-1539) 1078 (876-1448) 1142 (839-1565) 
Glyoxal (nmol/L) 6079 (4967-7164) 6003 (5153-6939) 6067 (5108-7959) 6304 (5230-7642) 6036 (4928-7758) 6238 (5169-7332) 
3-deoxyglucosone (nmol/L) 5499 (4446-6555) 5211 (4204-6491) 5582 (4548-6846) 5311 (4304-6305) 5319 (4279-7111) 5657 (4184-6573) 
D-lactate (mmol/L) 13.8 (9.2-22.3) 14.0 (9.9-20.3) 14.8 (10.0-19.4) 15.2 (10.6-21.2) 15.4 (10.3-21.2) 14.9 (10.8-22.4) 
Free CML (nmol/L) 116.8 (98.4-158.1) 107.0 (84.6-134.9) 116.5 (92.5-154.8) 111.9 (92.6-134.5) 125.2 (98.8-155.3) 121.1 (96.5-154.7) 
Free CEL (nmol/L) 63.3 (49.1-81.1) 52.6 (42.4-70.4) 63.4 (43.4-80.7) 58.1 (47.6-77.6) 66.2 (51.0-84.7) 63.5 (50.2-82.9) 








The current analyses of the IRMA2 study showed that irbesartan at a concentration 
of 300mg versus placebo does not lower plasma levels of methylglyoxal or the 
other dicarbonyls glyoxal and 3-deoxyglucosone, D-lactate or the free plasma 
AGEs CML, CEL and MG-H1. 
These results suggest that ARBs, or at least irbesartan, does not act as a potent 
agent to lower systemic dicarbonyl stress as reflected by changes in plasma 
dicarbonyl, D-lactate or free AGE levels, although the effectiveness of irbesartan 
has been demonstrated by its ability to reduce progression of albuminuria in the 
original trial. Since plasma dicarbonyl levels are not lower than in previous 
investigations we performed 8,9,19, it seems unlikely that there was insufficient 
dicarbonyl stress in the current study to effectively detect a reduction by irbesartan. 
Our current finding is in line with prior analyses from our group in the IRMA2 
subset, in which we found that the plasma protein-bound AGEs CML and CEL 
were not affected by irbesartan 20. The current study expands upon this finding by 
direct measurements of dicarbonyls, as well as including free plasma AGEs and D-
lactate as a potential marker of methylglyoxal detoxification by Glo1.  
The IRMA2 study was performed in the clinical era prior to the newer glucose-
lowering drugs such as the sodium glucose reuptake inhibitors (SGLT2i) and 
glucagon-like peptide 1 (GLP1) analogues. This is actually an advantage in terms 
of specifying the effects of ARBs on plasma dicarbonyls, since we can exclude an 
interaction of these newer compounds with plasma dicarbonyls, which could have 
masked effects of irbesartan on plasma dicarbonyl levels. Adjustment for HbA1c did 
not change our results which makes it less likely that changes in glucose and thus 
dicarbonyls, covered the effect of ARBs on dicarbonyls.    
Previous experimental studies have mainly focused on in-depth analyses of the 
influence of ARBs on methylglyoxal and the glyoxalase expression in retinal and 
renal tissues 15,21,22 and it has been demonstrated that  ARBs  modulate 
methylglyoxal levels in specific microvascular beds 15. This is likely achieved by 
blocking angiotensin II signalling and related down-regulation of Glo1. In this study, 
however, we did not find an effect of irbesartan on plasma levels of methylglyoxal. 
Since we do not have data about tissue methylglyoxal levels, we cannot rule out 
the possibility that there is an effect of irbesartan on methylglyoxal levels in specific 
tissues that are not reflected by changes in plasma glycation levels. This was 
indeed suggested by a rodent study that showed decreased CML levels in diabetic 
kidneys by the ARB valsartan, while overall plasma fluorescence as a reflection of 
glycation was not altered 22. Therefore, we cannot disprove earlier pre-clinical 
studies based on our current investigation. Additionally, it might be that the 
beneficial effects of ARBs are restricted to experimental models of diabetes.  
This study also has the limitation that we have only data about plasma levels of 






dicarbonyls. In fact, it has been demonstrated that irbesartan significantly 
decreased urinary excretion of the dicarbonyls-derived AGEs MG-H1 and glyoxal-
derived hydroimidasolone (G‐H1).  As urinary free MG-H1 and G-H1 are thought to 
originate mainly from proteolysis of methylglyoxal and glyoxal-modified proteins 23, 
these changes may therefore indicate decreased dicarbonyl stress in renal tissues 
by irbesartan. This is in accordance with the effect of angiotensin blockade in 
regulation of glyoxalase 1 in vitro 15. However, because of the potent effect of 
glucose lowering treatment on plasma methylglyoxal levels in T2D 19,24, it is unlikely 
that ARBs constitute a main mitigating treatment to reduce dicarbonyl stress in 
diabetes.   
Conclusion 
In conclusion, irbesartan did not lower plasma dicarbonyls and it therefore it is less 
likely that ARBs attenuate renal and cardiovascular risk through attenuation of 
dicarbonyl stress. In addition, there is still an unmet need of compounds to 
effectively lower systemic dicarbonyl stress in order reduce the burden of CKD and 
CVD in diabetes. It is not known if more recent reno-protective agents like SGLT2 
inhibitors and GLP1 receptor agonists have an effect on dicarbonyl stress. 
Particularly SGLT2 inhibitors have demonstrated renal benefits and although 
initially introduced for their glucose lowering effect this seems not to explain the 
renal and cardiovascular benefits. 
Novelty Statements 
• The Angiotensin receptor blocker (ARB) irbesartan reduces progression of 
diabetic kidney disease independently of blood pressure in individuals with type 
2 diabetes.  
• Methylglyoxal is a major driver of diabetic kidney disease and may be lowered 
by ARBs.  
• Irbesartan (300mg) did not lower plasma levels of methylglyoxal, or any of the 
additional glycation markers we measured in this study. 
• This indicates that increased dicarbonyls in type 2 diabetes are not targetable 
by irbesartan, and other approaches to lower systemic dicarbonyls are needed 
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The renin-angiotensin-aldosterone system (RAAS) and advanced glycation 
endproduct (AGEs) are both implicated in the development of renal and 
cardiovascular disease. Methylglyoxal (MGO) is a highly reactive glucose-
metabolite and the main precursor in the formation of AGEs. Activation of the 
angiotensin II type I receptor (AT1R) has been linked to an increase of MGO, via 
downregulation of glyoxalase 1 (Glo1). We here investigated whether angiotensin 
II infusion reduces Glo1 expression and increases MGO levels and MGO-derived 
AGEs in kidney and the liver of C57BL/6J mice.  
Method 
C57BL/6J mice were infused with angiotensin II with a minipump (2.5 mg/kg/day) 
for 3 days (n=4) or 28 days (n=9) or vehicle (saline, n=4 for 3 days, n=6 28 days). 
The dicarbonyls MGO, glyoxal (GO) and 3-deoxyglucosone (3-DG), as well as 
the major dicarbonyl-derived AGEs 5-hydro-5 methylimidazolone (MG-H1), Nε-
(carboxyethyl)lysine (CEL) and Nε-(carboxymethyl)lysine (CML) were measured, 
in plasma and in kidney and liver homogenates by ultra-performance liquid 
chromatography tandem mass-spectrometry (UPLC-MS/MS). Changes in Glo1 
mRNA levels were measured in tissue by qRT-PCR. 
Results 
Relative to the controls, infusion of angiotensin II for 3 and 28 days reduced Glo1 
mRNA and activity in liver and kidney.  Although the several dicarbonyls and 
AGEs in tissues and in plasma showed mixed patterns, CML and MG-H1 were 
increased in the liver after 3 days of angiotensin II infusion and this was 
accompanied by an increase of plasma GO, MGO, CML and CEL levels.   
Conclusion 
Glo1 is downregulated in the kidney and the liver after angiotensin II infusion, 
with a concomitant increase in markers of dicarbonyl stress. Angiotensin II 
reduced expression of Glo1 accompanied by an increase in dicarbonyls stress 




















Activation of the Renin-Angiotensin-Aldosterone System (RAAS) and 
accumulation of advanced glycation endproducts (AGEs) is increased in diabetes 
1 and are both implicated in cardiovascular disease (CVD) and chronic kidney 
disease (CKD) in type 2 diabetes (T2D) 1,2.  
There are some indications that the RAAS and the AGE pathway are intertwined.  
Activation of the angiotensin II type I receptor (AT1R) by angiotensin II has been 
linked to an increase of methylglyoxal (MGO), a highly reactive glucose-
metabolite and a major precursor in the formation of AGEs 3. MGO and its 
derived AGEs are key players in the development of CVD and CKD 4,5. 
Glyoxalase 1 (Glo1) is the rate-limiting enzyme in the detoxification of MGO to D-
lactate and increased activation of AT1R by angiotensin II has been linked to 
decreased expression of Glo1 6. Glo1 expression is lower in kidneys affected by 
CKD in the setting of type 1 diabetes 8. In line, Glo1 knockdown caused a CKD-
like phenotype even in normoglycaemic mice 9, while Glo1 overexpression 
attenuated albuminuria in diabetic rats 10 and in diabetic ApoE deficient mice 11. 
These findings indicate that Glo1 is a major protective enzyme against CKD.  
Despite the indications in literature about the association of angiotensin II and 
MGO, we recently found in T2D that the angiotensin receptor blocker irbesartan 
does not lower plasma levels of MGO 7. However, we cannot rule out the 
possibility that there is an effect of irbesartan on Glo1 and methylglyoxal levels in 
specific tissues that are not reflected by changes in plasma glycation levels. 
Therefore, we explored the effect of angiotensin II on the expression of Glo1 in 
kidney and liver and whether angiotensin II increases the dicarbonyls MGO, 
glyoxal (GO) and 3-deoxyglucosone (3-DG), as well as the major dicarbonyl-
derived AGEs 5-hydro-5 methylimidazolone (MG-H1), Nε-(carboxyethyl)lysine 




Male 8-10-week-old C57BL/6J mice were fed standard mice chow and kept on a 
standard day/night cycle. Mice were injected with angiotensin II (Bachem) via 
Alzet Minipumps (2.5 mg/kg/day) for 3 days (n=4) or 28 days (n=9) or vehicle 
(saline) for 3 days (n=4) or 28 days (n=6). Systolic and diastolic blood pressure 
was monitored at 28 days by means of tail cuff (CODA, Kent Scientific, 
Torrington, CT). Animals were euthanized and plasma and organs were stored at 
-80oC after snap-freezing. All animal experiments were performed according to 
the European Directive (2010/63/EU) and approved by the Animal Care and Use 






RNA extraction and quantitative real-time PCR  
RNA was isolated from liver and kidney tissues using Trizol reagent (Sigma-
Aldrich). The RNA quantity and quality were determined by spectrophotometric 
readings at 260/280/230 nm. RNA from tissue was reverse transcribed using the 
iScript cDNA synthesis kit (Bio-Rad). Gene expression of GLO1, was determined 
using IQ SensiMix SYBR master mix (Bioline) on a CFX96 Touch with CFX 
manager software (Biorad) using the comparative cycle threshold (2−ΔΔCt) method: 
each sample was quantified against Cyclophillin (CYCLO) as a reference gene 
and normalized to the control group. The sequence of primer used in qRT-PCR 
were: GLO1-forward, 5’-ATGACGAGACTCAGAGTTACCACAA-3’, GLO1-
reverse, 5’-TAGACATCAGGAACGGCAAATCC-3’, CYCLO-forward, 5’-
TTCCTCCTTTCACAGAATTATTCCA-3’, CYCLO-reverse, 5’-
CCGCCAGTGCCATTATGG-3’ 
Glo1 activity assay 
Glo1 activity was measured in protein lysates of the liver and kidney as previously 
described  by McLellan et al.12 In brief, frozen liver and kidney tissues in liquid 
nitrogen, were crushed with a steel mortar and dissolved in phosphate buffer. 
Glo1 activity was assayed by a spectrophotometry analysis to monitor the 
increase in absorbance at 240 nm due to the formation of S‐D‐lactoylglutathione 
during 30 min at 25°C. Glo1 activity was adjusted for protein-concentration 
measured as measured by the Pierce® BCA Protein Assay Kit (Thermo 
Scientific) and expressed as units per milligram of protein. 1 Unit indicates the 
formation of 1 nmol/l S‐D‐ lactoylglutathione per minute. 
Measurement of dicarbonyl, AGEs, D-lactate   
Levels of MGO, GO, 3-DG, free and protein bound AGEs, 5-hydro-5 
methylimidazolone (MG-H1), Nε-(carboxyethyl)lysine (CEL) and Nε-
(carboxymethyl)lysine (CML), as well as D-lactate were analysed in plasma, liver 
and kidney homogenates by ultra-performance liquid chromatography tandem 
mass spectrometry (UPLC MS/MS) as previously described 13–15. 
Statistical analysis 
Statistical analysis was performed with GraphPad Software™ (vers. 9.02, San 
Diego, CA). Unpaired data was tested for significance using a two-tailed 
Student’s T-test. All data was expressed as the mean ± SD and were considered 
statistically significant at P<0.05. 
 
 










Effect of angiotensin II on Glo1, dicarbonyl stress and D-lactate in mice 
To investigate the effect of angiotensin II on Glo1 expression and activity, 
dicarbonyls and AGEs levels, we subjected mice to angiotensin II infusion for 3 
and for 28 days. At 28 days of exposure to angiotensin II, we found a significant 
increase in DBP and SBP as compared to sham mice, demonstrating the validity 
of the animal model (Table 9.1). 
We determined the effect of angiotensin II on Glo1 expression. We found a 
significant decrease of Glo1 gene expression in kidney and liver tissue of mice 
infused with angiotensin II for 3 days and 28 days (Figure 9.1A). We found a 
consistent pattern for Glo1 activity in kidney and liver after infusion with 
angiotensin II which was significant in the liver after 28 days and in the kidney 
after 3 days (Figure 9.1B). 
 
Table 9.1 Endpoint characteristics and plasma dicarbonyls, free and protein bound 




 Data are presented as mean ± SD. Diastolic blood pressure, DBP; Systolic blood pressure, SBP; 
heart weight, HW; tibia length, TL. 
 
 3 Days 28 Days 
 Saline Angiotensin II P     Saline Angiotensin II P  
       
    Mouse (n) 
 
4 4  6 9 - 
DBP (mmHg) - - - 102 ± 10 155 ± 34 0.02 
SBP (mmHg)) 
 
- - - 134 ± 9 189 ± 35 0.02 
HW/TL 
 
5.5 ± 0.5 7.1 ± 1.5 0.08 6.0 ± 0.4 7.1 ± 0.6 0.002 
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748 ± 42 
 
603 ± 42 
 
















      
CML 
 
382 ± 68 
 
550 ± 79 
 
0.02 450 ± 40 593 ± 245 0.2 
CEL 
 
77 ± 16 
 
159 ± 33 0.004 86 ± 8 120 ± 75 0.3 
MG-H1 
 
81 ± 22 
 











2373 ± 1468 
 
0.06 823 ± 437 
 








1771 ± 301 0.03 1630 ± 
 







2059 ± 436 0.4 2592 ± 
 









2837 ± 227 0.2 6182 ± 
  









Figure 9.1. Effect of Angiotensin II on the expression of Glo1 in kidney and liver in mice. Glo1 
gene expression (A) and Glo1 activity (B) in kidney and liver tissue after treatment of mice with 
angiotensin II (Ang II) for 3 and 28 days.  Data represent mean ± SD (Sham n=4; Ang II n=4). 
 
We next determined the concentration of MGO and the other dicarbonyls and 
AGEs in tissues and in plasma. We observed after 3 days of angiotensin II 
infusion higher levels of CML and MG-H1 in the liver and for CML also in the 
kidney (Table 9.2) and a significant decrease of MGO and 3DG in the liver but not 
in the kidney (Table 9.2). In plasma, we found higher concentrations of GO and 
MGO levels tended to be increased (p=0.06) (Figure 9.2A). Regarding the AGEs 
levels in these animals, higher CEL and CML concentration in free form was 
found in plasma after 3 days, but this was not the case for MG-H1 (Figure 9.2A). 
In mice infused for 28 days with angiotensin II we did not observe a change in 
plasma and tissues levels of dicarbonyls and AGEs (Figure 9.2B and Table 9.1). 
In addition, we found a significant decrease of protein-bound AGEs CML in 
plasma of these mice treated with angiotensin II after 3 days (Figure 9.2A and 
Table 9.1). Plasma levels of D-lactate did not change significantly in mice infused 
for 3 and for 28 days (Figure 9.2A and 9.2B and Table 9.1). 
 









Table 9.2. Tissue dicarbonyls and AGEs levels after 3 days and 28 days of exposure to 
angiotensin II. 
 
















 3 Days 28 Days 
 Sham Angiotensin II P     Sham Angiotensin II P  
       
Mouse (n) 4 4 - 6 9 - 




      
CML (nmol/g) 
 






66 ± 12 85 ± 8 0.3 57 ± 12 56 ± 11 0.8 
MG-H1 (nmol/g) 
 




      
MGO (nmol/g) 
 
442 ± 66 
 
457 ± 26 0.7 424 ± 19 
 






859 ± 132 1035 ± 219 0.2 907 ± 
 




24 ± 9 25 ± 5 0.9 23 ± 4 21 ± 6 0.7 









7.3 ± 0.5 0.03 6.5 ± 
 






3 ± 0.4 3.1 ± 0.4  0.8 2.9 ± 
 





1000 ± 224  0.01 540 ± 
 




      
MGO (nmol/g) 
 
416 ± 20 
 
387 ± 10 
 
0.03 423 ± 58 
 






811 ± 66 828 ± 63 0.3 906 ± 
 
888 ±78 0.8 
3DG (nmol/g) 
 
65 ± 8 48 ± 7 0.02 73 ± 10 68 ± 10 0.4 



























Figure 9.2. Effect of Angiotensin II on plasma levels of dicarbonyls, D-lactate and 
free and protein bound AGEs in mice. Plasma dicarbonyls, D-lactate, free and protein bound 
(PB) AGEs levels in mice after 3 days (Sham n=4; Ang II n=4) and 28 days (Sham n=6; Ang II n=9) of 
infusion with angiotensin II (AngII) (A); Data represent mean ± S 
 










The major finding of this study is that infusion of angiotensin II for 3 and 28 days 
reduced mRNA Glo1 and activity in liver and kidney.  The different dicarbonyls 
and AGEs in tissues and in plasma showed mixed patterns, but we found 
increased levels of CML and MG-H1 in the liver after 3 days of angiotensin II 
infusion and this was accompanied by an increase of plasma GO, MGO, CML 
and CEL.   
At 3 days and 28 days of infusion with angiotensin II we observed a reduction of 
Glo1 mRNA expression and activity in liver and kidney tissue. This finding is in 
line with a previous study which have shown a decrease of Glo1 activity in retinal 
cells by angiotensin II 6 and that the ARB candesartan attenuates MGO formation 
and Glo1 activity in the retina of diabetic rats overexpressing the renin-
angiotensin system6.  
Although Glo1 expression was reduced in the kidneys and liver of mice at two 
different time points, we observed an increase in plasma levels of dicarbonyls 
MGO and GO and free AGEs CML and CEL only after 3 days of angiotensin II 
exposure. In accordance, free CML was increased in liver and the kidney and 
MG-H1 only in the liver. In contrast, the dicarbonyls MGO and 3-DG were 
significantly decreased in the liver at 3 days. Because we have only data of 
plasma levels of dicarbonyls and AGEs and not urinary levels, we cannot exclude 
the possibility that renal clearance of dicarbonyls and AGEs may affect our 
results.  In addition, several biological factors might explain some apparent 
contrasting findings between Glo1 and dicarbonyls and AGEs in tissues and 
plasma. First, whether Glo1 downregulation is directly attributable to angiotensin 
II remains uncertain, since angiotensin II is also associated with more 
inflammation and oxidative stress, i.e. conditions which are associated with 
increased levels of dicarbonyls and AGEs 16 and reduced Glo1 activity. 
Furthermore, angiotensin II has indirect effects on cells and animals via its 
metabolites including Ang-1-7 that mediates antagonistic effects of angiotensin II 
through angiotensin-(1-7) receptor 17,18. Finally, a potential molecular mechanism 
linking the AT1R with the receptor for advanced glycation endproducts (RAGE) 
was identified 19. It was shown that angiotensin II by AT1R activation could induce 
the RAGE pathway regardless of RAGE ligands and maybe amplify the 
proinflammatory response or RAGE-dependent downregulation of Glo1 19,20. 
Although the relevance of these receptor interactions needs to be further 
elucidated, the activation of AT1R by angiotensin II and the transactivation of 
RAGE by AT1R may explain, at least partly, some of the contrasting effect 
between Glo1 expression in the liver and kidney and plasma and tissue 
dicarbonyls and AGEs.  Nonetheless, a role of angiotensin II on glycation stress 
is very likely and the result of a reduced Glo1 expression and the accumulation of 






In conclusion, the present study showed that upon angiotensin II infusion, Glo1 
was reduced in the liver and the kidney with effects on dicarbonyl stress, 
indicating a link between the glycation pathway and RAAS. Further studies 
should focus on many other biological aspects of angiotensin II in relation to 
dicarbonyl stress, in order to further elucidate how the RAAS and the AGE 
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An important hormonal regulatory system for both fluid balance and blood pressure 
regulation is the renin-angiotensin-aldosterone system (RAAS). Activation of the 
RAAS is therefore a vital mechanism to maintain homeostasis in the setting of 
decreased circulating volume (such as blood loss or dehydration). However, when 
the RAAS is chronically activated in the setting of cardiometabolic diseases, the 
two main effector hormones of this system, aldosterone and angiotensin II, have 
significant pathogenic actions on the cardiovascular and renal system, which 
include the stimulation of fibrosis, inflammation, cell proliferation, 
neovascularization and oxidative stress1. 
Aldosterone levels are increased in 50% to 80% of all hypertensive disorders and 
are associated with obesity and metabolic disorders such as impaired glucose and 
lipid metabolism and insulin resistance2. Moreover, patients with primary 
aldosteronism (PA), have increased cardiovascular risk, and more renal and 
metabolic complications than essential hypertension3. Despite several decades of 
investigation, the mechanism of excess aldosterone secretion in PA remains poorly 
understood.  
 
In addition to activation of RAAS, accumulation of the reactive glucose-metabolite 
methylglyoxal (MGO) is recognised as key a driver of cardiovascular disease and 
vascular complications in diabetes. There are some indications that the RAAS and 
the MGO pathway interact, but this is relatively underexplored. MGO is formed as a 
glycolytic intermediate and a byproduct of glycolysis 4. MGO is detoxified to D-
lactate by the glyoxalase system with the enzyme glyoxalase 1 (Glo1) as the rate 
limiting step 5. It has been demonstrated that Glo1 is impaired in diabetes, and that 
this impairment can be restored by the angiotensin receptor blocker (ARB) 
candesartan. In mice, has been demonstrated that candesartan prevents 
experimental diabetic retinopathy by restoring Glo1 function 6. In type 1 (T1DM) 
and type 2 diabetes mellitus (T2DM),  higher plasma MGO levels were associated 
with chronic kidney disease (CKD) and cardiovascular disease (CVD) 7,8. Blockade 
of the RAAS is one of the most successful interventions to combat diabetic 
complications 9–11, but  whether the beneficial effects of the blockade of the RAAS 
is due to a reduction of MGO has not be fully explored.   
The aims of this thesis were to explore: 1. the mechanisms underlying the 
aldosterone production in primary aldosteronism; 2. the implication of the RAAS in 
primary aldosteronism; 3. the interaction of RAAS with glycation. 
The topics covered in this thesis are introduced in the general introduction, 






• In Chapter 2, we reviewed the concept of epithelial-to-mesenchymal 
transition (EMT) and its role in renal diseases, with particular focus on 
hypertensive kidney disease, the second leading cause of end-stage renal 
disease after diabetes mellitus.  
• In Chapter 3, we described the role of angiotensin II type 2 receptor 
(AT2R) and the angiotensin-(1-7) receptor (MasR) on aldosterone and 
cortisol synthesis using a pharmacological approach. We did not find a 
significant effect of nanomolar concentrations of Compound 21 (C21), an 
AT2R agonist, on CYP11B1 (cortisol synthase) or CYP11B2 (aldosterone 
synthase) gene expression in the NCI-H295R and HAC15 adrenocortical 
cells lines. Furthermore, no effect of C21 was observed in aldosterone-
producing adenoma (APA), a condition featuring hyperaldosteronism, and 
in APA-adjacent tissue. However, micromolar concentration of C21 
markedly increased CYP11B1 and CYP11B2 gene expression through 
angiotensin II type 1 receptor (AT1R), as this effect was blunted by the 
angiotensin II type 1 receptor blocker irbesartan.  
• In Chapter 4, we have investigated the effect of the macrolide antibiotic 
clarithromycin on aldosterone synthesis in cells isolated from APA 
with/without somatic mutations in the potassium channel Kir3.4 (KCNJ5). 
Clarithromycin lowered, in a concentration-dependent manner, the 
expression of the CYP11B2 gene However, whether and aldosterone 
secretion in aldosterone-producing cells (CD56+ cells) from KCNJ5 
mutated APAs. However, when exposed to increasing concentrations of 
clarithromycin, the CD56+ cells obtained from wild-type APAs showed no 
change of CYP11B2 gene expression and aldosterone secretion in 
response to the macrolide.   
• In Chapter 5, we described that in adrenocortical cells HAC15  and in 
tissue strips obtained ex vivo from patients with APA,  the  G protein–
coupled estrogen receptor (GPER), is the main mediator of CYP11B2 
expression  in response to aldosterone exposure as this effect was 
abolished by the selective antagonist G36 or molecular silencing of GPER.  
Furthermore, angiotensin II potentiated the GPER-mediated effect of 
aldosterone on CYP11B2 through a crosstalk between GPER-1 and AT1R 
receptors. 
• We have studied in Chapter 6 the titer of angiotensin II type-1 receptor 
autoantibodies (AT1AA) is APA patients. I described that the titer of AT1AA 
is increased in APA patients, which persisted after surgical cure of 
hyperaldosteronism. Moreover, I found in HAC15 cells, that the stimulation 
with IgG purified from sera of APA increased both CYP11B2 expression 
and aldosterone release. 










In part 2 of this thesis, I have studied the link between RAAS and glycation. 
• In Chapter 7, we showed that in APA patients, serum levels of AT1AA are 
not associated with the serum dicarbonyls methylglyoxal, glyoxal and 3-
deoxyglucosone, or protein-bound and free advanced glycation 
endproducts (AGEs). Moreover, free AGEs Nε-(1-carboxymethyl)lysine 
(CML), Nε-(1-carboxyethyl)lysine (CEL) and Nδ-(5-hydro-5-methyl-4-
imidazolon-2-yl)-ornithine (MG-H1) serum levels were increased after 
adrenalectomy. 
• We reported in Chapter 8 that Irbesartan treatment did not change plasma 
levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, 
free AGEs or D-lactate in individuals with type 2 diabetes and albuminuria.   
• Despite the null finding in chapter 8, we have studied the effect of 
angiotensin II in mice and reported in Chapter 9 that angiotensin II infusion 
in mice downregulated Glo1 gene expression in the kidney and the liver in-
vivo with a concomitant increase in dicarbonyl stress. 







General Discussion  
The RAAS is the main regulator of aldosterone synthesis through the activation of 
AT1R in adrenocortical cells by angiotensin II. Dysregulation of the RAAS is known 
to contribute substantially to the pathophysiology of hypertension, renal disease 
and heart failure.  
Given the protective role of the non-canonical pathway of the RAAS, this protective 
pathway in the regulation of the human adrenocortical hormones was investigated 
further and described in chapter 3. First, we investigated gene expression of the 
receptors AT1R, angiotensin II type 2 receptor (AT2R) and the angiotensin-(1-7) 
receptor (MasR), in aldosterone-producing adenoma (APA) and in APA-adjacent 
tissue. In line with previous studies 12,13, we found  in both tissues a high AT1R 
gene expression as compared to AT2R gene expression. Moreover, a significant 
decrease of AT2R gene expression in APA compared to APA-adjacent tissue was 
observed. The expression of AT1R and AT2R in APA and APA-adjacent tissue was 
in agreement with previous studies 13,14, while the presence of MasR in the human 
adrenal gland is a novel finding. Immunoblots and immunohistochemistry 
confirmed the presence of AT1R and MasR in APA and in APA-adjacent tissue, 
with the highest MasR expression in the APA tissue. It has been demonstrated that 
AT2R and MasR play a cardiovascular protective role by counter-regulating AT1R-
mediated effects in various tissues, and our data support this.  Ang (1-7), by acting 
as a ligand for AT-2R and MasR, may oppose the cell proliferation and the sodium-
retaining actions of angiotensin II 15 and ameliorate endothelial function in 
experimental models of atherosclerosis, heart failure, and inflammation 16. In the 
fructose-fed rat model, used as a model of the metabolic syndrome, the Ang-(1-7) 
treatment had a chronic regulatory effect on aldosterone and plasma renin 
circulation 17. However, whether the presence of MasR receptor in the APA tissue 
plays a protective role by blunting the production of aldosterone in 
hyperaldosteronism is still unknown. 
The effects of the receptors/pathways involved in the protective arm of the RAAS 
on aldosterone and cortisol synthesis was investigated in chapter 4 using a 
pharmacological approach. A low concentration of Compound 21 (C21), an AT2R 
agonist, did not affect the gene expression of cortisol synthase (CYP11B1) and 
aldosterone synthase (CYP11B2) in the HAC15 and H295R adrenocortical cell 
lines. At these low concentrations, C21 had also no effect on aldosterone 
production such as in hyperaldosteronism. At higher concentrations, C21 increased 
CYP11B1 and CYP11B2 gene expression in the HAC15 and H295R cell lines, and 
enhanced the effect of angiotensin II in HAC15 cells only. Pretreatment with the 
AT1R antagonist irbesartan abolished the effect of angiotensin II. The effect of high 
concentrations of C21 on CYP11B1 and CYP11B2 gene expression, indicates that 
at higher concentrations C21 likely acts as an AT1R agonist. In addition to cell 
lines, we also used tissues from patients to study C21 effects on CYP11B2 and 
CYP11B1 gene expression. We found that at low concentrations C21 does not 
affect CYP11B2 expression. The low level of AT2R found in the adrenal cortex, 










along with the lack of any effect of C21 at low concentrations on CYP11B2, does 
not support the contention that the protective arm of RAAS blunts aldosterone 
synthase in the normal adrenal cortex and primary aldosteronism.  
Aldosterone-producing adenoma, a major subtype of primary aldosteronism, 
involves somatic mutations in the potassium channel Kir3.4 (KCNJ5). These 
mutations cause a loss of K+ selectivity, with increased sodium influx into APA 
cells, leading to membrane depolarization and activation of the calcium signaling 
pathway via opening calcium channels 18. Increased intracellular Ca2+ leads to 
increased expression of CYP11B2 and thus increased aldosterone production from 
the tumor.  
Some macrolide antibiotics and some synthesized derivatives without antibiotic 
activity, have been shown to specifically inhibit in vitro the altered function of 
somatic mutations (G151R or L168R) in the potassium channel KCNJ5 in cells with 
an overexpression of these channels 19. These agents blunted concentration-
dependently aldosterone production in vitro in HAC-15 cells that overexpress the 
KCNJ5 mutated channel19. In chapter 4 we demonstrated a similar concentration-
dependent blunting of CYP11B2 gene expression and aldosterone production with 
the macrolide antibiotic clarithromycin in APA cells isolated ex vivo from human 
APA with G151R and L168R mutations. Importantly, these effects were found to be 
selective in that it was ineffective in cells obtained from wild-type APAs. Whether 
the same effects are present in patients with PA will require further investigations. 
These results open new views for the diagnosis and treatment of aldosterone-
producing adenoma carrying this specific kind of mutations. Insights from these 
studies may allow detection of mutated tumors of the adrenal gland in the free DNA 
of circulating cells, to distinguish between the two main forms of primary 
aldosteronism and thus avoiding invasive investigations such as adrenal vein 
sampling (AVS) as the gold standard. Future studies addressing this topic are 
currently underway 20.  
The adrenocortical zona glomerulosa is the main site of aldosterone biosynthesis. 
The molecular mechanisms underlying aldosterone oversecretion in primary 
aldosteronism are so far poorly understood, despite renin suppression and 
undetectable angiotensin II levels. Multiple observations have also suggested a 
role for oestrogens in the regulation of aldosterone under physiological and 
pathophysiological conditions 21,22. GPER, a G-protein coupled receptor initially 
described as an oestrogen-specific receptor 23,24 is a promiscuous receptor capable 
of binding of aldosterone or other steroids 25 and  to mediate mineralocorticoid 
receptor (MR)–independent aldosterone effects in different cell types. Moreover, 
GPER is highly expressed in the normal human adrenocortical zona glomerulosa26. 
In chapter 5, we propose an autocrine paracrine mechanism whereby aldosterone, 
acting via GPER, can swiftly increase its own biosynthesis. By using an in vitro 
model of the human adrenocortical cell line, that produces relatively small amounts 






substantial amounts of aldosterone, we could identify GPER as the main mediator 
of CYP11B2 activation in response to aldosterone stimulation. After specifically 
blocking the MR or the GPER, or knock-down of GPER, aldosterone potently 
stimulated aldosterone synthase expression through a mechanism involving GPER 
stimulation. We could not find detectable changes of cytosolic Ca2+ levels in 
response to aldosterone. In line, a previously study demonstrated that GPER-
mediated stimulation of aldosterone secretion was associated with upregulation of 
CYP11B2 and appeared to be PKA/cAMP dependent but did not involve cytosolic 
Ca2+ mobilization26. However, the possibility that GPER activation of CYP11B2 can 
involve Ca2+ influx into the mitochondria need to be investigated by using 
mitochondria-specific Ca2+ sensitive probes. This autocrine-paracrine mechanism 
of aldosterone may play a pathophysiological role in maintaining inappropriately 
high secretion of aldosterone in PA patients and could explain the occurrence of 
aldosterone-producing cell clusters (APCCs), which can coexist with APA, and 
possibly represent an early stage of the latter27. 
   
We found that APA patients have an increased titer of angiotensin II type-1 
receptor autoantibodies (AT1AA) in serum (chapter 6). Our data were in line with 
previous reports 28,29. We investigated the effect of surgical cure of PA by unilateral 
laparoscopic adrenalectomy on AT1AA titers. We found no rapid normalization of 
the raised autoantibodies titers, suggesting that PA by itself does not increase the 
titer of AT1AA, although we cannot fully exclude that at longer follow-up times after 
surgery, the AT1AA levels normalize. However, since blood pressure normalization 
already had been achieved, the persistence of AT1AA might not simply represent a 
biomarker of the excess cardiovascular damage, which in PA has been well 
documented at the level of the heart, kidney, and vasculature. Furthermore, we 
investigated AT1AA bioactivity towards AT1-R with multiple assays, showing an 
increase in aldosterone biosynthesis and secretion only when using a sensitive in 
vitro technique. Although these results suggest a pathogenetic role of AT1AA in 
raising aldosterone biosynthesis in primary aldosteronism, it is still not clear if a 
similar effect exists in vivo. 
 
 











Figure 10.1 Overview of aldosterone production in adrenal cells. 1. C21 binds to AT1R and AT2R, 
but is effective on CYP11B2 gene expression only via AT1R; 2. Clarithromycin lowered the expression 
of the CYP11B2 gene and aldosterone secretion in aldosterone-producing cells; 3. Aldosterone, acting 
via GPER, can swiftly increase its own biosynthesis. 4. APA patients, have an increased titer of AT1AA 
that stimulate aldosterone biosynthesis.  
Abbreviations: angiotensin II type 1 receptor (AT1R); angiotensin II type 2 receptor (AT2R); angiotensin-
(1-7) receptor (MasR); aldosterone synthase (CYP11B2); potassium channel Kir3.4 (KCNJ5); G-protein 
coupled estrogen receptor (GPER); angiotensin II type-1 receptor autoantibodies (AT1AA). Figure 
created with BioRender.com 
 
 
In addition to RAAS, also methylglyoxal (MGO) and its derived advanced glycation 
endproducts (AGEs) are key players in the development of CVD4,5. MGO can be 
detoxified by glyoxalase 1 (Glo1), glyoxalase 2 and reduced glutathione into D‐
lactate, thereby preventing accumulation of MGO and MGO‐derived AGEs 30. Glo1 
is the rate‐limiting enzyme in this reaction. Literature provides evidence that Glo1 
overexpression is able to prevent endothelial dysfunction and diabetic micro‐
vascular complications 31,32. Accumulation of AGEs and activation of the RAAS are 
both implicated in diabetic vascular complications 33,34. 
The activation of AT1R by angiotensin II has been linked to an increase of MGO6. 
Since AT1AA have agonistic properties to the AT1R, at least in vitro, and similar to 
angiotensin II 29,35, we investigated the association between AT1AA and serum 
MGO levels in patients with APA. We found that serum AT1AA levels were not 






free and protein-bound AGEs CML, CEL and MG-H1, and the MGO metabolite D-
lactate. To our surprise, we found an increase of free AGEs CML, CEL and MG-H1 
serum levels after-adrenalectomy, which are likely due to changes in kidney 
function or the use of less co-medication after surgery (chapter 7). 
 
We next determined in chapter 8 the effect of the angiotensin receptor blocker 
(ARB) irbesartan treatment on plasma levels of the dicarbonyls MGO, GO and 
3DG. Levels of these dicarbonyls were determined, in samples from a randomised 
double-blind, placebo-controlled randomised trial  of irbesartan with hypertensive 
patients with type 2 diabetes (T2D) and persistent microalbuminuria 11, at baseline 
and follow-up of 1 and 2 years.  We reported in chapter 8 that irbesartan treatment 
did not change plasma levels of the dicarbonyls, free AGEs or D-lactate. 
 
Although the results as described in chapter 8 suggest that ARBs are unlikely to 
mitigate renal and cardiovascular risk through the attenuation of plasma levels of 
dicarbonyl stress, we decided to investigate the role of angiotensin II on the 
expression and activity of Glo1 in tissues (chapter 9). In mice, we found decreased 
expression of Glo1 mRNA after infusion with angiotensin II and this was associated 
with slightly increased MGO levels. In addition, we also found that levels of free 
AGEs CML and protein-bound AGEs CEL were higher in plasma of mice subjected 
to 3 days of angiotensin II infusion. Moreover, angiotensin II promotes 
accumulation of the major AGE CML in kidney and liver and MG-H1 in liver after 3 
days of treatment, indicating that the AGE accumulation in tissues is likely due to 
impaired detoxification of MGO i.e. the major precursor in the formation of AGEs. 
These findings are in line with in-vivo studies, since Glo1 expression was lower in 
ruptured carotid atherosclerotic plaques, in comparison with stable plaque 
segments36 and in renal glomeruli in diabetic nephropathy37 indicating the 
importance of Glo1 against CKD. Furthermore, Glo1 knockdown caused a CKD-
like phenotype even in non‐diabetic mice38. 
Although the glyoxalase system is considered to be the major pathway by which 
MGO is detoxified, other enzyme system have been described in relation to MGO 
detoxification. Since we have focused solely on Glo1, it is not known whether 
compensation pathways involving aldehyde dehydrogenases (ALDH) and aldoketo 
reductases (AKR) are also over important, as these pathways have also been 
linked to modulation of MGO levels by angiotensin II.  
In summary, the inhibiting effects of ARBs on the concentration of AGEs in mice, 
as show in several studies 6,9,39–41 are  thus due, at least partly,  to the  inhibitory 
effects of ARBs on the accumulation of methylglyoxal, the major precursor in the 
rapid formation MGO-derived AGEs, via a reduction of glyoxalase 1. We can 
therefore not exclude that the positive effect of ARBs on outcomes may be partly 
due to this potentially protective mechanism. However, it is unlikely that ARBs can 










be used to effectively reduce systemic dicarbonyl stress, and other approaches 
should be evaluated to achieve this goal.  
Figure 10.2 Overview of the role of angiotensin II on methylglyoxal stress. The glyoxalase 
system, is the main system involved in the detoxification of methylglyoxal to D-lactate. Angiotensin II 
(Ang II) contributes to methylglyoxal (MGO) stress by a reduction of glyoxalase 1 (Glo1) expression i.e. 
the rate-limiting enzyme in the glyoxalase system for the detoxification of MGO.  MGO and MGO-
derived AGEs can impact on organs and tissues affecting their functions and structure. We showed in 
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This thesis evaluated 1) several aspects that regulate the biosynthesis of 
aldosterone in primary aldosteronism 2) the interaction between the glycation 
pathway and renin-angiotensin-aldosterone system (RAAS). Inhibition of the RAAS 
in the context forms the cornerstone of the treatment of hypertension, diabetes and 
chronic kidney disease, and therefore a deeper insight and further optimisation of 
the RAAS is likely to have a large impact on clinical practice. 
In the last decade, multiple discoveries have made primary aldosteronism (PA) a 
model for improving mechanistic knowledge in hypertension. Several mechanisms 
were identified to cause the inappropriate over-secretion of aldosterone in PA, such 
as elevated serum levels of parathyroid hormone, downregulation of TASK-2 K+ 
channel, gene mutations affecting ion channel 1. In addition, PA patients show a 
higher cardiovascular disease (CVD) rate at the time of diagnosis than primary 
hypertensives 2,3. Despite the identification of these mechanistic markers, 
understanding the molecular mechanisms involved in primary aldosteronism is 
important to improve diagnosis and therapeutic approaches of the disease.  
The first part of this thesis provided compelling evidence that over secretion of 
aldosterone can be specifically blunted ex-vivo in aldosterone producing adenoma 
(APA) with KCNJ5 mutations by the use of macrolides, opening a new perspective 
for the diagnosis and treatment of PA patients. Current ongoing clinical studies aim 
to determine the diagnostic and therapeutic effect of macrolide treatment in 
patients with APA carrying KCNJ5 mutations, allowing non-invasive diagnosis and 
targeted treatment 4. Currently APA is often treated with adrenal surgery, but not all 
individuals are eligible for this procedure, and therefore my findings in chapter 
chapter 4 are of potential interest for patients with APA. 
 
In chapter 6 we focussed on the measurement of angiotensin II type-1 receptor 
autoantibodies (AT1AA).  
The possibility to measure serum levels of AT1AA is a promising step to improve 
the diagnosis of primary aldosteronism. These AT1AA autoantibodies indicate loss 
of immunological tolerance towards tissues that express the angiotensin II type I 
receptor (AT1R) and are a target of arterial hypertension. This will be a major focus 
of future research. However, the presence of AT1AA not only in APA but also in 
some healthy donors, requires more studies to investigate the cut-off between 
normal subjects and APA patients and the specificity of these antibodies. 
Furthermore, as we identified a G protein–coupled estrogen receptor (GPER) as 
additional mediator of aldosterone secretion, GPER may also be a useful 





In the second part of this thesis, the relation between advanced glycation 
endproducts (AGEs) and the activation of RAAS as a key driver of CVD and 
vascular complications are described. 
Higher levels of specific AGEs are associated with a higher risk of CVD and 
inhibition of AGE formation and/or the blockade of the interaction between the 
RAAS and AGEs could be a viable option for therapy to prevent the progression of 
chronic kidney disease (CKD) and CVD in diabetic individuals. 
Several compounds have been identified that lower AGE levels and/or inhibit AGE 
formation, including anti-hypertensive drugs such as angiotensin receptor  blockers 
(ARBs) and angiotensin converting enzyme (ACE) inhibitors 5–8. Although it has 
been demonstrated in a major clinical trial that the ARB irbesartan reduced 
progression of albuminuria, independently of blood pressure 9 and that this can 
have beneficial effects on cardiovascular outcome, we could not show any changes 
in plasma of dicarbonyl stress. However, it remains possible that the potential 
beneficial effects of ARBs are restricted to experimental models of diabetes. This 
finding is important for clinical practice as we show that at least the ARB irbesartan 
is unlikely to lower systemic glycation markers and therefore the glycation pathway 
likely remains untargeted in individuals with diabetes. 
Furthermore, as we show in the first part of the thesis, higher levels of AT1AA are 
identify in APA, and persisted after cure of hyperaldosteronism suggesting a 
pathogenetic role of AT1AA in raising aldosterone biosynthesis in primary 
aldosteronism; it may be worth considering whether these antibodies that activate 
AT1-R are associated with higher methylglyoxal MGO levels and MGO-derived 
AGEs in individuals with APA. Experimental studies have shown that increased 
activation of AT1R by Ang II has been linked to increased formation of 
methylglyoxal  10. However, our findings of no associations of plasma AT1AA with 
AGEs suggest that plasma levels of AT1AA may not adequately represent AGE 
accumulation in plasma, although we found an increase of AGEs after 
adrenalectomy. Larger studies with a long-term follow-up time are required to 
further clarify the importance of post-adrenalectomy levels on AGEs. 
Evidence of the interconnection between the RAAS and the glycation pathway on 
cardiovascular disease remains incomplete, although our studies have added 
some evidence for a role of angiotensin II to decreased expression of Glo1 enzyme 
and subsequent increase formation of AGEs. Based on these findings future 
research should focus on many other biological aspects of angiotensin II in relation 
to dicarbonyl stress, to further elucidate how the RAAS and the AGE pathway are 
intertwined. 
In conclusion, the glycation pathways and RAAS may be promising targets improve 
both prediction and treatment of CVD, and that additional research may lead to the 
identification of novel targets to reduce the global impact of CVD and diabetic 
complications. 
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